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Abstract
An introduction to this work presented in this thesis involves an overview of nucleic acids and 
the use of nucleoside analogues in antiviral therapy.
Bicyclic furano pyrimidine nucleosides (BCNA)s were discovered by the McGuigan group as 
potent and selective inhibitors of Varicella-Zoster Virus. A brief description of Structure 
Activity Relationships of this class of compounds is presented, identifying a long lipophilic 
chain as a specific requirements for antiviral activity.
We herein report the synthesis and biological evaluation of a new series aimed to further 
investigate the specific requirement for biological acitivity.
Two sites of BCNAs were modified on the lead compound, the side chain and the sugar 
moiety.
A series bearing electron-donating and electron-withdrawing aryl groups was synthesised in 
order to investigate the role of the position of the substitutent.
Then, the phosphoramidate approach was applied to the lead compound in order to broaden 
the spectrum of activity, which was limited only to VZV.
Modifications of the sugar moiety include the inversion of all the stereo-centres of the lead 
compound, obtaining the L-enantiomer, and the inversion of the stereochemistry at the C - l’ 
obtaining thus the a-derivative. Furthermore the replacement of the furano ring of the sugar 
with a cyclopentane was thought as a good strategy in order to increase the resistance to 
enzymatic cleavage.
Given the poor bioavailability of the lead compound, the valyl ester was synthesised making 
also the hydrochloric and succinate salts to increase the chemical stability and water solubility 
Finally, using the intrinsic fluorescence of these derivatives, a cell study was carried out in 
order to investigate the distribution of the compound inside the cell.
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Chapter 1: Introduction
1.1 Constituents of DNA and RNA: Nucleosides and Nucleotides'
The nucleic acids DNA and RNA are very suitable carriers of genetic information due 
their covalent structures. These macromolecules are linear polymers built up from similar 
units connected end to end. Each monomer unit within the polymer is a nucleotide that 
consists of three components: a sugar, a heterocyclic base and a phosphate group. The 
sequence of bases in the polymer uniquely characterizes a nucleic acid and constitutes a 
form of linear information.
The sugar in deoxyribonucleic acid (DNA) is deoxyribose. The deoxy prefix indicates 
that the 2'-carbon atom of the sugar lacks the oxygen atom. The sugars in nucleic acids are 
linked to one another by phosphodiester bridges. Specifically, the 3'-hydroxyl (3'-OH) 
group of the sugar moiety of one nucleotide is esterified to a phosphate group, which is 
joined to the 5'-hydroxyl group of the adjacent sugar.
Two of the bases of DNA are derivatives of purine, adenine (A) and guanine (G) and two of 
pyrimidine, cytosine (C) and thymine (T). Ribonucleic acid (RNA) differs from that of 
DNA in two respects. Firstly, the sugar units are riboses rather than deoxyriboses. Secondly, 
thymine (T) is replaced by the base uracil (U).
A unit consisting of a nitrogen base bonded to a sugar is referred to as a nucleoside. The four 
nucleoside units in RNA are called adenosine, guanosine, cytidine, and uridine, whereas those 
in DNA are called deoxyadenosine, deoxyguanosine, deoxycytidine, and thymidine. In each 
case, N-9 of a purine or N-l of a pyrimidine is attached to C -1' of the sugar. The base lies 
above the plane of sugar when the structure is written in the standard orientation; that is, the 
configuration of the N-glycosidic linkage is p. The site of attachment in naturally occurring 
nucleotides is the hydroxyl group attached to C-5' of the sugar. A compound formed by the 
attachment of a phosphate group to the C-5' of a nucleoside sugar is called a nucleoside 5- 
phosphate or a 5'-nucleotide (fig 1.1).
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Fig 1.1 : structure o f  nucleotides in DNA and RNA
1.2 The double helix is stabilised by hydrogen bonds and hydrophobic 
interactions1
The formation of specific base pairs was discovered during the determination of the three- 
dimensional structure of DNA by the use of X-ray diffraction. The characteristics of these 
diffraction patterns indicated that DNA is formed of two chains that wind in a regular helical 
structure. From these data and others, Watson and Crick deduced a structural model for DNA 
that accounted for the diffraction pattern.
The features of the Watson - Crick Model of DNA deduced from the diffraction patterns are:
1. Two helical polynucleotide chains are coiled around a common axis and run in opposite 
directions.
2. The sugar-phosphate backbones are on the outside and the purine and pyrimidine bases lie 
on the inside of the helix.
2
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3. The bases are nearly perpendicular to the helix axis, and adjacent bases are distant 3.4 A. 
The helical structure repeats every 34 A, so there are 10 bases per turn of helix.
4. The diameter of the helix is 20 A.
Watson and Crick discovered that by hydrogen bonds guanine could be paired with cytosine 
and adenine with thymine to form base pairs that have essentially the same shape (fig 1.2). 
These base pairs are held together by specific hydrogen bonds, which stabilise the helix 
because of their large numbers in a DNA molecule. These base-pairing rules account for the 
observation, originally made by Erwin Chargaff in 1950, that the ratios of adenine to thymine 
and of guanine to cytosine are nearly 1:1 in the DNAs of all species studied.
H
N —  H M l li 11 o
N lll l l llH  —  N
O l ■ I ■ 11 ■ H —  N
\
H
N —  H lll l l I lN
=  N
11.1 A 10.8 A
Fig 1.2 : base pairs
Inside the helix, the bases are stacked one on top of another. The stacking of base pairs 
contributes to the stability of the double helix in two ways. First, the double helix is stabilised 
by the hydrophobic effect. The hydrophobic bases cluster in the interior of the helix away 
from the surrounding water, whereas the polar surfaces are exposed to water. The stacked 
base pairs attract one another through Van der Waals forces. In addition, base stacking in 
DNA is favored by the conformations of the somewhat rigid five-membered rings of the 
backbone sugars.
1.3 DNA replication
Replication is the fundamental molecular process to pass genes from one generation to the 
next by copying a double strand of DNA. It starts with the unwinding and separation of DNA 
creating the replication fork (fig 1.3). The two strands of parent DNA are used as a template 
for the synthesis of new DNA by the DNA-polymerase2 (three different polymerases have 
been found in eukaryotic cells, DNA-polymerase I, II and III)3 adding deoxynucleoside 5'-
3
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triphosphates at the terminal 3'-OH of the growing DNA strand. A primer with a free 3'-OH is 
needed for this process, which is synthesised by the RNA-polymerase primase at the 
replication fork. Once this primer is made, DNA synthesis can begin, elongating the 
polynucleotide chain originating with the RNA primer. Due to the fact that the two strands of 
DNA are antiparallel, the leading strand can be copied continuously down its entire length in 
direction 5 '-*3\ However, the other parent strand, called lagging strand, must be copied 
discontinuously in short fragments (Okazaki fragments)4 as the DNA unwinds in the direction 
5’—*3*. Both the strands are synthesised by DNA polymerase III, which also has nuclease 
activity with error correction capacity. DNA polymerase I removes the primer and fills the 
gaps between the Okazaki fragments. Finally, DNA ligase joins the fragments.
fragment
strand
Leading strand 
template
O
DNA polymerase III
1 ielicase
O
o
Egging
template
Okazaki
Parent DNA
DNA-binding proteins
RNA primase
DNA polymerase III
Fig 1.3: replication fork5
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1.4 Nucleoside analogues as antiviral agents
Viruses can be defined as packets of infectious nucleic acid surrounded by protective coats.6 
Unlike bacteria or eukaryotic cells, viruses are unable to generate metabolic energy or to 
synthesise proteins. They also differ from cells in having either DNA or RNA, but not both. 
Due to the extreme simplicity of their reproductive apparatus, they are obligate parasites, that 
is, they multiply exclusively within living cells, forcing the host cell to synthesise viral 
proteins and viral nucleic acids, followed by final assembly into new virions. A virus is 
biologically silent outside the cell, and it becomes biologically active and pathogenic only 
when it has entered the host cell. The viral genome always encodes one or more enzymes, 
which have vital functions in the replication of the viral nucleic acids. A chemotherapeutic 
agent that could selectively interact with such viral enzymes, thus disrupting the synthesis of 
viral DNA or RNA at non-toxic concentration for the host cell, would have the potential as an 
antiviral drug.
When a virus takes over the host cell's biosynthetic machinery, the replication of its genome is 
fundamental to viral reproduction. It is not surprising that nucleoside analogues, interacting 
primarily with the replication of the viral genome, constitute the major class of compounds 
that exhibit significant in vitro and in vivo antiviral activity. Viral polymerases use nucleoside 
triphosphates as monomeric substrates, in the same way as cellular DNA polymerases use 
deoxynucleoside triphosphates for the replication of cellular DNA. This means that a 
nucleoside analogue must be available in the triphosphate form to interact with viral 
polymerases. Most nucleoside derivatives are phosphorylated within the cell by viral or 
cellular kinases7 to the 5'-monophosphate analogue, which is further converted into the 
triphosphate form, the active form of the drug. Once the nucleoside is converted into the 
triphosphate form, it could act either as an inhibitor of the viral polymerase or as a substrate 
for the viral polymerase and thus being incorporated in the growing viral DNA. These two 
mechanisms of action may sometimes coexist in the same antiviral nucleoside analogue. 
Selective inhibition of the viral polymerase at non-toxic concentrations for the host cell may 
be achieved by selective activation by the viral kinase, but not by the cellular kinase (i.e. 
acyclovir in HSV-1) or by activation in both infected and non-infected cells, but then the 
triphosphate form being a good substrate only for the viral polymerase and not for the cellular 
DNA polymerase (i.e. AZT in HIV).
5
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1.5 Pyrimidine analogues phosphorylated by viral thymidine kinases
Br
Br HN
HN
HO
HO
HO OH
HO
HN
HO
HO
HN
HO
HO OH
5
Br
HN
HO
HO
4
Fig 1.4: 5-substitued uridine nucleosides
Iodoxuridine (5-Iodo-2'-deoxyuridine, IDU, 1) was the first antiviral nucleoside - discovered 
in the late fifties9 - that showed to be an effective treatment of HSV infections.10 In HSV 
infected cells, IDU is phosphorylated by the viral kinase to monophosphate, which is further 
converted to the active triphosphate. IDU triphosphate acts as an inhibitor/substrate for viral 
DNA polymerase. In fact the replacement of thymidine by IDU in the viral DNA seems to be 
primarily responsible for the antiviral activity of IDU.8 IDU is phosphorylated by normal 
cellular enzymes as well as by virally encoded enzymes, ultimately producing IDU- 
triphosphate in normal cells, and thus incorporating IDU into cellular DNA resulting in 
toxicity.9,11 The unfavourable therapeutic index of IDU prompted the search for more 
selective and less toxic anti-herpes agents. These studies resulted in the discovery of potent 
inhibitors of HSV and VZV, like Brivudine12 (5-[(E)-(2-bromovinyl)]-2'-deoxyuridine, 
BVdU, 2) which is selectively phosphorylated by the viral thymidine kinase of HSV-1 and 
VZV, to the mono- and diphosphate form13,14, then cellular enzymes mediate the third
6
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phosphorylation. HSV-2 TK is unable to phosphorylate BVdU-monophosphate to the 
corresponding diphosphate, and this accounts for the observed selectivity of the compound 
against HSV-1.13
Fig 1.5: activation pathway o f  BVDU
BVdU-triphosphate may act either as a competitive inhibitor of viral DNA or as a substrate 
for this enzyme. When acting as a substrate, the compound is integrated into viral DNA 
affecting stability and functioning of the viral DNA.15,16 Sorivudine (5-[(E)-(2-bromovinyl)]- 
uracil arabinoside, BVaraU, 3) exhibits high potency against HSV-1 and particularly good 
activity against VZV.17 As BVdU, BVaraU shows a considerable specificity in its antiviral 
activity: it is highly potent against HSV-1, but not HSV-2.18 The carbocyclic analogue of 
BVdU (4) also proved to be a potent and selective inhibitor of HSV-1 and VZV, but not as 
good as the parent nucleoside analogue.19
7
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Another antiviral nucleoside analogue, the activity of which depends on selective activation 
by the viral TK, is Netivudine20 ((l-P-D-arabinofiiranosyl)-5-prop-l-ynyl-uracil, 882C, 5). 
This compound is a potent and selective inhibitor of VZV replication. As with the other 
pyrimidine analogues, it is selectively converted to the monophosphate form by VZV TK, 
which also mediates the second phosphorylation. HSV-TK is able to convert netivudine to 
netivudine-MP, but then does not catalyse the following conversion to the diphosphate, which 
explains the selectivity of the compound for VZV.21
1.6 Pyrimidine analogues phosphorylated by cellular thymidine kinase
HNHN
HOHO
76
HO
NH,
O ^ N
Fig 1.6: Anti-HIV dideoxypyrim idine nucleosides
n h 2
OH
10
Not every virus encodes its own specific TK and in the case of HIV, a nucleoside analogue 
must be a good substrate for the cellular kinases, in order to be phosphorylated to the 
triphosphate form. An example of a virus that does not encode for a specific TK is HIV. 
Since the anti-HIV nucleosides need to be phosphorylated by the cellular kinases in order to 
be active, only minor modifications in the structure of natural nucleosides would be 
tolerated in order to be a good substrate and to be activated to the triphosphate form.
8
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Azidothymidine (AZT, zidovudine 6) is the prototype of the pyrimidine dideoxynucleoside 
analogues that dominate the treatment of HIV infection.22 Its initial discovery led to the 
development of several other related nucleosides with antiviral activity against HIV, such as 
Stavudine23 (d4T, didehydrodideoxythymidine, 7) and Zalcitabine24 (ddC, dideoxycytidine, 
8). In addition, several cytidine analogues with the "unnatural" L-configuration have been 
found to selectively inhibit HIV replication and these compounds are now in the market: 2',3'- 
dideoxy-3'-thiacytidine (Lamivudine,25 3TC, 9), and its 5-fluoro-substituted counterpart 2',3'- 
dideoxy-5-fluoro-3'-thiacytidine (Emtricitabine,26 FTC, 10).
All pyrimidine dideoxynucleoside analogues exhibit the same mechanism of action: they need 
to be phosphorylated to the triphosphate form and then they can act as 
inhibitors/substrates/chain terminators at the HIV reverse transcriptase level. This mechanism 
of action, originally demonstrated for AZT,27 seems to be applicable to several other
• • 28 29dideoxynucleoside analogues, including the L-dideoxycytidine analogues. ’
1.7 Acyclic guanosine analogues
o o
HN
>
HN
o  h 2n
HO
NH2
HN
H2N
HO
HO
? \  H 2N
HN
H2N
HO
HO
14
Fig 1.7: A cyclic guanosine nucleosides
9
Marco Migliore Chapter 1
The first acyclic nucleoside with selective antiviral activity against HSV-1, HSV-2 and VZV 
was acyclovir30 (ACV, 11), becoming the treatment of choice for most of the herpesvirus 
infections. Acyclovir is highly active against HSV, even if it is 50 fold less active against
31VZV. The compound is recognised by the viral TK and it is selectively phosphorylated in 
infected cells. The monophosphate is then further phosphorylated by the cellular kinases to its 
active form of triphosphate.33,34
Acyclovir triphosphate inhibits viral DNA synthesis by acting as a substrate for viral DNA 
polymerase.31 Furthermore, while being a potent inhibitor of viral DNA polymerase, ACV- 
triphosphate is a poor inhibitor of cellular DNA polymerases.31 Thus the selectivity of 
acyclovir is achieved at two different levels: the compound is activated in infected cells only, 
and its active form is only recognised by the viral enzyme. ACV-triphosphate also acts as 
substrate for viral DNA polymerase.35 When acting as a substrate of the viral DNA 
polymerase, it is incorporated into the growing DNA strand acting as a chain terminator.
A big disadvantage of acyclovir is its poor oral bioavailability. To overcome this problem 
valacyclovir37 (12), the L-valyl-ester of acyclovir, has been developed as a prodrug. 
Valacyclovir is hydrolysed in the body to acyclovir, giving a greater oral bioavailability 
compared to acyclovir itself.
Ganciclovir35 (GCV, 13) is highly active against HSV-1 and HSV-2, only poorly active 
against VZV, but more active than ACV against HCMV (Human Cytomegalovirus). 
Although GCV is phosphorylated by the viral TK in HSV infected cells, HCMV does not 
code for a thymidine kinase. However, it is known that HCMV encodes a protein, the gene
2 ft •product UL97, responsible for the rate-determining initial phosphorylation of GCV. This 
enzymatic difference of HCMV compared to other herpesviruses explains why the majority of 
anti-HSV and anti-VZV nucleosides often prove to be inactive against HCMV. GCV-TP 
appears to act both as a faulty substrate and as an inhibitor of HCMV DNA polymerase.39 
The corresponding carbocyclic equivalent of ganciclovir is penciclovir40 (PCV, 14), which is 
reported to be similar to that of ACV, in that it shows potent activity against HSV and VZV, 
but only weak activity against HCMV.41
Famciclovir42 (FCV, 15), is an orally bioavailable prodrug of penciclovir that is metabolised 
to PCV by de-acetylation and 6-oxidation of the purine ring.
10
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1.8 Purine Analogues
Chapter 1
19 20
Fig 1.8: Purine analogues
Other purine analogues have been developed as antiviral agents, in particular some 
dideoxynucleoside analogues show to be active against HIV. Didanosine43 (2’,3’- 
dideoxyinosine, ddl, 16) is an alternative treatment to AZT44 (7). ddl is phosphorylated to 
ddIMP , converted to ddAMP and then converted to ddATP which is the active species.45 ddl 
was one of the first purine analogues and other purine derivatives have been synthesised. 
Iodenosine46 (2,-fluoro-2’,3’-dideoxyarabinosyladenine, FddA, 17) was rationally designed as 
a more chemically and enzymatically stable anti-AIDS drug than its parent compound 
didanosine. Vidarabine47 (9-P-D-arabinosyladenine, Ara-A, 18) was the first nucleoside 
antiviral analog to be given systemically and was the first agent to be licensed for the 
treatment of systematic herpes virus infection in man, although it has limited potency. 
Carbovir48 (carbocyclic analog of 2',3'-dideoxy-2',3'-didehydroguanosine, CBV, 19) is a 
potent inhibitor of HIV, but the poor bioavailability and the toxicity limited its potential 
clinical use.49 Abacavir50 (1592U89, 20) was originally synthesised to overcome the poor 
availability and it can be considered as a prodrug of CBV. Within the cell it is converted to
11
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CBV-MP and further into CBV-TP, which is the active metabolite against HIV.51 The anti- 
HIV mechanism of the purine dideoxynucleoside analogues is similar to that of the 
pyrimidine dideoxynucleoside analogues. They are converted into the triphosphate form and 
then they can interact with HIV reverse transcriptase as inhibitor / substrate / chain 
terminator.
1.9 Acyclic nucleoside analogue phosphonates
0
ii
HO P —
1
OH
The activity of acyclic nucleosides analogues depends on the phosphorylation steps, a process 
that it does not occur in cells deficient of kinases. A rational approach to by-pass this 
requirement is to develop a monophosphate form of the acyclic nucleosides, but it has limited 
use as a drug for two main reasons. First, the charge of the phosphate group prevents the drug 
crossing the cell membrane and second shows instability in vivo due to the rapid hydrolysis. 
To overcome this problem, a new class of nucleoside analogues has been develop of 
introducing a phosphonate moiety that is far more chemically and metabolically stable than 
the phosphate moiety.
PMEA52 (21) is active against HSV, EBV and HIV. Its diphosphate acts as a potent inhibitor 
of HSV DNA-polymerase as well as chain terminator when it is incorporated into viral DNA. 
Cidofovir53 (HPMPC, 22) shows a broad-spectrum antiviral acivity, being active versus all 
members of herpes family including HSV-TK', VZV-TK' and CMV-UL96 .
NH,
NH
N.
N
21
HO P
OH
OH
22
Fig 1.9: Acyclic nucleoside phosphonates
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1.10 Non-nucleoside analogues
Although nucleosides provide a major class of antiviral treatment some non-nucleoside 
therapies have been developed against herpes viruses, HIV and flu.
Foscarnet54 (23), an organic analog of inorganic pyrophosphate, selectively inhibits the 
pyrophosphate binding site on viral DNA polymerases at concentrations that do not affect 
human DNA polymerases. Because foscarnet is not activated by thymidine kinase, it 
maintains activity in some viruses that have lost thymidine kinase activity to gain resistance to 
aciclovir or ganciclovir. Therefore, foscarnet is often used in aciclovir or ganciclovir resistant 
disease.
Amantadine55 (24) is an amphiphilic primary amine that has both prophylactic and 
therapeutic efficacy against type A influenza virus infections. This compound blocks the M2 
ion channel, and thus prevents the passage of H+ ions that are required for the necessary 
acidity to allow for the viral uncoating process.56
o
ii
HO P
O
Fig 1.10: Non-nucleoside antivirals
Protease Inhibitors (Pis) are reversible competitive inhibitors of HIV protease that are able to 
displace HIV polyproteins acting as peptide-like molecules, binding onto HIV proteases to 
prevent the accumulation of structural proteins required for new virion formation.57 Immature 
virions normally arise after assembly and packaging of these structural polyproteins. HIV-1 
protease cleaves these precursor proteins to produce the final structural proteins of a mature 
virion core and to activate reverse transcriptase for new infection cycles. Since protease is 
necessary for the production of mature virions, its inhibition renders the virus noninfectious as 
the body rapidly clears immature virions.57 Although PI therapy does not prevent destruction 
of already infected CD4+ lymphocytes, further spread of infection to uninfected cells is 
prevented. Currently, there are eight available HIV-1 Pis: Saquinavir (25), Ritonavir (26), 
Indinavir (27), Nelfinavir (28), Amprenavir, Atazanavir, Lopinavir and Tripanavir.
n h 2
24
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Chapter 2: BCNAs
2.1 Varicella Zoster Virus
VZV is one of the eight members of the Herpes-viridae family, 
more specifically it is classified with herpes simplex viruses 
(HSV). Although HSV replicates in cells of numerous animal 
species, VZV has a narrow host range including only human 
and simian origin. The VZV particle is 125-175 nm in
diameter, and has a lipid envelope bearing glycoprotein
spikes.1
VZV is the cause of both Varicella (chickenpox) and herpes Zoster (shingles). Chickenpox is 
the primary manifestation of VZV infection and 90% of cases occur by 10 years of age. The 
virus becomes permanently established in sensory ganglia, persists in latent form, and recurs 
when reactivated as herpes Zoster. VZV reactivation occurs in up to 15% of those who have 
had Varicella manifesting by a vesicular rash, affecting the sensory nerve.3 
The drugs of first choice for the treatment of herpes Zoster by oral administration are ACV 11 
and its prodrug valacyclovir 12, while vidarabine 18 has been used intravenously. These 
drugs have a beneficial effect on reducing acute pain caused from shingles and on speeding 
healing.4
Valacyclovir 12 and famciclovir 15 have been licensed for the treatment of herpes-zoster 
virus infections.5 Their pharmacokinetic profile is better than ACV and their half-life is 
longer, making of these compounds better drugs for treatment of VZV.6 
BVDU 2 and BVaraU 3 are the most potent inhibitors of VZV that have reported to date, 
inhibiting VZV replication in cell culture at an EG*, less than 10 pM. BVDU is a substrate for 
thymidine phosphorylase that metabolises BVDU to BVU f(E)-5-(2-bromovinyl)uracilJ and
2-deoxyribose-l-phosphate.7 The rapid conversion to BVU, which is inactive as an antiviral
agent, reduces the antiviral potency of BVDU. However, BVU can be re-converted to BVDU, 
through a pentosyl transfer reaction with any 5-substituted 2’-deoxyuridine, including also 
thymidine, as the pentosyl donor, restoring in part the antiviral activity of the compound.8 
Moreover BVU is a potent inhibitor of dihydropyrimidine dehydrogenase (DPD), the enzyme
Fig 2.1: Varicella Zoster Virus
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responsible for the catabolism of pyrimidines. DPD is needed for the degradation of 5- 
fluorouracil, an anti-cancer agent, and BVU increases its half-life. The combination BVDU 
with 5-fluorouracil results in an increase in plasma levels of 5-fluorouracil,9 and it has lead to 
fatalities in the clinic.
2.2 BCNAs : Discovery of a new class of anti-VZV agents
A number of nucleosides with potent biological properties have arisen by substitution at the 
5-position of deoxyuridine analogues. In particular 5-alkynyl analogues have shown to be 
potent inhibitors of herpes viruses.10 This class of nucleosides is rather cytotoxic and its viral 
selectivity is low.11
During the research program, aimed to improving the biological activity of 5-alkynyl-2’- 
deoxyuridine analogues with long alkyl side chains, a new class of antiviral nucleoside 
derivatives bearing an unusual bicyclic base was discovered in our laboratory.12 
The synthesis of 5-alkynyl-2’-deoxyuridine involves Sonogashira coupling of terminal 
alkynes with 5-iodo nucleosides. An unwanted by-product in such coupling reaction is the 
fluorescent furano-pyrimidine, observed by a number of researchers as a more polar spot on 
T L C .,3-1415 The treatment of the target 5-alkynyl nucleoside with methanol, triethylamine and 
copper iodide leads to the total conversion to the fluorescent spot 25.12
The previously only well characterized by-products 
in the 2’-deoxy series were the compounds 29a and
29a R = H
29b r  = c 3h7 29c. However the parent compound 29a was
29c R = C4H9
29e r ^ q h ^  inactive against HSV, CMV, VZV. A novel series
29f R = C7h |5
29gR = c 8H17 of 29, bearing a long alkyl side-chain, has been
29h R = C^Hm
29j r = c ,(h21 sy n th e s ise d  and ev a lu a ted  fo r  their a b ility  to  in h ib it
29k R =
29i r  = c , ^  th e  rep lica tio n  o f  h erp es v iru ses  (HSV-1, HSV-2, 
VZV, CMV).
The bicyclic nucleosides show considerable potency and selectivity against VZV and the 
length of the side-chain plays a crucial role in the activity. In fact the optimal length is 
between 8 and 10 carbon atoms, with an EQo of 7-20 nM (29g-i). These compound are ca. 
300 fold more active than ACV and roughly equipotent with BVDU.16 
Furthermore the low cytotoxicity ( C C ^  50 pM) results in a high selectivity index (SI) 
>5000. The structure-activity relationships (SAR) regarding the long alkyl chain is clear: a
A
HO
HO
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short chain ^C6 leads to little antiviral activity, C7, C l 1 and C12 confer a moderate activity, 
while C8-10 give a high potency.15
200
180
160
80
60
40
C8 C9 CIO C ll C12 C14ACV BVDU C3 C5 C6
ECso yiM*
OKA YS TK 07 TK YS MCCnMb
CC50
p.M°
29a H 28 33 >200 >200 >200 >200
29b C3 0.8 0.5 >200 >200 >200 >200
29d C5 1.8 3.5 >50 >50 >50 >50
29e C6 1.3 2.8 >50 >50 200 >200
29f C7 0.12 0.33 >50 >50 >50 >50
29g C8 0.008 0.024 >50 >50 >50 >50
29h C9 0.02 0.02 >200 >200 >200 >200
29i CIO 0.015 0.008 >50 >50 >50 >50
29j C ll 0.37 0.3 >50 >50 200 >200
29k C12 0.8 12 >50 >50 50 >200
291 C14 >50 >50 >50 >200 >200 >200
BVDU 0.005 0.005 >200 >200 >200 >200
ACV 2.9 1 74 125 >200 >200
Table 2.1
a) effective concentration required to reduce virus plaque formation by 50%
b) minimal cytotoxic concentration
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
2.2.1 Terminal Halogen Substitution
Given the apparent necessity for a long alkyl chain, a new series retaining this moiety has 
been synthesised introducing a halogen in the co-position to probe SARs in this region. 
However, compounds 30a-d do not show any significant difference from the parent 
compound 29h.15,17
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40
ACV
(CH2),X
HO
29h X=H 
30a X=F 
30b X=CI 
30c X=Br 
30d X=I
HO'
EC50 fiM*
MCC
pMb
CC50
pMcOKA YS TK 07 TK' YS
29h H 0.02 0.02 >200 >200 >200 >200
30a F 0.022 0.014 >20 >20 >50 200
30b Cl 0.04 0.02 >20 >50 >200 200
30c Br 0.026 0.025 >50 50 >200 >50
30d I 0.061 0.034 >50 >50 >50 >200
ACV 2.9 1 74 125 >200 >200
Table 2.2
a) effective concentration required to reduce virus plaque formation by 50%
b) minimal cytotoxic concentration
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
2.2.2 Terminal Unsaturation
A range of medium to long chain co-alkenyl (31a-d) and co-alkynyl (32a-d) derivatives have 
been prepared, but although these compounds retain antiviral activity at non-toxic 
concentration, they are less active than the corresponding alkyl analogues.18 (data on the C8 
alkyl 29g are shown for reference).
32a n=3 
32b n=4 
32c n=5 
3 2d n=6
31a n=3 
31b n=4 
31c n=6 
31d n=8
HO
HO
Hcf
HO
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Alkenyl A nalogues 31e-d
MO]
1201
_  100-f
i *>
f  60
20 j __ mm
y  7 —r ~  &  1— V '
ACV 29g CS C6 CS CIO
Alkynyl Analogues 32a-d
ACV
EC50 jaM*
MCC
HMb
CC50
iMcOKA YS TIC 07 TIC YS
31a C5 >200 >200 >200 >200 >200 >200
31b C6 14 13 >200 >200 >200 >200
31c C8 0.27 0.06 >200 >50 >200 >200
31d CIO 0.09 0.1 >200 >200 >50 >200
32a C5 8 10 >200 >200 >200 >200
32b C6 25 33 >200 >200 >200 >200
32c C l 79 37 >200 >200 >200 >200
32d C8 5 4 >200 >200 >200 >200
29g 0.008 0.024 >50 >50 >50 >50
ACV 2.9 1 74 125 >200 >200
Table 23
a) effective concentration required to reduce vims plaque formation by 50%
b) minimal cytotoxic concentration
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
An important role for the activity is given by Iipophilicity. A calculated figure LogP of 
between 2.5-3.5 appears optimal. In fact comparing the octyl 29g to the corresponding alkenyl 
31c and alkynyl 32d, it is notable that the presence of an unsaturation has a very negative 
effect on the activity following the trend Alkyl »  Alkenyl > Alkynyl. Partly, this may be 
explained by the impact of the insaturation on log P.
LogP
EC50
OKA YS
29g 3.01 0.008 0.024
31c 2.52 0.27 0.06
32d 1.65 5 4
Table 2.4: LogP vs EC 5 0  ( 8  carbons chain)
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2.2.3 Alkylaryl analogues
In order to introduce a conformational constraint in the alkyl chain keeping a high logP, some 
p-alkylaryl compounds have been synthesised (33a-i). The introduction of a phenyl moiety 
between the base and the alkyl chain resulted in an increasing of potency up to subnanomolar 
concentration for the pentylphenyl 33f, which is 10,000 fold more active than ACV and ca. 20 
fold more active than BVDU with no cytotoxicity.19
HO
33a R=H 
33b R=CH3 
33c R=C2H5 
33d R=C3H7 
33e R=C4R, 
33r R=C5H,, 
33g R=QH13 
33h R=C^H15 
33i R=QH17
HO
nii «i
^  a ?  >
m o s (liM®
OKA YS TK 07 TK YS
MCC
jtMb
CC50
pMc
33a H 0.16 0.28 >200 >162 >20 >200
33b Cl 0.06 0.06 103 >200 >200 >200
33c C2 0.07 0.09 >50 >50 >20 123
33d C3 0.008 0.01 >50 >20 >50 188
33e C4 0.001 0.0008 >20 >20 >200 >200
33 f C5 0.0003 0.0001 >5 >5 >50 >200
33g C6 0.0008 0.0002 >5 >5 >20 18
33h C7 0.0074 0.0057 >5 >5 5 18
33 i C8 0.065 0.05 >20 >20 >20 >200
BVDU 0.005 0.005 >200 >200 >200 >200
ACV 2.9 1 74 125 >200 >200
Table 2.5
a) effective concentration required to reduce virus plaque formation by 50%
b) minimal cytotoxic concentration
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
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The further substitution of the phenyl ring constraining the side chain with an unsaturation on 
the a-position has been done, moving also the substituent in the various positions other than 
para (3 4a -l).
EC50
OKA YS TIC 07 TIC YS
MCC
\iMb
CC50
HMC
34a C3 12 - >80 - 80 102
Ortho 34b C4 33 - >80 - 400 103
34c C5 8.4 - >16 - 80 41
34d C3 13 58 >200 >200 >200 >200
Meta 34e C4 1.9 2.3 >20 >15 >20 68
3 4 f C5 1.1 1.3 >20 >20 >20 >200
34g C2 0.07 0.08 41 - 200 93
34h C3 0.003 0.003 >5 >5 >5 >200
Para
34i C4 0.0003 0.0006 >5 >5 >5 >200
34j C5 0.00011 0.0009 1.1 >5 >5 >200
34k C6 0.0024 0.0069 >16 - 80 >200
341 C7 0.0061 0.0084 >16 - 80 >200
3 3f 0.0003 0.0001 >5 >5 >50 >200
ACV 2.9 1 74 125 >200 >200
Table 2.6
a) effective concentration required to reduce virus plaque formation by 50%
b) minimal cytotoxic concentration
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
For this series is very clear that the substitution on the positions ortho and meta is not 
acceptable, while the para-subtitution follows the trend of the corresponding saturated series 
33. In fact the pentenyl 34j shows potency equal to the pentyl analogue 33f.
34a R= 0-CH3
34b R= o ^ H s
34c R= o-C3H7
34d R= m-CH3
34c R=: m-C2H5
34f R=: m-C3H7
34g R= p-H
34h R= p-CH3
34i R= P-C2H5
34j R= p-C3 H,
34k R= P-C4H0
341 R= P-C5H,,
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The introduction of a triple bond at the a-position, and a further constrain of the chain, lead to 
the alkynyl series 35a-d, which resulted in a loss of activity.20
K
, o ,
HO
ACV 33f CH3 CSH7 C7H11
m n o
MCC
\xMb
CC50
HMCOKA YS TK  07 TK  YS
35a C3 0.011 0.0071 >2 >2 >2 >200
35b C5 0.0029 0.0018 >1.4 >5 >5 >200
35c C6 0.003 0.005 35 - >50 200
35d C7 0.0043 0.0053 >20 - >20 >50
3 3f 0.0003 0.0001 >5 >5 >50 >200
ACV 2.9 1 74 125 >200 >200
Table 2.7
a) effective concentration required to reduce virus plaque formation by 50%
b) minimal cytotoxic concentration
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
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2.2.4 Haloaryl derivatives
A different moiety from alkyl chains on the phenyl ring has been introduced leading to halo­
aryl analogues (36a-I).
The SARs of this series is not very clear, but it is evident that the introduction of a halogen in 
the phenyl ring affects the antiviral activity suggesting that the decreasing order of the 
potency is ortho > para > meta.21
36a X= o-F 
36b X= o-CI 
36c X= o-Br 
36d X= m-F 
36c X= m-CI 
36f X= m-Br 
36g X= p-F 
36h X=p-Cl 
36i X= p-BrHO
HO
■  Ortho
■ Para
ACV
OKA
EC
YS
50 pMa 
TIC 07 TK YS MCCHMb
CC50
fiMc
Ortho
36a
36b
36c
F
Cl
Br
0.04
0.016
0.01
0.03
0.011
0.02
>20
>20
>5
>20
>5
>20
>5
>200
137
>200
36d F 1.5 2.4 >200 >200 >200 >200
Meta 36e Cl 2 1.8 >20 >20 >20 >200
36f Br 1.3 1.2 >5 >5 >5 36
36g F >50 >50 >50 >50 200 171
Para 36h Cl 0.09 0.08 >20 >20 >20 >200
36i Br 0.29 0.2 >5 >5 > 2 96
33a H 0.16 0.28 >200 162 >20 >200
ACV 2.9 1 74 125 >200 >200
Table 2.8
a) effective concentration required to reduce virus plaque formation by 50%
b) minimal cytotoxic concentration
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
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2.2.5 Base modification: pyrrolo and thiophene analogues
It was of interest to probe modifications in the base, synthesising two novel series bearing a 
nitrogen22 rather than oxygen in the furan ring (3 7 a -d )  and (3 8 a -d ).
HO
HO'
HN
HO
Pyrrolo analogues 37a-d
140
120
100
80
60
40
20
0
C8 CIO C12ACV 29g C6
OKA YS TK 07 TK YS
MCC
nMb
CC50
HMC
37a C6 >50 >50 >50 >50 >50 >50
37b C8 0.15 0.48 >20 >20 20 >50
37c CIO 0.12 0.15 >200 >200 >20 >200
37d C12 2.4 14.5 73 80 >200 >200
38a Me 6 8 >50 >20 >50 179
38b Et >5 >5 >5 >5 20 34
38c Pr >5 >5 >5 >5 20 47
36d Bu 7.1 7 >50 23 200 57
29g 0.008 0.024 >50 >50 >50 >50
ACV 2.9 1 74 125 >200 >200
Table 2.9
a) effective concentration required to reduce vims plaque formation by 50%
b) minimal cytotoxic concentration
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
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The replacement of the ring oxygen with nitrogen results in a loss of activity compared to the 
corresponding octyl derivatives 29g. Although the reasons of this poor activity are not very 
clear, one possible explanation is the change of a H-bond acceptor |OJ with a H-bond donator 
|N H |.15 The introduction of an alkyl chain on the nitrogen (38a-d) led to a further loss of 
activity (data not shown), clearly suggesting that replacement of the oxygen with nitrogen is 
not tolerated and the introduction of an alkyl chain on the nitrogen is not accepted.20 
The next change was the substitution of the oxygen with sulphur, synthesising a series bearing 
an alkyl23 (39a-f) and alkyl-phenyl moiety24 (40a-g).
The introduction of sulphur lead to variations in activity depending on the series, in fact it is 
interesting that that in the alkyl series 39 this modification is well tolerated leading in general 
to a slight improvement on the antiviral activity21 while in the alkyl-phenyl series 40 lead to a 
reduction in potency.22
39a R=C4H9 
39b R=C6H,3 
39c R= CgHj7 
39d R=C9H19 
R= C|oH2I 
R= C12H25
39c
39f
Alkyl 3 9 a -f
SOO
aM
40C
j  350 
$  30° 
-  250
200
ISO
100
C9 CIO C12C4 C6 C8ACV
Alkyl Aryl 40a-g
1500
r =c 2h 5
r =c 3h 7
r =c 4h9
r=C5H„
R=C6H,3
r =c 7h ,5
r =c «h 17
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EC50 fiM*
OKA YS TK' 07 TK' YS MCCnMb
CC50
^Mc
39a C4 0.16 0.15 >200 153 >100 >200
39b C6 0.14 0.14 >50 >50 125 >200
39c C8 0.002 0.005 >5 >5 20 53
39d C9 0.01 0.01 >20 >20 >20 >20
39e CIO 0.03 0.06 >5 >5 20 54
39f C12 0.2 0.3 >5 >5 12 49
40a C2 0.2 0.15 20 - >200 >200
40b C3 0.06 0.09 >16 - 80 >200
40c C4 0.02 0.028 >3.2 - 50 >200
40d C5 0.014 0.025 20 - 50 >200
40e C6 0.043 0.08 >50 - 200 >200
40f C7 0.18 0.27 >20 - 50 >200
40g C8 3.4 - >20 >20 >200
29g 0.008 0.024 >50 >50 >50 >50
33f 0.0003 0.0001 >5 >5 >50 >200
ACV 2.9 1 74 125 >200 >200
Table 2.10
a) effective concentration required to reduce virus plaque formation by 50%
b) minimal cytotoxic concentration
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
2.2.6 Sugar Modifications
So far, every modification that has been made was carried out on a 2’-deoxyribose 
nucleosides, without altering the sugar moiety. As the antiviral effect is strictly dependent on 
the kinase activity, a deoxyribose nucleoside is the ideal substrate for the enzyme and only 
small modifications are tolerated in order to have a good antiviral activity.15 Thus, different 
sugar-derivatives have been synthesised bearing different alkyl chains just to probe the SARs 
on the sugar moiety.
The introduction of a hydroxyl group in position 2’ results in a loss of activity (ara 41a and 
ribo 41b).15 The removing of the 3’-OH from the sugar led to a loss of activity for the d425 
(41c) and dd26 (41d), but the latter surprisingly gained a modest anti-HCMV activity.27 
The shifting of the 3’-OH to position 2’ (3’-dRibo 41e) is not well tolerated, as this compound 
is poorly active.28 The corresponding analogue of ACV has been synthesised (41f), showing 
that this compound retains antiviral activity comparable to ACV and that the presence of a 3’- 
OH is beneficial for activity.29 However, the 3’-OH has to be in Ribo position, as the dXylo 
derivative (41g) does not have an activity as good as the corresponding dRibo analogue 
(29g).30
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From this data, it seems that for a good activity, the dRibo is the best sugar accepted as a good 
substrate, confirming that even very small modifications are not very well tolerated.
R R R
HO
O. ,o.
HO HO
4U  R=C«H17 R,=R4=H R2=R3=OH 41c R= C 10H2, 4 lf  R= Q H p
41b R=CgHl7 R,=R,=H R3=R4=OH
4 1 d R =C8H ;7 R ,= R 2=R3=R4=H
41 e R=C«H17 R,=R2=R3=H R ^ H
41g R=C10H2i R,=OH R2=R3=R4=H
140
tag
100
40
20
ACV 29g dd 3dRibo Acyclo dXytoRibo d4
EC50 pMa
MCC
fiMb
CC50
pMcOKA YS TK' 07 TK YS
41a Ara 3.6 3.3 200 67 >200 >200
41b Ribo 23 21 >20 >20 50 >50
41c* d4 >50 >50 >50 >50 200 16
41 d dd 40 20 >200 >50 >200 >200
41e 3dRibo >50 - >200 - >50 >50
41 f Acyclo 11 - >16 - >80 >200
41g* DXylo 24 >20 >50 >50 >50 >22
29g dRibo 0.008 0.024 >50 >50 >50 >50
ACV 2.9 1 74 125 >200 >200
Table 2.11
a) effective concentration required to reduce virus plaque formation by 50%
b) minimal cytotoxic concentration
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
* CIO derivatives
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2.2.7 Modifications at 3’-position
42a R= CH3 
42b R= Q H j 
42c R=C3H7 
42d R= C4H„ 
42c R= Bn
HO
0>
\
R
Many anti-viral nucleosides have the requirement for a free 3’-hydroxyl function for 
biological activity, in contrast to compounds such as AZT, ddC, d4T that act as chain 
terminators. Thus, 3’-0-alkyl ethers have been prepared15,23 (42a-e), and the loss of activity 
compared to the parent analogue 29g supports the hypothesis that a free 3’-OH is needed for a 
good antiviral effect.
EC50 ftMa
OKA YS TK' 07 TK YS
MCC
fiMb
CC50
pMc
42a Me >200 >200 >200 >200 >200 >200
42b Et 100 93 >200 >50 >200 -
42c Pr 1.2 0.64 >20 8.8 >20 -
42d Bu 1.4 26 >50 >50 >200 >200
42e Bn >50 >50 >50 >20 >50 -
29g H 0.008 0.024 >50 >50 >50 >50
ACV 2.9 1 74 125 >200 >200
Table 2.12
a) effective concentration required to reduce virus plaque formation by 50%
b) minimal cytotoxic concentration
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
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2.2.8 Modifications at 5 ’-position
The mechanism of action of the BCNAs is still not fully understood, but it is clear the 
presence of a viral TK-mediated phosphorylation is needed. To further prove this theory, 
compounds that cannot be phosphorylated at the 5’-position have been synthesised (43a-d) 
resulting in a drastic loss of activity. This lack of activity can be seen as further evidence of a 
mechanism of anti-VZV action involving an obligate 5’-phosphorylation.31
R
43a R= C8H17 X= H 
43b R= C8Hi7 X= Cl 
43c R= PhC5HM X=H  
43d R= PhC«Hn X=CI
X
HO
EC5o HM*
MCC
nMb
CC50
pMcOKA YS TK* 07 TK' YS
43a H 14 - >3.2 - 80 120
43b Cl 15 - >200 - >200 >200
43c H >5 >5 >5 >5 20 95
43d Cl >5 - >5 - 20 >50
29g OH 0.008 0.024 >50 >50 >50 >50
33a OH 0.0003 0.0001 >5 >5 >50 >200
ACV 2.9 1 74 125 >200 >200
Table 2.13
a) effective concentration required to reduce virus plaque formation by 50%
b) minimal cytotoxic concentration
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
2.2.9 Enhancement of water solubility: Ether, Glycol and Pyridyl analogues
The alkyl side chain and resulting high logP of this class of compounds is a requirement for 
the activity, and this might be useful to cross cell membranes and for a topical formulation for 
the treatment of shingles. However, the range of logP for optimal activity is between 2.5 and 
3.5 implying very low water solubility. In order to overcome this problem for a possible oral 
formulation, the introduction of ether or glycol moiety (44a-g3233, 458-f34) would increase the 
water solubility due to the presence of oxygen atoms in an alkyl chain. In fact compounds 44
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and 45 are more water-soluble than the corresponding alkane, ca 100 fold for ethers and 1000 
fold for glycols,32 but this is accompanied by a considerable reduction of activity.3132
45a R= (CH2)20(CH2)6CH3
45b R= (CH^CKCH^sCHj
45c R= (CH2)40(CH2)4CH3
45d R= (CH2)50(CH2)3CH3
45c R= (CH2)2CKCH2)20(CH2)3CH3
45f R= (CH2)30 (CH2)20 (CH2)2CH3
HO
E t h e r s  4 4 a g
3500
3000
|  2500 
2  2000
1500
1000
an
0
ACV 33f He Et Pr Bu Pen
e c 50 HM8
MCC
fiMb
CC50
\xMcOKA YS TK 07 TK YS
44a C l 0.05 0.045 >50 >50 200 >200
44b C2 0.009 0.012 45 >50 >50 >200
44c C3 0.002 0.002 11 >50 >200 >200
44d C4 0.0015 0.0021 - - >200 >200
44e C5 0.001 0.001 3.2 >20 >20 >200
44f C6 0.0015 0.0014 >5 >20 >20 >200
44g C7 0.006 0.006 >50 >20 >20 >200
45a 2 5.9 8.1 >50 >50 200 >200
45b 3 17 22 >50 >50 200 >200
45c 4 0.5 0.75 >50 >50 >200 >200
45d 5 7.9 9.3 >50 >50 >200 >200
45e 2,2 >200 >200 >200 >200 >200 >200
45f 3,2 120 97 >200 >200 >200 >200
29g 0.008 0.024 >50 >50 >50 >50
33a 0.0003 0.0001 >5 >5 >50 >200
ACV 2.9 1 74 125 >200 >200
Table 2.14
a) effective concentration required to reduce virus plaque formation by 50%
b) minimal cytotoxic concentration
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
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For this reason, the substitution of the phenyl ring of the compound 33f with a pyridine ring 
has been performed, decreasing the lipophilicity of the molecule without producing any major 
modification on the lead compound. The logP of the compounds 46a-b is less than 33f, and 
their activity is so low that it clearly shows that the replacement of the phenyl ring with a 
pyridyl ring is extremely damaging for the activity.35
33f X = Y = CH 
46a X = N Y= CH 
46b X = CH Y= N
HO
HO
EC50 HM#
CLogP OKA YS TK' 07 TK' YS MCCHMb
CC50
pMc
46a 2.23 >80 - >80 - 400 >200
46b 2.02 0.1 - >50 - 80 >200
33f 3.52 0.0003 0.0001 >5 >5 >50 >200
ACV -2.42 2.9 1 74 125 >200 >200
Table 2.15
a) effective concentration required to reduce virus plaque formation by 50%
b) minimal cytotoxic concentration
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
2.2.10 Side Chain Modifications: branched chain derivatives
Taking into account that polar groups in the side chain decrease activity and that the presence 
of a phenyl ring results in a significant boost, the introduction of a lipophilic branched-chain 
has been useful for an investigation on the steric hindrance effect and conformational 
restriction keeping the logP in the range of optimal antiviral activity (47a-i). However, the
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Marco Migliore Chapter 2
introduction of this branching on the side chain results in a decreasing of activity showing that 
a non-branched alkane is one of the requirements for good activity.36
R
47a R= iPr 
47b R= tBu 
47c R= iBu 
47d R= iPen 
47c R= neoPen 
47f R= iHex 
47g R= neoHex 
47h R= cHex 
47i R=Ph
HO
3500 I r=i
3000
! " •  
?  1500
1000
"i-JH _________41=_ _ _ _
ECso pMa
OKA YS TK 07 TK YS
MCC
nMb
CC50
pMc
47a 'Pr 6.9 7.9 >20 >50 >50 >200
47b 'Bu >50 >20 >50 >50 >50 >200
Ale ’Bu 0.081 0.051 >200 >2 >200 >200
47d 'Pen 0.0022 0.0011 >50 >2 >50 >200
47e neoPen >80 - >80 - 400 180
47f 'Hex >80 - >80 - 400 200
47g "“ Hex 0 2 7 - >80 - >80 >200
47h cHex 0.8 2.8 >20 >20 >20 >200
471 Ph 0.031 0.032 >5 >5 >200 >200
33a 0.0003 0.0001 >5 >5 >50 >200
ACV 2.9 1 74 125 >200 >200
Table 2.16
a) effective concentration required to reduce virus plaque formation by 50%
b) minimal cytotoxic concentration
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
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2.2.11 Aryl Alkyl substitution
Another substitution is the shifting of the phenyl ring to the end of the alkyl chain. Despite 
compounds 4 8 a -g  being chemically isomeric with 3 3 b -h , there is a dramatic reduction of 
antiviral activity, proving that logP is not the only main requirement for being active.37,24 
It would thus appear that conjugation between the two aryl rings is essential for biological 
activity.
3500
ACV 33/
(CH2)n
EC50 pMa
n
OKA YS TK 07 TK' YS MCCpMb
CC50
p.Mc
48a 1 >20 >20 >20 >20 50 >100
48b 2 >50 >50 >50 >50 200 >200
48c 3 2 1.4 >200 >200 >200 >200
48d 4 28 26 >200 >200 >200 >200
48e 5 9.4 9.2 >20 >20 50 84
48f 6 0.1 0.15 >20 - 50 2.7
48g 7 0.01 0.022 200 - >200 <2
33a 0.0003 0.0001 >5 >5 >50 >200
ACV 2.9 1 74 125 >200 >200
Table 2.17
a) effective concentration required to reduce virus plaque formation by 50%
b) minima] cytotoxic concentration
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
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2.2.12 Difluorophenyl analogues
To further study the effect of substitution on the phenyl ring, a series of difluoro analogues 
have been synthesised (4 5 a -f) . It is clear that the presence of fluorine in position 3 of the 
phenyl ring reduces the activity regardless of the position of the second fluorine.38 For 
comparison the mono-fluorinated derivatives 3 6 a , 3 6 d  and 3 6 g  are included.
,-----/  f.
20.00
49a 23 
49b 2.4 
49c 23 
49d 2.6 
49c 3,4 
49f 33
15.00
10.00 
5.00 
o.oo
ACV H O-F
HO
HCf
EC50 pMa
OKA YS TK 07 TK YS MCC^Mb
CC50
jiMc
49a 2,3 >80 - >80 - 400 >200
49b 2,4 <0.13 - 184 - >200 >200
49c 2,5 <0.13 - >32 - 16 29
49d 2,6 0.54 - >200 - >200 >200
49e 3,4 >80 - >80 - 400 >200
49f 3,5 19 - >80 - 200 >200
36a 2 0.04 0.03 >20 - - >200
36d 3 1.5 2.4 >200 >200 >200 >200
36g 4 >50 >50 >50 >50 200 171
33a H 0.16 0.28 >200 >162 >20 >200
ACV 2.9 1 74 125 >200 >200
Table 2.18
a) effective concentration required to reduce virus plaque formation by 50%
b) minimal cytotoxic concentration
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
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2.2.13 6-Alkyl-5-Aryl derivatives
The presence of a phenyl group with an alkyl side chain is beneficial for the activity. Moving 
of the phenyl ring from position 6 to position 5 was interesting in order to obtain information 
on the steric demands at active site of the enzyme (49a-i). The biological data show that this 
kind of substitution is extremely damaging for the antiviral activity with a 1000 fold loss of
activity.39
HO
HO
c ,»h 21
50a R= H 
50b R= CH3
50c R=C2H5 
50d R= iC3H7 
50e R=COCH3 
50f R=CF3 
50s R= o a t 3 
50h R= NHCOCF-, 
50i R=NH2
i  0.40 |
OKA
e c 50 HM4
YS TK 07 TK' YS
MCC
jiMb
CC50
jaMc
50a H >5 >5 >5 >5 20 37
50b Me 9 9 >5 >5 >20 89
50c Et >20 >20 >20 >20 50 >200
50d ‘Pr >5 >5 >5 >5 20 >200
50e CH3CO 8 5 >50 >50 200 >200
50f c f 3 >20 >20 >20 20 50 >200
50g OMe 6.7 4.4 - >20 >20 >200
50h n h c o c f 3 >200 >50 >50 >50 >200 >200
50i n h 2 40 3.7 - 8.1 >50 67
ACV 2.9 1 74 125 >200 >200
Table 2.19
a) effective concentration required to reduce virus plaque formation by 50%
b) minimal cytotoxic concentration
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
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2.2.14 Summary of SARs
Fig 2.2 is the plot of LogP versus activity of all the series above described. From this graph it 
can be seen that all the compounds cover a wide range of LogP, but when inside the range of 
2.5-4.0 the activity is maximum suggesting that the optimal LogP for this kind of compounds 
is inside this window.
— Alkyl
 Terminal Halogen
Terminal Alkene 
■^— Terminal Alkyne
 Alkylaryl
AlkenylAryl
AlkynylAryl
 Pyrrolo
 N-Alkyl Pyrrolo
Alkyl T hlophene 
AlkylAryl Thlophene
 3 '-E thers
 AlkyloxyAryl
 A ry lA lky l
S ugars 
Branched 
■ 5-Aryl______________
-1.2 -0.2 0.8 1.8 2.8 3.8 4.8 5.8 6.8
S 3
Fig 22: LogP vs Activity
4
3
2
iBu
1 nHex
0 jin
•  IPr
IPr ■ Ac • MeAcydo
■ ■ Et1 dXyloRibo
tBo dd d4
3d Ribo nPen
NHCOCF]2
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2.3 Mechanism of action of BCNAs
Unlike the BCNAs, all other anti-VZV drugs known so far have been shown to have antiviral 
activity against other herpes-viruses as well. Recent pharmacological studies revealed that the 
BCNAs are recognised as substrates for phosphorylation by VZV-TK .4 0 However, in contrast 
to BVDU, HSV-1 and HSV-2 TK do not recognise the BCNAs as substrates for 
phosphorylation, and the BCNA-5’-monophosphate is not a substrate for the dTMP kinase 
activity of HSV-1 TK. Furthermore the BCNAs are not recognised substrates by the cellular 
TK, therefore, the unique recognition of the BCNAs by VZV TK, but not by HSV TK or any 
other cellular TK, forms the basis of the unique specificity of the BCNAs for VZV . 41 
Interestingly, when NDP kinase was added to a mixture containing BCNAs and VZV TK, no 
trace of BCNA-TP could be detected. 39 Although it cannot be excluded that the BCNA-DPs 
can be recognized by other NDP kinase isoenzymes or by other cellular enzymes, the 
mechanism of anti-VZV activity of the novel class of BCNAs may be entirely different from 
that of BVDU (being a inhibitor of viral DNA polymerase and incorporated into viral DNA 
when it is converted into BVDU-5’-triphosphate).
Pyrimidine nucleoside analogues are susceptible to hydrolysis to their free base by the 
pyrimidine nucleoside catabolic enzyme uridine phosphorylase (UPase) or thymidine 
phosphorylase (TPase). The free bases usually do not have any significant therapeutic 
activity. Thus, the UPase and TPase enzymes inactivate the antiviral pyrimidine nucleoside 
analogues and BVDU is a well-known example of an anti-herpes virus drug. The BCNAs 
were found to be resistant to the phosphorolytic cleavage by TPase, and thus are expected to 
be relatively stable in biological fluids as human plasma does not catabolise BCNAs to their 
free bases. 42 BVU and related compounds are known to be good inhibitors of human DPD , 43 
the catabolic enzyme responsible of degradation of natural pyrimidines and pyrimidine 
analogues such as 5-FU. Given the potential complication of co-administration of BVdU and 
5-FU, it is of clinical importance to know whether the free base of BCNAs can inhibits this 
enzyme. In contrast to BVU ( IC^ lOpM against human liver DPD), free BCNA bases are 
completely inactive in inhibiting DPD at 100-250 pM. In addition, plasma levels of 5-FU 
were not affected by free BCNA base. 41
43
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Chapter 3: Improvement of the properties of BCNAs
The extraordinary potency BCNAs exhibit against VZV had never been reported before, in 
fact this new class of anti-VZV agents is ca 300-fold that of ACV for the early lead with long 
alkyl side chains (C8-C10) and equipotent to BVDU1, and the profile becomes even more 
pronounced when the alkyl side chain is replaced by a p-alkylphenyl. 2
The most potent analogue of this family is the p-pentylphenyl derivative, which exhibited 
activity against VZV at subnanomolar concentrations, with no cytotoxicity observed at 
concentrations of 200 pM. Thus, pentylphenyl 33f shows an antiviral selectivity of over 
1,000,000 and is ca. 10,000 times more potent than acyclovir against VZV. BCNAs are 
completely specific for VZV, being inactive against other viruses. 1 2
3.1 Improvement of the chemistry to BCNAs
Many analogues have been synthesised in order to have a global view of SARs of this kind of 
compounds. 3 ,4 ,5 Furthermore the pharmacology of the BCNAs has been studied in order to 
understand the mechanism of action of this new class of anti-viral, which now is not 
completely clear. After a preliminary selection, several derivatives have been identified as 
possible clinical candidates, and a scale up production process was needed for the synthesis of 
these compounds, free from any column chromatography purification. The early synthesis of 
BCNAs is performed by a Pd-coupling of 5-iodo-2’-deoxyuridine with the appropriate 
alkyne, and then converted into the bicyclic system in the presence of copper iodide and a 
base6 ,7 (scheme 3.1).
R
Scheme 3.1: i) DMF, alkyne, Tetrakis Pd(PPh3)4, Cul, DIPEA. ii) MeOH, TEA, Cul.
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The work up of this reaction is quite long and tedious involving the use of large amount of 
solvents for low scale synthesis. Finally the overall yield of these reactions is usually less than 
25% after column chromatography followed by a trituration with an organic solvent.
Other synthetic routes have been reported in order to synthesise BCNAs, involving 
microwave catalysis to reduce the time of the Sonogashira cross-coupling8 and the use of 
silver nitrate as catalyst to cyclise the coupled compound at room temperature. 9 Although 
these methods give a good yield, the same work up and purification by column 
chromatography is needed to isolate the desired compound and in some cases protection of 
starting material and de-protection of the product are necessary in order to avoid the 
formation of side-products, adding two more steps in the synthetic route. In order to remove 
the chromatographic purification, a Pd-coupling of 5-iodo-2’-deoxyuridine with an alkyne 
under Sonogashira conditions has been performed, and then the coupled compound has been 
cyclised in the same pot, warming the mixture in the presence of a base. The most potent 
derivative pentylphenyl 33f has been used in this new synthetic route as a sample (scheme 
3.2).
HN
HO
HO
HN
HO
HO'
R=
HO
Scheme 3.2: i) DMF, 4-pentylethynylbenzene, Tetrakis Pd(PPh})4, Cul, DIPEA. ii) Cul, TEA, A.
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After solubilisation of IDU 1 in DMF, a catalytic amount of tetrakis Pd° was added and 
allowed to react before 3 eq. of 4-pentylphenylacetylene were added, followed by the addition 
of a catalytic amount of copper iodide and 2 eq. of diisopropylethylamine (DIPEA). Under 
these conditions the reaction does not show any by-product, in fact when leaving it overnight 
four spots were seen on TLC: excess of alkyne that did not react, triphenylphosphine from the 
decomposition of tetrakis, tetrakis and the coupled compound 51. The rate of the reaction can 
be increased by heating to 45 °C allowing the reaction to complete in less than one hour. 51 
was then converted to 33f by addition of a further catalytic amount of copper iodide and a 
large excess of triethylamine, heating at 80 °C for 2-6 hours. It was noticed that the purity of 
copper iodide regulated the rate of cyclisation, in fact impure copper led to a slower 
cyclisation, which in some cases lasted 24 hours, while a purer reagent led to complete 
cyclisation in less than two hours. The solvents were removed under high vacuum keeping the 
temperature under 50 °C and the residue was washed with DCM and the resulting precipitate 
was filtered to give 33f more than 99% pure by HPLC with yields in the range of 50%-85%. 
This synthesis can be applied to lg scale reactions up to 20g scale without any significant loss 
in yield and any column chromatography purification. External contract laboratories have 
now used this process more or less as here up to Kg scale.
3.2 Bioavailability
The high logP of these compounds helps the membrane permeation, but it may present a 
problem due to low water solubility, significantly reducing the bioavailability. In fact the 
solubility of 33f in water is ca. 0.9 mg/110 and 29g is just slightly more soluble. 11 A potential 
candidate could be found on the alkoxyphenyl series 44, in particular 44c represents a good 
compromise between solubility and activity. 11 These three compounds 33f, 29g and 44c have 
been successfully re-synthesised in high yield and purity over 99% on HPLC with the new 
synthetic route (fig. 3.1).
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C«H PhCsH
HO HO HO
Fig 3.1: potential BCNA derivatives for pre-clinical studies
Preliminary studies of rodent bioavailability on these compounds were performed by external 
laboratories, showing that 29g exhibits the best bioavailability with an estimated value less 
than 25%, followed by 33f with a value less than 15%. Instead the more water-soluble 44c 
shows a bioavailability value of 0% (table 3.1).
EC50
pMa
Solubility
mg/1
Bioavailability
%F
29g 0.008 1.9 <25
33f 0.0003 0.9 <15
44c 0.002 4.7 0
Tab 3.1: Solubility, Potency and Bioavailability data 
a) effective concentration required to reduce virus plaque 
formation by 50%
The poor bioavailability of 29g and 33f was somehow expected, due probably to the low 
water solubility of this kind of compounds. It was surprising that no trace of 44c was 
detected, assuming that a rapid metabolism converts 44c into a compound that is immediately 
eliminated.
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3.3 Biological Tracker: Isotope Dilution Assay (IDA)
The use of an external standard to measure bioavailability can lead to a significant error that 
in some cases can reach even 30%12. Therefore an internal standard would be more suitable 
for this kind of assay as the maximum error often is not more than 1%. The internal standard 
used in this kind of assay has to possess the same biological properties but different mass. An 
isotopic version of the target compound matches all the characteristics required. BCNA levels 
of 33f can be measured by this assay, the Isotope Dilution Assay (IDA), based on stable 
isotope dilution mass spectrometry. A known amount of a deuterated analogue of 33f is used 
as internal standard and added to the sample before sample processing. After analysis by 
HPLC and mass spectroscopy, the ratio of relative intensities of the signal of BCNA and its 
deuterated analog in the mass spectrum is used to determine the exact concentration of BCNA 
in the sample.
In order to synthesise this isotopic tracker, a stable deuterium-carbon bond has to be formed 
in order to obtain the target molecule with the requested features.
A first attempt was made treating 33f with ‘butyl lithium. Three equivalents were used in 
order to deprotonate the two hydroxyl groups and one carbon on the molecule.
Treatment of the reaction mixture with deutereted water should have led to the desired 
compound (scheme 3.3). When 33f was treated with ‘BuLi the TLC showed signs of 
decomposition of the starting material.
PhC5H „ri
N* Y  \  /
HO
H c f 33f
XJ>
X
PhC5H „
3- PhC5H,
DO
Scheme 3.3: i) pyridine, 'BuLi. ii) D20
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Another attempt was made coupling IDU with 4-pentylphenylacetylene under Sonogashira 
conditions (scheme 3.4). When the starting material was completely consumed the solvent 
was evaporated and the residue washed with cold DCM obtaining a precipitate that was 
identified as compound 51 but not fully characterised. Compound 51 was then dissolved in 
deuterated methanol (CH3 OD) in order to convert the exchangeable hydrogens with 
deuterium and then the solvent removed under high vacuum. This operation was repeated 
until no trace of OH and NH was present (checked by ‘H-NMR) to obtain compound 52 that 
was dissolved in a mixture CH3 OD and triethylamine (7:3) in the presence of catalytic amount 
of copper iodide under reflux to obtain compound 53, deuterated on position 5 of the base.
PhCcH
HN
HO
HO
HN
HO
HO
PhC5H
HO
HO
PhCsH
DN
DO
DO
Scheme 3.4: i) DMF, 4-pentylphenylacetylene, Tetrakis Pd(PPh3) 4, Cul, DIPEA. ii) CH3OD. Hi) CH3OD, TEA, 
Cul, A  iv) MeOH.
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The success of the reaction was verified by mass spectrometry, H-NMR, H-NMR and C- 
NMR. The mass spectrum of compound 3 3 f  presents a peak at 398 m/z, while the spectrum of 
53  shows a peak at 399 m/z. Evidence of deuteration can be seen in then 1 H-NMR. The 
spectrum of 3 3 f  presents a singlet at 7.20 ppm that represents the signal of H-5, the 
substitution of the hydrogen with deuterium results in the disappearance of this signal as 
shown in fig. 3.2.
ra m  ^ rj tPP™]
Fig. 3.2: red spectrum 33f, blue spectrum 53
Regarding the 13C-NMR, the signal of the carbon that bears the deuterium atom was so small 
that it was not possible to detect it clearly. The PENDANT spectrum of 5 3  showed a weak 
broad ‘up’ signal at 98.48 ppm, where in 3 3 f  shows a sharp intense ‘down’ signal at 98.65
ppm. This happens because deuterium increases the relaxing time of the carbon to which it is
11attached and the resulting effect is more dramatic than in quaternary or carbonyl carbons. 
Furthermore the chemical shift is slightly different (fig 3.3). This small difference in chemical 
shift is often observed in 19F-NMR of molecules containing chlorine or bromine atoms. 
Isotopes do not show any difference in their electronic environment within the Bom- 
Oppenheimer approximation, but they show different chemical shifts due to different 
vibrational levels. 14
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Fig 3.3: red spectrum 33f, blue spectrum 53
A further analysis to prove the deuteration was given by the 2 H-NMR experiment. The 
spectrum in fig 3.4 shows the presence of a peak at 7.20 ppm indicating the success of 
reaction. Usually 2 H-NMR experiments are run in fluorinated solvents as a lock signal, but in 
this case the spectrum has been acquired without lock in normal DMSO as the magnetic field 
was stable enough for the duration of the experiment.
f|
I
10 •  S 4 2 0 (ppm]
Fig 3.4: 2H-NMR o f 53
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3.4 Phosphate prodrug
Since the above mentioned ether analogue results were not satisfactory, the monophosphate of 
33f has been thought as a solution, as the presence of a charge should increase significantly 
the water solubility. This strategy has been used for fludarabine15, an anti-cancer nucleoside 
used against chronic lymphocytic leukaemia. This drug is administrated as a monophosphate 
salt, which is rapidly de-phosphorylated in human plasma and once it is inside the cell, it is 
converted into tri-phosphate inhibiting the ribonucleotide reductase and DNA-polymerase. 
Based on this strategy, the monophosphate analogue of 33f was synthesised following the 
Yoshikawa procedure obtaining the compound 54 as the tributylammonium salt (scheme 3.3). 
Compound 54 has been reported before, 16 but the replacement of ammonium bicarbonate with 
tetrabutylammonium bicarbonate resulted in an easier purification by column 
chromatography. As expected, compound 54 is >100 fold more water-soluble than parent 
drug 33f, but despite the solubility enhancement, the bioavailability did not show any 
significant improvement over 33f.
PhCsH | ! PhC5Hn
HO P O
OH
HO
HO
Scheme 3.3: i) PO(OEt)h PO C l3. ii) HNBu3H C 0 3, H20
In a previous work, 15 the triphosphate analogue of 33f was successfully synthesised. The 
conversion of 54 into 55 (scheme 3.4) led to the formation of a more polar fluorescent by­
product, and while 55 has been isolated and purified in moderate yield, the purification of this 
second fluorescent spot was difficult and it could not be possible to isolate it in pure form but 
it has been obtained in a mixture with the tri-phosphate 55. This mixture, called X, has been 
sent to test exhibiting a better inhibition against the viral DNA-polymerase then 55. In order 
to identify and isolate this X-compound, 55 was synthesised again reproducing the exact
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conditions reported, using 54 as starting material (scheme 3.4). Only 55 was detected, isolated
in pure form and fully characterised, matching with the data reported. 15
The identity of the putative more active inhibitor in the mixture is currently unclear.
PhC<H5 n  11
AI , 11, I I I ,  IV
PhCcH5 n  1 1
HCf 54 '  '  H tif  55
Scheme 3.4: i) DMF, CDI. ii) MeOH. iii) tributylammoniumpyrophosphate. iv) TBAB.
3.5 Ether analogues: enhanced solubility
It is known that the intrinsic lipophilicity of the lead compounds has a negative effect on the 
water solubility, affecting directly the bioavailability. The introduction of one or two atoms of 
oxygen in the alkyl chain has been reported, leading to the alkoxyphenyl series 44 11 ,17 and 
glycol series 45 . 18 The first one retains a good antiviral activity but it is rapidly metabolised in 
vivo as the best compound 44c was found to have bioavailability of ca 0%, while the second 
instead shows a dramatic loss of activity.
The modification of the alkoxyphenyl series 44 would be a good strategy in order to enhance 
the water solubility whilst keeping a high antiviral activity. The shifting of the oxygen 
through the side chain should retain the water solubility without affecting the antiviral activity 
converting the aromatic ether into an aliphatic ether, making it harder to metabolise.
A new series of arylalkyl ethers 56-61 has been synthesised, 10 keeping fixed the total length 
of the aliphatic chain at 8  atoms and moving the oxygen along it.
The synthesis involves the Pd-coupling of I DU with the corresponding acetylene under 
Sonogashira conditions and then cyclising the ethynyl analogue in the presence of 
triethylamine at 80 °C (scheme 3.5).
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HN
HO
HO
HN
HO
HO
56 n= 6 R=Me
57 n= 5 R=Et
58 n= 4 R=Pr
59 n=3 R=Bu
60 n=2 R=Pen
61 n=l R=Hex
HO
HO
Scheme 3.5: i) DMF, 4-ethynylalkylbenzene, Tetrakis Pd(PPh3) 4, Cul, DIPEA. ii) Cul, TEA,
The 4-ethynylalkylbenzene derivatives were not commercially available, and they had to be 
synthesised starting from the appropriate alcohol, according to scheme 3.6.
The alcohol was protected by acetylation of the hydroxyl group in the presence of a catalytic 
amount of concentrated sulphuric acid, in a solution of acetic acid at 100 °C. Then the 
aromatic ring was halogenated by reaction of iodine with sodium iodate. The crude of this 
reaction, after extraction, was treated with 1 0 % sodium methoxide in methanol in order to 
deprotect the acetyl group, leading to the iodophenyl alcohols 62-67 in high yield. Although 
this reaction shows some regioselectivity for the para position, ‘H-NMR showed traces of the
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ortho by-product (<10%). The separation of the two regioisomers by column chromatography 
was not achieved and the mixtures were used for the next step without any further 
purification. Compounds 62-67 were treated with sodium hydride and then coupled with the 
corresponding alkyl mesylate under reflux in THF to obtain the ethers 68-73. These iodo- 
ethers underwent a Pd-coupling with TMS-acetylene, and the elimination of TMS was 
performed in the presence of TBAF, yielding acetylenes 74-79.
OH
74 n=l R=Me
75 n=2 R=Et
76 n=3 R=Pr
77 n=4 R=Bu
78 n=5 R=Pen
79 n=6 R=Hex
62 n=l
63 n=2
64 n=3
65 n=4
66 n=5
67 n=6
68 n=l R=Me
69 n=2 R=Et
70 n=3 R=Pr
71 n=4 R=Bu
72 n=5 R=Pen
73 n=6 R=Hex
Si
Scheme 3.6: i) a. CH3COOH, H2S 0 4 b. I2, N a I0 3 c. MeONa, MeOH. ii) THF, NaH, Alkyl-mesylate, iii) CH3CN,
Tetrakis PdC l2, Cul, DIPEA. iv) TBAF.
3.6 Biological results and solubility studies
The synthesised ethers 56-61 were evaluated for their ability to inhibit the replication of VZV 
according to previously described methods. 19 Data are shown in table 3.1 for the activity of 
56-61 versus two strains of thymidine kinase-competent (TK+) VZV and also two strains of 
thymidine kinase deficent (TK') VZV with data also included for the reference anti-herpetics 
ACV 11 and 33f.
The main purpose for preparing this new series was to enhance the water solubility whilst 
retaining lipophilicity and antiviral potency. Water-solubility studies have been carried out on 
this series10 alongside parent pentylphenyl 33f (table 3.1).
Although these compounds retain full antiviral activity at non-toxic concentration, the 
introduction of an atom of oxygen in the alkyl chain did not achieve significant water
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solubility enhancement. Along this new series, only compound 56 exhibits water solubility 
greater than 33f, but the enhancement obtained is not significant.
In contrast to earlier reported ether and glycol series, where solubility enhancement were 
achieved to the detriment of activity, and aryloxy series, where bioavailability was close to 
0 %, this new series retains full antiviral activity with no significant improvement of water 
solubility.
EC'so pMa
R ClogP
Sol.
mg/1
VZVO KA VZV YS TK VZV 07 TK VZV YS
MCC
pMb
C C 5 0
pMc
5610 Me 2.78 2.13 0.001 0.0084 >20 >0.5 100 >50
5710 Et 2.64 1.01 - - - - - -
5810 Pr 2.64 0.74 0.0002 0.0005 >20 >20 20 >50
59 Bu 2.64 0.96 0.012 0.01 20 - 50 >200
6010 Pen 2.79 - - - - - - -
61 Hex 3.33 0.66 0.038 0.072 >100 >100 >100 >50
33f - 3.52 0.9 0.0003 0.0001 >5 >5 >20 >200
ACV - -2.42 250020 2.9 1 74 125 >200 >200
a) effective concentration required to reduce virus plaque formation by 50%
b) minimal cytotoxic concentration required to alter microscopically detectable cell morphology
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
Table 3.1
R
56 n= 6 R=Me
57 n= 5 R=Et
58 n= 4 R=Pr
59 n=3 R=Bu
60 n=2 R=Pen
61 n=l R=Hex
HO
HO
Fig 3.5 : Ether series
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Chapter 4: Substitution at the phenyl moiety
The investigation of the effect of halogen substitution on different sites of the aryl moiety of 
BCNAs has been reported before. The SARs of this series are not very clear, but it is evident 
that the introduction of a halogen in the phenyl ring affects the antiviral activity. Comparison 
of the different regioisomers reveals a marked dependence on the nature and position of the 
halogen for the anti-viral activity. In general the decreasing order of the potency is ortho > 
para > meta. 1 Although this series is less active against VZV than pentylphenyl 33f, the ortho 
derivatives 36a-c are more potent than the phenyl parent 33a (fig 4.1).
[■Ortho;
■  Meta
■ Para
Fig 4.1: Halophenyl derivatives
In view of these results, the ortho position has been further investigated in a previous study, 2 
showing that the introduction of polar and non-polar groups at this position of the phenyl 
moiety appears very damaging for the potency (table 4.1) and that the target enzyme does not 
tolerate such kind of substitutions. 2 The introduction of a very large substituent causes a 
significant reduction of biological activity as can be observed with isopropyl derivative 81, 
which is 30 time less potent than ethyl derivative 80.
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80 R= Et
81 R= ‘Pr
82 R= CF3
83 R= OMe
84 R= N02
HO
HO
Fig 4.2: Ortho derivatives
R
E C 5 0 pMa
C C 5 0
pMc
VZV OKA VZV YS TK VZV 07 TK VZV YS
MCC
pMb
80 Et 0.22 0.33 >200 - >200 >200
81 'Pr 6.7 - >80 - 400 165
82 c f 3 6.7 7.6 >80 - 400 >200
83 OMe 0.08 0.09 >200 - >200 >200
84 n o 2 4.8 - >16 - 80 88
33a H 0.16 0.28 >200 >162 >20 >200
ACV - 2.9 1 74 125 >200 >200
Table 4.1
a) effective concentration required to reduce virus plaque formation by 50%
b) minimal cytotoxic concentration required to alter microscopically detectable cell morphology
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
4.1 Synthesis of target molecules
In order to further probe and complete the SARs in this region of the molecule, the synthesis 
of a new series of BCNAs was planned, introducing the same kind of substituents in the meta 
and para position.
The standard procedure for the synthesis of target BCNAs was applied to the compounds 
where the acetylenes were commercially available, involving a Pd-catalysed coupling reaction 
between IDU (1) and the appropriate acetylene (scheme 4.1). Only for compound 85, the 
isolation of the intermediate was needed in order to cyclise it in dioxane in the presence of 1
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eq. of copper iodide and large excess of TEA under reflux as reported for the ortho 
derivatives. 2
o
HN
HO
HO
HO
HO
85 R
86 R
87 R
88 R
89 R
90 R=
91 R=
92 R=
93 R=
94 R=
= o-Me 
m-Me 
m-OMe 
m-CF3 
p-CF3 
m-N02 
p-N02
p-NHCOCF-,
m-NHCOF3
p-NH2
Schem e 4.1: i) DMF, Arylacetylene, Tetrakis Pd(PPh3)4, Cul, DIPEA. ii) a: TEA, Cul. b(85 only): Dioxane, Cul.
4.1.1 Nitro-Der ivatives
The acetylene required to synthesise the nitro derivatives 90 and 91 were not commercially 
available, therefore a new synthetic pathway was planned (scheme 4.2). IDU was coupled 
with trimethylsilyl acetylene under Sonogashira conditions to obtain 5-(trimethylsilyl- 
ethynyl)-2’-deoxyuridine 95, which was de-protected with methanolic ammonia to give EDU 
96 in 65% overall yield. In this reaction, the use of acetonitrile rather than DMF was found to 
be more convenient in terms of purification by column chromatography.
Schem e 4.2: i) ACN, TMS-acetylene, Tetrakis Pd(PPh3)4, Cul, DIPEA. ii) MeOH/NH3
The standard Pd-catalysed coupling was applied to EDU 96 (scheme 4.3), which was reacted 
with 3 eq. of p-iodonitrobenzene. At this stage the TLC showed the total conversion of 96
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into 97. The addition of TEA and further copper iodide under heating did not lead to the 
formation of 91, but the intermediate 97 was totally converted into the di-substituted 
derivative 98. Evidences for the formation of 98 were given by mass spectra, NMR and CHN, 
which are consistent with the proposed structure.
n o 2
n o 2
h n HN
HO HO HO
HO HO HOn o 2
n o 2
HO
HO' 98
Schem e 4.3: i) DMF, p-iodontrobenzene, Tetrakis Pd(PPh3)4, Cul, DIPEA. ii) Cul, TEA.
A second attempt was made, carrying out the same reaction using this time 3 eq. of EDU and 
1 eq. of p-iodonitrobenzene. This time compound 91 was obtained and no trace of 98 was 
observed. However, the purification of 91 represented a problematic job due to the presence 
of impurities with an r.f. similar to 91 and it was not possible to obtain it in pure form after 
two chromatographic columns. In view of this result, 4-ethynylnitrobenzene 99 and 3- 
ethynylnitrobenzene 1 0 0  were synthesised, coupling the corresponding iodonitrobenzenes 
with TMS-acetylene followed by deprotection with methanolic ammonia in high yield after
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purification by flash column chromatography (scheme 4.4). These acetylenes were used for 
the coupling with IDU 1 using the standard procedure.
NO,
Si
NO,
99 para 
100 meta
Schem e 4.4: : i) DMF, TMS-acetylene, Tetrakis Pd(PPh3)4, Cul, DIPEA. ii) MeOH/NH3
4.1.2 Amino derivatives
The synthesis of amino derivatives was previously attemped2 3  using different synthetic routes 
without reaching the target molecules. According to scheme 4.5, IDU 1 was totally converted 
into 101 when coupled with 4-ethynylaniline, but when the cyclisation was attempted, the 
TLC showed multiple spots and the most yellow fluorescent product was isolated and 
identified as a mixture of unknown compounds.3
n h 2
n h 2
HNHN
HOHOHO
1 HO' 101
Schem e 4.5: i) DMF, 4-ethynylaniline, Tetrakis Pd(PPh3)4, Cul, DIPEA. ii) Cul, TEA.
HOHO
The protection of the amino group with BOC was though to be a solution to prevent the 
formation of by-products. The elimination of the protecting group would have carried out 
after achieving the cyclisation of the nucleoside (scheme 4.6). The coupling of IDU with 4- 
ethynyl-BOC-aniline followed by cyclisation led to compound 102 without formation of any 
by-product. However the deprotection of the BOC in acidic conditions failed to give the target 
compound 94, resulting in a cleavage of the glycosidic bond and yielding compound 103.3
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Scheme 4.6: i) DMF, 4-ethynyl-BOC-aniline, Tetrakis Pd(PPh3)4, Cul, DIPEA. ii) Cul, TEA. Hi) TFA, i
An alternative synthetic pathway was tried, involving the reduction of the nitro grouj 
into an amino group using hydrazine in the presence of Pd on carbon at reflux4 (schen 
Unfortunately this reduction was found to be too aggressive and decomposition of ! 
non-fluorescent spots was observed on TLC.
n o 2 n h 2
h oHO
HO
Scheme 4.7: i) EtOH, N2H4, 5 %  Pd/C
HO
After the successful cyclisation reaction with a protected amino group 102, an alte 
protecting group has been sought in order to achieve the deprotection in milder com 
The trifluoroacetyl group represented a good solution as it can be easily removed ii
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conditions. According to scheme 4.8, ethynylanilines were reacted with trifluoroacetic 
anhydride, giving the protected acetylenes 104-106.
H,N NH
104 ortho
105 meta
106 para
Schem e 4.8: i) THF, trifluoroacetic anhydride
Compound 106 was then used for the coupling with IDU under standard conditions followed 
by cyclisation in order to obtain compound 92. Mild hydrolysis of the latter, in the presence of 
1 eq. of potassium carbonate in methanol, gave the desired compound 94 in high yield 
(scheme 4.9).
H N  COCFi
Schem e 4.9: i) DMF, 106, Tetrakis Pd(PPh3)4, Cul, DIPEA. ii) Cul, TEA. Hi) MeOH/K2CO.
The synthetic route used to prepare 94 was used also to synthesise the meta (107) and ortho 
(109) derivatives. Compound 93 has been obtained in 40% overall yield according scheme
4.10, but when the deprotection was attempted, compound 93 decomposed into non- 
fluorescent unidentified compounds. Another attempt of deprotection was made using 
methanolic ammonia obtaining the same kind of decomposition.
72
Marco Migliore Chapter 4
Schem e 4.10: i) DMF, 105, Tetrakis Pd(PPh3)4, Cul, DIPEA. ii) Cul, TEA. iii) Me0H/K2C03.
At the same time the synthesis of the ortho derivative 109 was tried following the scheme
4.11.
Schem e 4.11: i) DMF, 104, Tetrakis Pd(PPh3)4, Cul, DIPEA. ii) Cul, TEA. iii) Me0H/K2C03.
Coupling IDU with acetylene 104 led to clean formation of the coupled compound that would 
have been cyclised after addition of copper iodide and triethylamine to obtain 108. Although 
on TLC a fluorescent spot was observed, the cyclisisation did not form the expected furan 
ring, but it occurred via the amido group onto the carbon-carbon triple bond to generate an 
indolic system, removing at the same time the protecting group and obtaining compound 110 
(fig 4.3). Evidence of this cyclised by-product was given by !H-NMR, confirmed from the 
presence of two different NH signals over 11 ppm, one given by the pyrimidine ring and the 
other by the indole ring. Compound 110 is reported in the literature5 involving a 5 step
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synthesis starting from IDU. Herein one-pot synthesis of 110 has been reported starting from 
the same starting material.
HN
HO
h o n no
Fig 4.3: 5-(2-indolyl)-2’-deoxyuridine 110
4.2 Naphthyl derivatives
It was of interest to further examine the effects of extending the conjugation of the bicyclic 
furano system. The substitution of the pentyl chain of 33f with a phenyl moiety led to the 
biphenyl derivative 47i6 that was found to be less active but still active in the nM range (0.031 
pM). In order to further investigate this kind of substitution, a new series of BCNAs bearing a 
naphthyl moiety have been synthesised. The standard procedure was applied in order to 
synthesise compounds 111-113, coupling IDU with the corresponding naphthyl acetylenes 
(scheme 4.12).
R
HN
111 R= 1-naphthyl
112 R= 2-naphthyl
113 R= 6-methoxy-2-naphthyl
HOHO
HOHO
Schem e 4.12: i) DMF, arylacetylene, Tetrakis Pd(PPh3)4, Cul, DIPEA. ii) a: Cul, TEA. b(only 111): Acetone, 
TEA, AgN03.
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2-ethynylnaphthalene 114, needed for the synthesis of 112, was not commercially available, 
but it was easily synthesised starting from 2-bromonaphthalene in quantitative yield (scheme 
4.13).
114
Schem e 4.13: i) ACN, TMS-acetylene, Tetrakis Pd(PPh3)4, Cul, DIPEA. ii) TBAF.
While compound 112 and 113 were obtained in good yield, compound 111 presented some 
difficulties during the synthesis. Appling the standard condition to synthesise compound 111, 
it was observed the total conversion of IDU into compound 115 (scheme 4.14), but when 
copper iodide and TEA were added no reaction occurred, recovering compound 115 in almost 
quantitative yield after column chromatography. Synthesis of 111 was attempted in the past, 
without obtaining the target molecule due to many complications encountered carrying out the 
reaction and purification.6 Cyclisation of 115 was then performed in dioxane, as for ortho 
derivatives, heating at reflux in the presence of 1 eq. of copper iodide and a large excess of 
TEA, but after 24 hours the TLC did not show any trace of target compound. The reaction 
was then left under reflux for other 6 days, adding at regular intervals fresh copper iodide, 
after which TLC showed only a trace of a fluorescent spot that was quantified by HPLC 
resulting in less than 2% of the potential product. The most probable reason of the failed 
cyclisation is steric hindrance of the naphthyl ring.
The failure of the ring closure under standard conditions, led to use another method in order 
to complete the cyclisation. In the literature many methods are reported for this kind of 
cyclisation, but most of them are similar to one used so far. Agrofoglio reported a ring closure
• * 7that occurs at room temperature in the presence of silver nitrate. When compound 115 was 
reacted with silver nitrate at room temperature a fluorescent spot was observed after 24 hours, 
although most of the starting material was still present. After this promising result, compound 
115 was treated with silver nitrate and TEA in methanol at reflux (scheme 4.14). After 6 
hours compound 115 was completely converted into 111 without any formation of by­
products or decomposition.
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HNHN
HO HOHO
HO
Schem e 4.14: i) DMF, l-ethynylnaphthalene, Tetrakis Pd(PPh3)4, Cul, DIPEA. ii) Acetone, TEA, AgNO
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4.3 Biological results
The synthesised compound 85-94 and 111-113 were evaluated for their ability to inhibit the 
replication of VZV in cell culture. Table 4.2 contains data relating to two strains of thymidine 
kinase-competent (TIC) VZV and also two strains of thymidine kinase-deficient (TK ) VZV, 
with data also given for ACV, 33a (phenyl) and 33f (pentylphenyl) as reference compounds.
R OKA
EC50
YS
pMa 
TIC 07 TK YS
MCC
pMb
CC50
pMc
85 o-Me 0.12 0.09 >100 >100 >20 >50
86 m-Me 1.62 1.79 >100 >100 >20 >50
87 m-OMe 4.6 0.71 >100 >100 >50 >50
88 m-CF3 5.6 4.6 >100 >100 >50 >50
89 p-c f 3 2.7 2 87 >100 >50 >50
90 m -N02 >20 - >20 >20 100 8.4
91 p-N 02 2 - >4 >20 20 6.9
92 p-NHCOCF3 9 - >100 >100 >100 >50
93 m-NHCOCF3 - - - - - -
9 8 bis 5,6-p-N02 >20 - >20 - 100 >50
94 p-NH2 >20 - >100 - >100 >50
111 1-Naph - - - - - -
112 2-Naph >100 >100 >100 >100 >100 >50
113 MeO-Naph >20 - >20 - >100 >50
3 3 a H 0.16 0.28 >200 >162 >20 >200
33f p-Pentyl 0.0003 0.0001 >5 >5 >20 >200
ACV - 2.9 1 74 125 >200 >200
Table 4.2
a) effective concentration required to reduce virus plaque formation by 50%
b)minimal cytotoxic concentration required to alter microscopically detectable cell morphology
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
Compounds 85-94 were found to be less active than lead compound 33f, although they show 
an activity comparable to ACV and compound 33a. The SAR for this series is very complex, 
but in general the substitution in meta position always presents a negative effect on biological 
activity, while the para derivatives, as expected, are the most active followed by the ortho, 
suggesting that this position seems to be tolerated. Furthermore, the nature of the substitutent
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affects the potency. In fact non-polar electron-donating groups (Me and MeO) were found to 
be the most potent derivatives of this series, while introducing an electron-withdrawing group, 
such as N02 or CF3, the potency dramatically drops (fig 4.2).
Interesting to notice that the trifluoroacetamido derivatives 92, 93 and the amino derivative 
94, although they have electron-donating groups on the phenyl ring, were found to be less 
active than ACV.
■  Ortho
■ Meta
■ Para
ACV H Me OMe CF3 N 02 NHCOCF3 NH2
Fig 4.2 : Ortho-Meta-Para Derivatives
Regarding the naphthyl derivatives 112 and 113, the extension of the conjugation with the 
introduction a naphthyl ring is extremely damaging for the activity, as this compound can be 
said to be inactive. One possible explanation for the inactivity of these compounds could be 
given by steric hindrance due to the size of the naphthyl system, suggesting that some 
flexibility is required for antiviral activity.
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4.4 Conformational Studies
The difficulty to cyclise the ortho derivatives lead us to investigate the influence of a 
substitutent on the planarity of the phenyl ring respected to the bicyclo pyrimidine. First a 
molecular modelling study was carried out on compounds that bear a methyl group on the 
phenyl ring in position ortho 85, meta 86 and para 86, calculating the dihedral angle between 
the carbon in ortho to the phenyl and the C6 of the bicyclo (fig 4.3).
Using a computational stochastic search, it was calculated that dihedral angle of the para 
derivative 33b was 17°, the phenyl ring is almost co-planar to the bicyclo pyrimidine (fig 
4.4). In this compound there is an extensive conjugation between the bicyclo and phenyl.
Fig 4 3 : Dihedral angle calculated
Fig 4.4: Para 17°
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The meta derivative 86 was found be very similar to para derivative showing a rotation of 
18°(fig 4.5), in this case there is still an extensive conjugation.
Fig 4.5: Meta 18°
Regarding the ortho derivative 85, a massive rotation of the phenyl ring was predicted 
measuring a dihedral angle of 50°. This significant distortion should affect significantly the 
conjugation and electronic properties of the molecule (fig 4.6).
Fig 4.6: Ortho 50°
UV and fluorescence were carried out in order to support these predicted conformations.
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4.4.1 UV
With the rotation of the phenyl ring the conjugation between the bicyclo and phenyl decreases 
affecting consequently the UV spectra of the derivatives. In order to confirm this hypothesis, 
the UV spectra of 85, 86 and 33b were recorded at a fixed concentration of 95pM in MeOH.
«uc  Ortho
 Meta
Para
54-
0 .5 -
200 220 240 260 280 300 320 340 360 380 400 420 440 460 480 500
W avelenght X nm
Fig 4.7: UV spectrum of 8 5 ,8 6 ,33f
When the conjugation is perturbed the parameters that are affected are the wavelength X of 
the maximum of absorbance and the extinction coefficient £.8 These parameters for 
compounds 85, 86 and 33f are summarised on table 4.3.
Peak 1 (Log e0) Peak 2 (Log e0) Peak 3 (Log e„)
Ortho 338 (5.84) 268 (5.95) 206 (5.99)
Meta 349(6.18) 279 (6.24) 208 (6.30)
Para 352 (6.22) 281 (6.31) 209 (6.31)
Table 43
As predicted, the para and meta derivatives show the maximum conjugation, presenting the 
same electronic properties, even if there is a small difference that shows that the para 
derivative is more conjugated.
Regarding the ortho derivative, the maximum of absorbance is at shorter wavelengths, but the 
significant difference can be observed on extinction coefficient. In fact the absorbance is
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halved compared to the other two compounds giving a further prove that this compound 
presents a lesser conjugation.
4.4.2 Fluorescence
Given the intrinsic fluorescence of BCNAs, the spectra of the three derivatives were recorded. 
A “fluorescence excitation spectrum” is obtained by scanning the excitation monochromator 
at a fixed emission wavelength. Thus for each compound a 3pM solution in MeOH was 
scanned within the range of 190 nm to 650 nm at a fixed emission wavelength of 395 nm (fig 
4.8).
2 .5  n
 O rtho
 Meta
 Para
o 0.5 -
1 9 0  2 2 0  2 5 0  2 8 0  3 1 0  3 4 0  3 7 0  4 0 0  4 3 0  4 6 0  4 9 0  5 2 0  5 5 0  5 8 0  6 1 0  6 4 0
Excitation W avelength X nm
Fig 4.8 : Fluorescence excitation spectra
The fluorescence intensity is reported in arbitrary units, due to the need for calibration with a 
series of standards to obtain quantitative information. As fig 4.8 shows, the optimal excitation 
wavelength is slightly different for the 3 derivatives. As expected the order found is para (359 
nm), meta (357 nm) and ortho (355 nm), which are close to the values of 366 nm of the UV 
detecting lamp.
When the emission monochromator is scanned at a fixed excitation wavelength, an 
“emission” or “fluorescence” spectrum is recorded. Thus, the same solutions were scanned at 
the fixed excitation wavelength of 359 nm for para, 357 nm for meta and 355 nm for ortho 
(fig 4.9).
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£ 5tflcv 4  Ortho
 Meta
 Para
u.
1 9 0  2 2 0  2 5 0  2 8 0  3 1 0  3 4 0  3 7 0  4 0 0  4 3 0  4 6 0  4 9 0  5 2 0  5 5 0  5 8 0  6 1 0  6 4 0
Emission W avelength X nm
Fig 4.9 : Fluorescence emission spectra
The change observed is not as evident as for the UV, the emission spectra for each compound 
are very similar, suggesting that the rotation of the phenyl does not affect in significant way 
the fluorescence of the compounds.
Wavelength nm Intensity 
Ortho 424 4.09
Meta 426 4.97
Para 427 5.72
Table 4.4
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Chapter 5: Protide Approach on BCNAs
5.1 Protide approach: background
Nucleoside analogues have been a subject of numerous studies as antiviral and anticancer 
agents.1 In order to show a biological activity they must be converted into nucleotides by viral 
and/or cellular kinases. This activation process follows the pathway utilized by natural 
nucleosides. In the first step nucleosides are phosphorylated to give monophosphates. The 
latter are converted to diphosphates by the action of nucleotide kinases. In the next step, they 
are further phosphorylated to triphosphates with the aid of NDP kinases. Triphosphates of 
nucleoside analogues then compete with their natural counterparts for DNA or RNA 
polymerases. They can either act as terminators of the growing polynucleotide chain or get 
incorporated into the chain thus modifying the properties of the nucleic acid.
o o o
nucleoside II nucleotide || ||
Nuc OH -----------------► Nuc-----O ------P ---- OH ------------------ ► Nuc---O ----- P ------O ----- P -----OH
kinase | kinase | |
OH OH OH
nucleotide
diphosphate
kinase
o o o
DNA or RNA ^ , „Polymerase N n c------------Q ---P ------O ----- P ------O ---- P  OH
OH OH OH
S ch em e 5.1: m echanism  o f  activation o f  nucleosides.
Selectivity of the antiviral effect is then achieved by a differential inhibition of viral 
incorporation and cellular polymerases by the corresponding nucleoside triphosphates. It is 
then clear that intracellular introduction of nucleoside analogues as phosphorylated 
metabolites could avoid difficulties associated with the use of non-phosphorylated analogues 
and even activate inactive or less active compounds. Such an approach obviates the crucial 
first phosphorylation step and delivers the monophosphate into the cells.2 However, 
nucleotides are highly polar charged species which are unable to cross the cellular membrane 
and moreover the ready degradation with phosphatases makes the use of free nucleotide
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analogues not useful. Therefore, much of the recent efforts were focussed on finding suitable 
prodrugs of monophosphates of nucleoside analogues (pronucleotides).
It is clear that necessary requirements for achieving a successful pronucleotides are:
1) resistance to degradation by phosphatases
2) capability of penetrating the cellular membrane
3) delivery of the nucleotide analogues inside the cell.
Three groups of pronucleotide approaches, each with a different mechanism of action, are 
emerging as promising platforms against HIV.
The SATE pronucleotides elaborated by Perigaud,3 the Phosphoramidates derived from 
amino acids introduced by McGuigan4 and, finally, CycloSal designed by Meier5 (fig 5.1). In 
the case of amino acid phosphoramidates, the studies were largely focussed on phenyl 
phosphoralaninates of AZT and d4T. Extensive structure-activity relationship studies4,6,7’8’9 
indicated that a combination of alanine ester and phenyl phosphate provides for the most 
effective agents. Consequently, the Phosphoramidate technology was used by several groups 
of investigators as antiviral pronucleotides10,11,12,13,14,15 and potential antitumor agents.16,17
Nuc O
5.2 SATE-Nucleotides
The SATE approach is based on the enzymatic activity of carboxyesterases, used to trigger 
the nucleotide delivery. The esterase cleaves a thioester moiety of 116 to yield a carboxylic 
acid as well as the thioethyl phosphate diester 117 which undergoes a spontaneous 
fragmentation to episulphide and the phosphate monoester 118. Then a phosphodiesterases 
cleaves the other ester to yield the free nucleotide 119 (scheme 5.1).18 This approach was
o
o
s
R
O
O
O
S '  R
SATE
Nuc O P  NH O -----R
I
° \
Ar
Phosphoramidate
F ig 5.1 : Pronucleotides approaches
Nuc O  P
cycloSal
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successfully applied to d4T19 and AZT20 in order to by-pass thymidine kinase and ddA to by­
pass adenosine deaminase.20
o o
o.
R
O  P  ONuc
/—7 i
Carboxyesterase
O
R
/
O  P  ONuc
y  i,o
H S '  117
O '  R 
116
o
°  O ----- P ------ONuc
|| Phosphodiesterase /  |
H O  P  ONuc ---------------------  O /-------- '
i v rOH y  b
OH
118
119 R
Schem e 5.2: Activation o f  SATE pronucleotide
5.3 CycloSal Nucleotide
The CycloSal nucleotide approach does not rely on enzymatic activation, but the release of 
the free nucleoside and the carrier is achieved by a controlled, chemically induced hydrolysis 
involving a successive coupled cleavage of the phenyl and benzyl esters of the 
phosphotriester.21 The rationale of this prodrug is based on the different hydrolysis properties 
of the phenyl and benzyl phosphate esters. As the negative charge arising from the cleavage 
of the phenolic moiety can be delocalised on the aromatic ring, the phenyl ester is the most 
labile and then selectively cleaved to 2-hydroxybenzylphosphodiester 120. In contrast, the 
alternative cleavage of the ester to 2-hydroxymethylphenyl phosphodiester 121 is 
unfavourable. As consequence of the first step, the remaining masking group (P-Oeenzyi) is 
activated by the strong electron-donating hydroxy group in the ortho position, resulting in a 
spontaneous cleavage of the di-ester to yield the free nucleotide and salicyl alcohol. This 
approach was successfully applied to d4T,22,23 acyclovir,24 BVdU25,26 and ddA.27 As for 
SATE, in the case of d4T the CycloSal prodrug was designed to by-pass thymidine kinase, 
while the ddA analogue was used to by-pass adenosine deaminase.
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O  P  ONuc
ONuc
M inor
O  P  ONuc
121
OH
CH2OH
+  H O  P  ONuc
Schem e 5.3: Activation o f  CycloSal pronucleotide
5.4 Aryl Phosphoramidate Approach
Aryl phosphoramidates are a class of membrane soluble prodrugs characterised by a 
phosphate moiety linked to a nucleoside, a phenyl group and to an amino acid ester. This
9Q i n  i t
approach was applied to different nucleoside analogues (ddU, AZT, d4T, ddA, 
PMPA,32 PMEA,32 BVdU,33 etc.). The mechanism of activation of phosphoramidate 
analogues was the object of extensive studies. In the bioactivation of phosphoramidate 
prodrug, the first step is the hydrolysis of the carboxylic ester function of the amino acid 
moiety by an enzyme with esterase activity to yield the derivative 122. This enzyme is 
thought to belong to class of proteases, such as catepsin B and proteinase K.34,35 The cleavage 
of the ester moiety is followed by an intramolecular nucleophilic attack of the phosphorus by 
the carboxylate, with spontaneous elimination of phenol forming a five-membered cyclic 
anhydride 123. Immediate hydrolysis of 123 gives the aminoacyl phosphoramidate diester 
124, which was described as an important depot form for the free nucleotide.36 Compound 
124 then undergoes the cleavage of the P-N bond mediated by a phosphoramidase or 
phosphatase to delivery the free nucleotide.
88
o.
HO
R,
O
124 OH
Phophoramidase
or
Phosphatase
NMP
Phenol
|| Spontaneous
H N  P  ONuc
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Scheme 5.4: Activation o f Phosphoramidate pronucleotide
In order to study the SARs o f  phosphoramidate analogues, many compound 
synthesised modifying the different components that build the prodrug.
Ester moiety: modifying this part o f the molecule the activation o f the cascade o f  ev< 
be modulated in relation to the activity o f the esterase.
Aryl moiety: the introduction o f electron-withdrawing groups can be used to enha 
leaving group ability o f the aryl moiety, increasing the formation o f the key ami 
intermediate. Instead, electron-donating groups decrease the rate o f formation < 
intermediate.
Amino Acid: introduction o f different amino acids has a different effect on both the < 
and the phosphoramidase activity, affecting the rate o f cleavage o f the 
phosphoramidate and the rate o f the subsequent cleavage to monophosphate.
As a result o f these modifications, it was observed that the introduction o f an a-am i
*2 H
ester is essential for biological activity and that replacem ent with an alkyl amine or f 
acids resulted in a complete lack o f activity.8 Among the natural amino acids, L-alan 
found to be most effective, while L-valine resulted in extremely poor activity. Furtl
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improve the biological properties. Biochemical studies pointed out that the BCNAs, 
being efficiently phosphorylated by VZV-TK, are not good substrates for cellular kin 
well as for HSV-1 TK. This observation is taken as explanation o f the extrao 
specificity o f this class o f compounds as anti-VZV agents. Due to their extremely s< 
mechanism o f activation, these analogues rely only on activation by the viral TK f  
biological activity and failing that they would become inactive.
Moreover, it was expected that the phosphoramidate approach could convert the analo; 
into an active compound against other viruses that are not able to phosphorylate E 
Furthermore, it was o f interest to observe if  the extraordinary potency o f  BCNAs was i 
also in infected cells unable to express VZV-TK (TK‘), where normally BCNAs wen 
to be inactive.
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thionyl chloride easily afforded the corresponding ester salts in quantitative yield.
h 3n .
Cl 
h A
a R = Me 
b R = Et 
c R = nPr 
d R = iPr 
e R = lBu 
f R = Bn
O
PhO P Cl
I
.NH ™
125a-f
O
PhO P
NH
HO
126a-f
Scheme 5.5: i) ROHSOCl2. ii) DCM, PhOPOCl2, TEA. iii) Pyr, 33f  NMI.
The commercially available phenyl dichlorophosphate was reacted with L-alanine est 
at low temperature and in the presence o f TEA to give the phenyl(L-alaninyl 
phosphorochloridates (125a-f), which were used in the final step after purification by < 
chromatography. The phosphorochloridates could be used also as a crude, witho 
column chromatography, but it was observed that the purification process was found 1 
an important enhancement during the coupling stage, improving significantly the yield.
T 1The P-NM R spectra o f phosphorochloridates 125a-f showed the presence o f two sig 
showed in table 5.1. This is due to the lack o f stereoselectivity o f this reaction that c< 
the achiral phosphorus o f the substrate into a chiral centre, giving a diasteromeric mixti 
ratio 1:1.
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125f Bn 68% 7.97, 7.60
Table 5.1: Phenyl phosphorochloridates
The final coupling between 33f and the target phosphorochloridates was performed ao 
to Van Boom procedure41 in the presence o f  1 -methylimidazole (NMI), which a 
coupling reagent. Due to the chirality o f  the phosphorus centre, the final phosphorai 
126a-f were prepared as mixture o f  two diasteroisomers in a ratio 1:1. No separator 
two diateroisomers was performed.
In the case o f the methyl, n-propyl and i-propyl derivatives, the 3 ’,5’-diphosphor; 
derivatives 126m-o were isolated in consistent yield to allow the characterisati 
biological evaluation. This side reaction occurred because 4 eq. o f phosphorochlorida 
reacted with 33f as the usage o f  less amount resulted in a poor reactivity o f the substral
c m
126m R = Me 
126n R = nPr 
126o R = 'Pr
PhO P O
NH
0 = P  NHR
OPh
Fig 5.2: 3 \5 ’-diphosphoramidates
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The low yield of the coupling reaction with the phosphorochloridates is due to an extensive 
purification process, which involved repeated column chromatographies and usage of 
preparative TLC.
Compound R Yield % J1P-NMR 6
126a Me 12% 4.41,4.17
126b Et 6% 4.45,4.36
126c nPr 11% 4.61,4.43
126d 'Pr 15% 4.49, 4.43
126c lBu 17% 4.59, 4.52
126f Bn 24% 4.22,3.49
Table 5.2: Phenyloxy phosphoramidates
5.7 Amino Acid variations
In order to identify any structure activity relationships and improve the biological activity, 
other derivatives containing modifications to the amino acid moiety were prepared. In fact, 
the nature of the amino acid group seemed from the previous SARs to be of fundamental 
importance for the biological activity of phosphoramidates. A different amino acid core 
would modulate the kinetics of the esterase- and phosphoramidase- type enzyme, leading to 
different biological results.
In order to understand the role of the amino acid, the natural amino acid phenylalanine (Phe) 
and the unnatural amino acid dimethylglycine (DMG) were employed as methyl, ethyl and 
benzyl esters.
The procedure used to prepare compounds 126g-l was based on the same chemistry 
previously described (scheme 5.6). The amino acid ester salts were commercially available or 
readily prepared by reaction of the appropriate alcohol with either thionyl chloride or tosylic 
acid in toluene using Dean-Stark apparatus.42
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HiN,
g R = Me Rj=R2=Me 
h R = Et R,=R2=Me 
i R = Bn R,=R2=Me 
j R = Me R,=Bn R2=H 
k R = Et R,=Bn R2=H 
1 R = Bn R,=Bn R2=H
Cell5"  11
HO
Schem e 5.6: i) a.ROH, SOCl2. b. Toluene, TosOH, ROH. ii) DCM, PhOPOCl2, TEA. Hi) Pyr, 33/ NMI.
Compound R Amino Acid Yield (%) J1P-NMR 6
125g Me DMG 54% 6.97
125h Et DMG 45% 7.05
125i Bn DMG 11% 6.98
125j Me Phe 63% 9.43, 9.25
125k Et Phe 58% 9.36, 9.26
1251 Bn Phe 46% 9.10, 9.07
Table 5.3
Phenyl dichlorophosphate was coupled to corresponding amino acid ester salts under standard 
conditions to give the phosphorochloridate 125g-l. As for the L-alanine analogues, also 
compounds 125g-l were purified by column chromatography in order to improved to yield on 
the final step. Compounds 125g-i were obtained as enantiomeric mixture given the presence 
of only one signal on 31P-NMR. Compounds 125j-i were instead obtained as mixture of two 
diasteroisomers in a ratio 1:1.
The coupling of the synthesised phosphorochloridates with 33f was performed as previously 
described obtaining the target phosphoramidates 126g-l. Also in this case the 
diphosphoramidate adduct was detected, but this time it was not possible to isolate it in 
consistent yield.
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Compound R Amino Acid Yield % 31P-NMR 6
126g Me DMG 22% 3.01,2.93
126h Et DMG 19% 3.01,2.87
126i Bn DMG 15% 4.61,4.43
126j Me Phe 12% 4.49, 4.43
126k Et Phe 13% 4.59, 4.52
1261 Bn Phe 17% 4.22, 3.49
Table 5.4: Phenyl Phosphoramidates amino acid variation
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5.8 Biological evaluation
The synthesised compound 126a-l were evaluated for their ability to inhibit the replication of 
VZV in tissue culture. Table 5.5 contains data relating to two strains of thymidine kinase- 
competent (TK+) VZV and also two strains of thymidine kinase-deficient (TK') VZV, with 
data also given for ACV and 33f as reference compounds.
Amino Acid Ester LogP OKA
e c 50
YS
pM a 
TK 07 TK YS
MCC
pM b
CC50
pM c
126a Ala Me 5.53 0.031 0.024 >16 - 80 41.5
126b Ala Et 6.06 0.010 0.009 >16 - 80 21
126c Ala nPr 6.59 0.0066 0.0046 >3.2 - 16 9
126d Ala 'Pr 6.37 0.029 0.014 >3.2 - 16 9.3
126e Ala *Bu 6.76 0.473 0.485 >3.2 - 16 8.6
126f Ala Bn 7.24 0.0067 0.0072 >3.2 - 80 34
126g DMG Me 5.84 0.100 0.230 15 - >20 >50
126h DMG Et 6.37 0.036 0.045 >4 - >4 27
126i DMG Bn 7.55 0.010 0.024 >4 - >4 26
126j Phe Me 6.95 0.015 0.032 >4 - 20 24
126k Phe Et 7.47 0.016 0.036 >4 - 20 12
1261 Phe Bn 8.66 0.010 0.020 >4 - 20 20
126m* Ala Me 7.30 0.43 - >100 - >100 >100
126n* Ala nPr 9.42 0.040 0.030 >40 - >40 >20
126o* Ala 'Pr 8.98 0.180 0.118 >40 - >40 >50
ACV - - -2.42 2.9 1 74 125 >200 >200
33f - - 3.52 0.0003 0.0001 >5 >5 >50 >200
Table 5.5: Biological Data. *Diphosphoramidate derivatives
a) effective concentration required to reduce virus plaque formation by 50%
b) minimal cytotoxic concentration
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
Although the synthesised phosphoramidates did not show any enhancement of the activity of 
the parent nucleoside 33f, they still retain a good potency, being in some cases over 400 fold 
more active than ACV. This reduction of activity is probably due to the fact that the 
phosphorylation of 33f by VZV-TK is much more efficient than the activation of the prodrug.
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For VZV-TK competent cell lines (OKA and YS), lipophilicity seems to play an important 
role for the biological activity of phosphoramidates: the activity of these compounds 
increased when the chain of the ester was extended, increasing consequently the LogP, 
reaching the maximum with the n-propyl ester 126c and the benzyl ester 126f. However, the 
lipophilicity is not the only factor that affects the biological activity of this class of 
compounds, in fact the introduction of a branched ester such as i-propyl, lead to a significant 
reduction of activity suggesting that the enzyme responsible for the activation of the prodrug 
prefers primary esters. This hypothesis is supported by the fact that the introduction of a very 
bulky ester like the t-butyl is extremely damaging for the activity if compared to the other 
phosphoramidates.
Fig 5.2: Alanine Phosphoramidates
The replacement of L-alanine with the unnatural amino acid dimethylglycine showed that the 
antiviral activity follows the same trend seen for the previous series, even though it is clear 
that this amino acid slightly reduces the biological results.
■  OKA BYS
100
90
8 0
5 0
4 0
S 3 -
MeACV Bn
Fig 5.3: dimethylglycine Phosphoramidates
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The introduction of an amino acid such as phenylalanine raised significantly the lipophilicity 
of the phosphoramidates and it seems that the activity of such derivatives does not show any 
dependence on LogP.
■  OKA S Y S
100 | 
90
80
60;
40
20 I 
10
ACV Me Bn
Fig 5.4: Phenylalanine Phosphoramidates
Regarding the VZV-TK deficient cell line, all phosphoramidates were found active at 
concentrations greater than 3pM. This dramatic loss of activity is probably due to the fact that 
this cell line does not express VZV-TK and then incapable to phosphorylate BCNA-MP to 
diphosphate. This suggests that the VZV-TK plays a fundamental role for activation of 
BCNA, and that this important enzyme for the activation of this class of compounds performs 
the second phosphoryation, or that BCNA protides function as BCNA prodrugs, not of NMP 
and thus require VZV-TK for the first phosphorylation.
This series was also tested against HCMV, HSV-1, HSV-2, HIV, but no antiviral effect was 
observed below 20pM for any of the viruses considered.
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5.9 3’-Phosphoramidates
The diphosphoramidates 126m-o, isolated as by-products, were tested and found to be active 
below pM concentrations against VZV. This interesting result lead us to think that the 
phosphoramidates in 3’ position of BCNA could show some activity, and thus a few 
derivatives were synthesised according to scheme 5.6. In order to achieve a 3’ selectivity, the 
position 5’ of the sugar was protected with dimethoxytrityl group (DMT). Then the tritylated 
BCNA 127 was reacted with the corresponding phosphorochloridate under standard 
conditions to obtain the target 3’-phosphoramidate derivatives 128. The use of DMT was 
found very useful because it was instantaneously removed after acid extraction in order to 
remove the NMI, circumventing the deprotection step.
CcH
128a R = Me X = Me 
128b R = Me X = Et 
128f R = Me X = Bn 
128j R = Bn X = Me 
128k R = Bn X = Et
HOHO
HO* 33f
I
PhO--------------P NH O
5 H
R O----X
Scheme 5.7: i) Pyr, DMT-Cl. ii) THF, 1 2 5 a ,b J J A  NMI. Hi) D O W EXH +
As table 5.6 shows, the general yield of this new series of phosphoramidates is higher then the 
previous one. For these analogues no extensive purification was needed as the compound was 
easily obtained with just one flash column chromatography. Also in this case the 3’-
phosphoramidates synthesised showed two peaks by 31P-NMR, due to the presence of two
diasteroisomeric compounds in a ratio 1:1 and no separation was performed.
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Compound Ester Amino Acid Yield (%) J1P-NMR 6
128a Me Ala 25% 3.14,2.21
128b Et Ala 32% 3.13,2.05
128f Bn Ala 56% 3.00, 1.92
128j Me Phe 52% 3.19,2.49
128k Et Phe 58% 3.23,2.46
Table 5.6: 3 ’-Phosphoramidate
5.10 Biological Evaluation
The synthesised compound 128a,b,f,j,k were evaluated for their ability to inhibit the 
replication of VZV in tissue culture. Table 5.7 contains data relating to two strains of 
thymidine kinase-competent (TK+) VZV and also two strains of thymidine kinase-deficient 
(TK') VZV, with data also given for ACV, BVdU and 33f as reference compounds.
ECso p M a
Amino Acid Ester LogP OKA YS TK 07 TK YS
MCC
pM b
CC50
pIVF
128a Ala Me 4.64 0.011 0.0094 >20 - >5 >50
128b Ala Et 5.17 0.015 - >100 - - -
128f Ala Bn 6.35 0.005 0.0059 >20 - >20 >50
128j Phe Me 5.81 0.0041 0.0050 >20 - >20 >50
128k Phe Et 6.34 <0.009* <0.032* >20 - >20 >50
ACV - - -2.42 2.9 1 74 125 >200 >200
BVdU - - -0.82 0.005 0.005 - - >200 >200
33f - - 3.52 0.0003 0.0001 >5 >5 >50 >200
Table 5.7: Biological Data. * Preliminary data, to be repeated
As shown in table 5.7, the 3’-phosphoramidates were found to have an activity comparable to 
5’-phosphoramidates. This result is not easy to interpret, a possible explanation is that the 
phosphoramidate is converted to the phosphate inside the cell and then it is hydrolysed to 
parent drug, which is phosphorylated again by the VZV-TK. As for the previous series, in 
VZV-TK deficient cell line this series also lacks of biological activity, suggesting again the 
viral TK is fundamental for the biological activity. Also this series was tested against HCMV,
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HSV-1, HSV-2 and HIV. Against HCMV these derivatives were found to active 
concentrations above 4pM, while for the other viruses biological data are still awaited.
■  OKA B Y S
250
200
3 150UJ
£ 100
ACV BVdU 128a 128b 128f 128j 128k
Fig 5.5: 3 ’-Phosphoramidates
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Chapter 6: Modified Stereochemistry on BCNA
6.1 L-Nucleosides
L-nucleosides are the enantiomers of the natural nucleosides that have an inverted 
configuration of at all chiral centres. By analogy with the natural D-nucleosides, the 
nucleobase is designated to be in P-orientation if it is cis to the 4 ’-hydroxymethyl group in the 
sugar moiety (fig 6.1). At molecular level, biologically active nucleosides have the natural P- 
D-configuration as most amino acids have the L-configuration. Enzyme reactions are 
normally highly stereospecific, acting mainly on one enantiomer, such D-nucleosides and L- 
amino acids. It was believed that optically active compounds, such as natural nucleosides, 
would be considerably more active than ‘unnatural’ L-enantiomers.1
HO
Rt—R?
R ,— R, B O
OH
R?— Ri
h c ^ v /  y  —
o
HO
Ra — Ri B
D-Nucleoside L-Nucleoside
Fig 6.1: D,L-Nuclesides
Although the first L-nucleoside was synthesised in the 1960s, little attention was given to L- 
nucleosides until the emergence of Lamividine 9. This nucleoside was synthesised for the first 
time as a racemic mixture ((±)-2’,3’-dideoxy-3’-thiacytidine (BCH-189)) which shows a good 
anti-HIV activity.2 Subsequently, the resolution of (±)-BCH-189 showed not only that the 
anti-HIV activity resided in both enantiomers, but also that the L-enantiomer (3TC, 
Lamivudine, 9) was more active then its D-counterpart and that the cytotoxicity resided 
mainly in the latter.2
The explanation for the different activity and toxicological profiles of (+)-BCH-189 and (-)- 
BCH-189 (3TC) is given to their metabolic and pharmacodynamic properties. Lamivudine is 
resistant to enzymatic deamination, while (+)-BCH-189 is deaminated to 2’,3’-dideoxy-3’- 
thiauridine by deoxycytidine deaminase. Both enantiomers are substrates of deoxycytidine
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kinase that converts them to the monophosphate form. Further phosphorylation to 
diphosphate and triphosphate is performed by deoxycytidylate kinase and NDP kinase 
respectively. Since the first phosphorylation is the key step in their conversion to the active 
triphosphates, the major affinity of Lamivudine for deoxycytidine kinase gives a good 
explanation to its greater activity over its D-enantiomer.2
n h 2 n h 2
HO OH
(+) BCH-189 (-) 3TC
n h 2
HO
(±) BCH-189
Fig 5.2: BCH-189 and 3TC
The interest in L-nucleosides was encouraged by the expectation that L-nucleosides would be 
recognised not by mammalian enzymes, but by virus-encoded or bacterial enzymes. The most 
surprising aspect of L-nucleosides was the fact that some cellular enzymes are able to 
phosphorylate L-nucleosides to the triphosphate form, providing antiviral/biological 
activities.1 The physical and chemical properties of L-nucleosides are identical to with those 
of D-counterparts except for optical rotation. Their pharmacological properties, in a chiral 
environment, can be different for each enantiomer. The explanation of these differences can 
be given by active transportation of nucleosides into the cells, anabolic and catabolic enzymes 
that act on these compounds and interaction with the viral/cellular target enzymes.1
5.2 L-Nucleosides as anti-Herpes agents
HSV-l TK is a virus-encoded enzyme essential for viral infection and reactivation that does 
not have such precise specificity as the human TK, in fact it can phosphorylate also deoxy­
cytidine and a variety of purine and pyrimidine analogues, which represent most of the anti- 
herpetic drugs in the clinic.
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Recently it has been reported that L-thymidine is not recognised by human TK but that it acts 
as a good substrate for HSV-1 TK, reducing proliferation in HeLa cells, with little or no toxic 
effect on host cells.3
IdU is an effective antiviral agent, but its therapeutic value is limited by the fact that also 
human TK recognises it as a substrate. Instead BVdU shows a remarkable potency, although 
it was found to have potential drawbacks due to interactions with other drugs.
L-IDU and L-BVdU show an inhibitory activity against HSV-1 TK similar to that of their D- 
counterparts, while being inactive against human TK (table 5 .1).3
iQo pM
SIHSV-1 TK HeLa TK
D-IDU 0.12 6.05 50
L-IDU 0.35 >2000 >5000
D-BVdU 0.07 >600 >8000
L-BVdU 0.26 >600 >2000
Table 6.1
In view of these results, the L-enantiomer 129 of the most potent anti-VZV analogue pentyl 
phenyl 33f was synthesised in order to explore the possibility if this compound may possess 
different biological properties from 33f.
OHHO
Fig 6.3 : D- and L- derivatives of pentylphenyl of BCNA
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6.3 Synthesis of target L-Nucleoside
Since it was not possible to start from L-5-iodo-2’-deoxyuridine or L-2’-deoxyuridine, it was 
necessary to plan a new synthetic route for compound 129. After a retrosynthetic analysis 
(scheme 6.1), it was though that target compound could be synthesised by condensation of the 
unusual nucleobase 130 with L-deoxyribose 131 under Vorbriiggen conditions.
C5Hn
CSH
OH
130
Schem e 6.1
HO
OH
Compound 130 was easily obtained in good yield reacting 5-iodouracil with 4- 
pentylethynylbenzene under standard conditions. The derivative thus obtained was impure of 
metallic Pd, that was not possible to remove either by crystallisation, due to the insolubility of 
130 even in boiling DMSO, nor column chromatography as it crystallised on silica. It was 
decided to use 130 without any further purification for the successive step. The silylation, 
required from Vorbriiggen procedure, was performed in boiling HMDS obtaining 132 in high 
yield (scheme 6.2).
c 5h
132TMSOH 130
HN
Scheme 6.2: i), DMF, 4-pentylethynylbenzene, Tetrakis Pd(PPhi)4, Cul, DIPEA. ii) Cul, TEA. Hi) HMDS.
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Given the high cost and lack of a prompt source of L-deoxyribose, the sugar 131 was 
synthesised according to the scheme 6.3.4
iii
HO
OH
131 OH
,0 .
BzO
OBz
,0^ Jd
Bn"
Schem e 6.3: i) BnOH, HCl(&. ii) Acetone, Dimethoxypropane, TosOH. iii) DCM, Phenyl-chloro-thionoformate, 
Pyr. iv) Toluene, AIBN, Tributyl-t inhydride. v) H2O, TFA. vi) DCM, BzCl, Pyr.
The inexpensive p-L-arabinopyranose was reacted with benzyl alcohol in the presence of 
gaseous hydrochloric acid in order to obtain compound 134 in high yield. The protection of 
the anomeric OH with a benzyl group led to three main advantages. Firstly, the introduction 
of a chromophore allows the visualisation of the compound on TLC in order to monitor the 
successive reactions more easily. Secondly, the benzyl group can be removed in mild 
conditions and thirdly, the reaction is stereospecific giving exclusively the p-anomer 134, 
simplifying the interpretation of NMR spectra of the following derivatives. Treatment of 134 
with an excess of dimethoxypropane in the presence of a catalytic amount of tosylic acid 
afforded 135 in very high yield. The successive step was the reduction of the free hydroxy 
group to alkane by the Barton-McCombie deoxygenation. In order to perform this reaction it 
was necessary to convert 135 into a Barton ester 136, that it was done in quantitative yield, 
and then the deoxygenation was carried out through a radical reduction with tributyltin
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hydride obtaining 137 in very high yield. Elimination of the protecting groups with diluted 
aqueous trifluoroacetic acid afforded L-deoxyribose 131 (44% overall yield).
In order to perform the Vorbuggen condensation, L-deoxyribose was fully protected with 
benzoyl groups affording compound 138. It was noticed that carrying out the reaction at 
different temperatures, a mixture of isomers was observed, all having the mass of tribenzoyl- 
L-deoxyribose. L-deoxyribose can exist in four possible forms, the a  and p anomers 
combined with the furano and pyrano forms (fig 6.4).
HO/
OH
OH
P-L-deoxyribofuranose
OH
OH
a-L-deoxyribofuranost
HOj ,o
OH OH
OH
P-L-deoxyribopyranose
OH
a-L-deoxyribopyranose
Fig 6.4: possible forms o f  L-deoxyribose
A brief study on the protection of 131 was performed in order to understand the role of the 
temperature on the ratio of pyrano and furano forms. When carried out at 30 °C, the reaction 
led to the exclusive formation of the furano form, but decreasing the temperature the ratio 
between pyrano and f increased at the point that at -30 °C only the pyrano form was
detected (table 6.2). Regarding the ratio between a  and p, no significant difference was 
observed along the different experiments, always obtaining a mixture a  / p in a ratio ca 1:1 in 
the case of the furano form and only the a  anomer for the pyrano form.
Temperature (°C)
Pyrano / Furano 
Ratioa
30 0 /1 0 0
15 30/70
-10 65 /35
-30 100/0
a) Approximate ratio measured by H-NMR
Table 6.2
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The coupling between the protected sugar 138 and the silylated base 132 was performed 
under Vorbuggen conditions according to scheme 6.4.
The TLC analysis of the reaction showed the total conversion of 132 into a more polar 
fluorescent compound. After purification by column chromatography it was found that the 
isolated spot was the free base 130. It was though that the catalyst could be responsible, being 
too reactive at room temperature and decomposing the silylated base 132. The reaction was 
then performed at low temperature (<5°C) resulting again in the formation of the free base 
130. The use of another catalyst such as TMS-triflate was not found useful for this reaction 
and the free base 130 was isolated again. An explanation for these failures is probably due to 
the fact that the silyl group is very labile in the presence of a Lewis acid, inactivating the base 
and then quenching the reaction.
OBz
OBz
132TMSO
BzO
OB;+
Schem e 6.4: i) DCM, SnCl4
Assuming that the base 130 cannot be coupled with the sugar 136 in a traditional way, an 
alternative route was planned using a linear synthetic pathway rather than a convergent 
synthesis (scheme 6.5).5,6,7,8 The target of this new route was to synthesise L-5-iodo-2’- 
deoxyurine 144 in order to react it with 4-pentylethynylbenzene under the standard reaction. 
p-L-arabinopyranose was reacted with cyanamide in basic environment to give the oxazoline 
139. When refluxed with methyl propiolate in aqueous ethanol, compound 139 afforded in 
high yield O2’2 -anhydro-L-uridine 140, that was treated with acetyl bromide under reflux in 
order to protect the hydroxy groups and break the 2,2’ anhydro-bond, obtaining compound 
141. The bromo derivative was de-halogenated with tributyltin hydride to afford the protected
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2’-deoxy-L-uridine 142. The selective iodination of position 5 of the base was achieved using 
eerie ammonium nitrate and molecular iodine in acetic acid at reflux to isolate in very high 
yield 143. Deprotection of the acetyl groups was performed with sodium methoxyde to obtain 
L-IDU 144 in quantitative yield.
The coupling of L-IDU with 4-pentylethynylbenzene was performed as for the D-analogue, 
affording in good yield nucleoside 129 (17% overall yield).
o o
PhCsH
NH NH
v ii, viii VI
OH OAcOH
O
NH
X , ^ N >o
OAc
142 % A c
Schem e 6.5: i) MeOH, cyanamide, H20 /  NH3. ii) 50% EtOH, methyl propiolate. iii) ACN, AcBr. iv )Toluene, 
AIBN, TBTH. v) AcOH, I2, CAN. vi) MeOH, MeONa. vii) DMF, 4-pentylethynylbenzene, Tetrakis Pd(PPh3)4, 
Cul, DIPEA. viii) TEA, Cul.
This procedure was found to be quicker and less problematic than the previous route, 
considering the fact that no column chromatography was performed during the synthetic 
pathway, as the intermediates were at least 95% pure by ’H-NMR. Another point was the 
selectivity of this route over the previous one. In fact with the first route a mixture of a  and p 
nucleosides would have be obtained, while with the latter only the p anomer was obtained.
The spectroscopic data acquired (NMR, Mass, CHN, HPLC, optical rotation) were consistent 
with the structure expected and perfectly matched with its D-enantiomer 33f, apart from the 
optical rotation that showed an [a]o20 of +80 for 33f and -80 for 129, confirming that the L- 
enantiomer was obtained.
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6.4 a-Nucleosides
Although a few a-nucleosides were found to occur naturally, all nucleotides found in nucleic 
acids and essentially all nucleosides and nucleotides occurring elsewhere are in the p 
configuration. For this reason a  anomers were assumed to be biologically inert, and only few 
have been examined for biological activity.9 Although growth-inhibitory activity was reported 
for some a  nucleosides of adenine analogues, the only a  nucleoside that was studied 
extensively as a biologically active agent is a-thiodeoxyguanosine 145, which is 
phosphorylated and incorporated into DNA by terminal addition.9 During examination of a 
variety of adenosine analogues, it was found that 9-a-D-arabinofuranosyl adenine 147 and 
and in particular 9-a-D-arabinofuranosyl-8-azaadenine 146 showed an antiviral activity 
against HSV, where the p anomer not only had no antiviral activity, but was found to be also 
to be cytotoxic.9 Recently, a new class of a-benzimidazole nucleosides was found to be 
generally active against HMCV, in particular compound 148 is active at under pM 
concentrations with very low or no cytotoxicity.10 However, at least in this case the agents 
appear to have a non-nucleoside mechanism of action.
As this kind of modification has never been attempted on BCNAs, it was of interest to 
synthesise a a-BCNA analogue bearing the pentylphenyl moiety as side chain.
H,N N
145 ’OH
NH
NH
OH
Cl
Cl
OH
HO 148 t)H147 ’OH
Fig 6.5: a  purine analogues and target a-BC N A  136
115
Marco Migliore Chapter 6
6.5 Synthesis of a-BCNA
The synthetic route used to prepare the a-BCNA was the same as for the L-derivative 129, 
but instead of starting from L-P-arabinose, D-ribose 150 was used as starting material 
(scheme 6.6). The conversion of D-reibose into oxazoline 151, was performed as described 
for the L-derivative, but the reaction instead of lasting 15 hours, lasted 3 days. As the TLC
i o
analysis of this reaction was inconclusive, the reaction was monitored by C-NMR until total 
conversion of 152. The pKa of ribose is 12.04, a value slightly lesser than arabinose (pKa 
12.43),11 and this small difference (ca 3 fold less acidic) could explain the slower rate of the 
formation of 151. The successive reactions were performed without encountering any 
difficulties, obtaining every intermediate in high yield. Also in this case no column 
chromatography was needed for the synthesis of the intermediates that were at least 95-97% 
pure by ^-NM R.
HO
H (f 150 *OH
151 ’OH 152 ’OH b /  153 OAc
OAc
PhC5H„
VI1 . VIII
O ^ N
149 ’bH 156 OH 155 ’bAc 154 ’bAc
Schem e 6.6: i) MeOH, cyanamide, H20 /  NHj. ii) 50% EtOH, methyl propiolate. Hi) ACN, AcBr. iv) Toluene, 
AIBN, TBTH. v) AcOH, I2, CAN. vi) MeOH, MeONa. vii) DMF, 4-pentylethynylbenzene, Tetrakis Pd(PPh3)4, 
Cul, DIPEA. viii) TEA, Cul.
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All data acquired (NMR, Mass, CHN) for compound 149 were consistent with the structure 
expected. However, ’H-NMR of 33f and 149 were compared together, showing a first glance 
only few differences in chemical shifts. An in-depth analysis of compound 149 and 33f 
carried out by NMR showed significant differences between these two derivatives in the sugar 
moiety. The exact assignment of 'H-NMR peaks was done on the basis of COSY (H-H 
correlation) and a NOESY experiment performed on both compounds.
For compound 33f, where the stereochemistry is known, the most relevant data emerging 
from the observation of the N O E S Y  spectrum are the cross-peaks between the H - 1 7 H - 2 ’ a and 
H - 2 ’ a/ O H - 3 ’ , assigning to H - 2 ’ a the a-configuration. H - 2 ’ b was assigned to be in p- 
configuration as no cross-peak was observed neither with O H - 3 ’ nor with H-l \  furthermore 
the cross-peak H - 2 ’ b / H - 3 ’ is stronger then the one H - 2 ’ a/ H - 3 ’ (fig 6.6).
The major piece of evidence for the stereochemistry of compound 148 is the presence of the 
cross peak H-17H-2’b and the absence of the cross peak H-2VOH-3’, suggesting that H-2’b 
and H -l’ are in p configuration and that the stereochemistry at 1’-carbon is the one of the 
expected structure. The configuration of H-2’a was assigned to be a  due to the presence of the 
cross peak OH-3’/H-2’a and absence of the cross peak H-2’a/H -l’.
It was observed also that the base has a shielding effect on the 2’ proton in cis, in fact in 
compound 33f the p-proton is the most shielded while in compound 149 is the a-proton. 
Furthermore the base has a deshielding effect on the 4 ’ proton, in the P-nucleoside the proton 
is at 3 . 9 5  ppm while in the a-nucleoside is at 4 . 4 3  ppm. The other protons of the sugar are not 
affected. These effects of shielding and deshielding are due probably to the aromatic nature of 
the base resulting in anisotropic effects that affect the chemical shift of the protons involved.
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Fig 6.6: Noesy spectrum o f 33f
118
F1 
[p
pm
]
Marco Migliore Chapter 6
PhCsHj,
JLJUL
H-r 0H-T h-j
 A 1_____ L*___ A_A___
H-Zb
A I H-?* »_AA JU .  .  a  A.
<;
<
-  n
-  00
F2 [ppm]
Fig 6.7: Noesy spectrum o f 148
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6.6 Biological evaluation
The L-nucleoside 129 and a-nucleoside 149 were evaluated in vitro for their ability to inhibit 
the replication of VZV, according to reported methods.12 Data are shown in table 5.3 for the 
activity of 129 and 149 versus two strains o f TK-competent (TK*) VZV and two strains of 
TK-deficient (TIC) virus. Data are included for the reference compounds ACV, 33f and the 
modified sugar derivatives 41a-41g that bear an alkyl chain (table 6.3). Cytotoxicity data are 
also included for each compound in two assays.
0 .8 0 0
0 .7 0 0
0 .6 0 0
0 .5 0 0
0 .3 0 0
0.200
0.100
0.000
ACV LdRibo adR ibo Ara Ribo d4 3dRibo A cyclo Dxylo
Fig 6.8: Biological data for modified sugar derivatives
EC50 pMa
OKA YS TK 07 TK YS MCCpMb
c c 50
pMc
129 L-dRibo 2.5 1 >5 >5 >20 >50
149 a-dRibo 1.3 3.1 13 - >100 100
41a Ara 3.6 3.3 200 67 >200 >200
41b Ribo 23 21 >20 >20 50 >50
41c d4 >50 >50 >50 >50 200 16
41d dd 40 20 >200 >50 >200 >200
41e 3dRibo >50 - >200 - >50 >50
41 f Acyclo 11 - >16 - >80 >200
41g dXylo 24 >20 >50 >50 >50 >22
33f dRibo 0.0003 0.0001 >5 >5 >50 >200
ACV 2.9 1 74 125 >200 >200
a) effective concentration required to reduce virus plaque formation by 50%
b) minimal cytotoxic concentration
c) 50% cytotoxic concentration required to inhibit cell growth by 50%
Table 6 3
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The L-enantiomer still retains a certain anti-VZV activity, although it is considerably less 
active then parent nucleoside analogue 33f at non-cytotoxic concentrations. Like the L- 
derivative, also compound 149 retains an anti-VZV activity being two fold more active than 
the L-derivative, but still less active than parent nucleoside 33f. Along all the modified sugar 
series, compound 129 and 149 were found to be the most active. In fact, compound 129 is 
equipotent to ACV while 149 is twice more active.
As a rule, also these compounds entirely lost antiviral activity against TK' VZV strains, 
pointing to the requirement for VZV TK-mediated phosphorylation for activation.
Concluding, the SARs of the modified sugar derivatives clearly suggest that any modification 
of the sugar moiety leads to a dramatic loss of activity and that any modification of the D-P- 
2’-deoxyribosyl moiety is not tolerated.
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6.7 Phosphoramidates
Given the dramatic loss of activity of compounds 129 and 149, the phosphoramidate approach 
was applied to these nucleosides in order to increase the antiviral effect and to observe if the 
high selectivity of VZV-TK applies also to the second phosphorylation.
The standard procedure to prepare the phosphoramidates was applied, synthesising just one 
phosphoramidate for each nucleoside: phenol alanine benzylester (Scheme 6.7). The 
corresponding nucleoside was reacted with the phosphochloridate 125f in the presence of 
NMI and as predicted the yield of this reaction was not very high: 20% for 129f and 23% for 
149f. These two derivatives were tested against VZV and other viruses as for the parent 
drugs, but biological data are still awaited.
PhCsH
O P NH
OPh
129f 'OH
OH
PhC5H
O BnO  P NH
OPh
149f 'OH
PhC5H
....
149 'o h
Schem e 6.7: i) Pyr, 125f  NMI
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Chapter 6: Modified Stereochemistry on BCNA
6.1 L-Nucleosides
L-nucleosides are the enantiomers of the natural nucleosides that have an inverted 
configuration of at all chiral centres. By analogy with the natural D-nucleosides, the 
nucleobase is designated to be in {3-orientation if it is cis to the 4 ’-hydroxymethyl group in the 
sugar moiety (fig 6.1). At molecular level, biologically active nucleosides have the natural P- 
D-configuration as most amino acids have the L-configuration. Enzyme reactions are 
normally highly stereospecific, acting mainly on one enantiomer, such D-nucleosides and L~ 
amino acids. It was believed that optically active compounds, such as natural nucleosides, 
would be considerably more active than ‘unnatural’ L-enantiomers.1
HO
Ri—R?
R, — R, B O
OH
R?—R* o
HO
R .— R? B
D-Nucleoside ; L-Nucleoside
Fig 6.1 : D,L-Nuclesides
Although the first L-nucleoside was synthesised in the 1960s, little attention was given to L- 
nucleosides until the emergence of Lamividine 9. This nucleoside was synthesised for the first 
time as a racemic mixture ((±)-2’,3’-dideoxy-3’-thiacytidine (BCH-189)) which shows a good 
anti-HIV activity.2 Subsequently, the resolution of (±)-BCH-189 showed not only that the 
anti-HIV activity resided in both enantiomers, but also that the L-enantiomer (3TC, 
Lamivudine, 9) was more active then its D-counterpart and that the cytotoxicity resided 
mainly in the latter.2
The explanation for the different activity and toxicological profiles of (+)-BCH-189 and (-)- 
BCH-189 (3TC) is given to their metabolic and pharmacodynamic properties. Lamivudine is 
resistant to enzymatic deamination, while (+)-BCH-189 is deaminated to 2’,3’-dideoxy-3’- 
thiauridine by deoxycytidine deaminase. Both enantiomers are substrates of deoxycytidine
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Chapter 7: Carbocyclic BCNA
The research for nucleoside analogues as selective inhibitors of kinases and polymerases 
whitout any cytotoxicity, for the control of viral disease and cancer, is the subject of intense 
research.1,2,3 Nucleoside analogues that are substrates for cellular kinases, but resistant to other 
host enzymes such as phosphorylases, are fundamental for the development of new useful 
therapeutic agents. The replacement of the ring oxygen in sugar moiety of the nucleoside with 
a methylene unit (CH2) led to carbocyclic nucleoside analogues that were found to be 
extremely resistant to phosphorylases and cleavage at the glycosidic bond.4 
Some natural carbanucleosides were found to be biologically active, in fact the adenosine 
analogues Aristeromycin 1575 and Neoplacine A 1586 displayed antibiotic and anticancer 
activity. Subsequently, other synthetic carbocyclic analogues with useful therapeutic effects 
were discovered. In particular Carbovir 197 and its analogue Abacavir 208 were found to be 
inhibitors of HIV.
n h 2
h o
158HO OH
NHj
HO
HO
HN
NH
NH2
HOHO
2019
Fig 7.1 : Purine carbocycle nucleosides
Among anti-herpetic drugs, the corresponding carbocycle analogues of IDU 159 and BVdU 4 
were found to be potent inhibitors of HSV-1 in vitro.9 The replacement of the furan ring of the
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Fig 7.2 : anti-HSV carbocycle nucleosides
MIC (pg/m l)
HSV-1 HSV-2 TK HSV-1
BVdU 0.01 2 ^400
IDU 0.1 0.4 £400
C-BVdU 0.05 7 >400
C-IDU 0.07 10 >400
Table 7.1
7.1 Carbocyclic analogue of BCNA
As mentioned above, the carbosugars make the nucleosides extremely resistant 
cleavage by the TPases, due to the increase of the stability of the glycosidic bond. All 
the BCNAs were found to be extremely resistant to phosphorylases in vitro, 
administered in vivo, a substantial cleavage of the glycosidic bond was detected. Furthf 
this class of nucleosides is more susceptible to acidic cleavage than the other nucle< 
This aspect could represent a problem, especially in a possible oral formulation 
compounds encounter an acidic environment generated by the stomach, resulting in s 
potentially base cleavage and reduction of bioavailability.
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Bearing in mind the retention of biological activity of C-BVdU and C-IDU against herpes 
virus, the carbocycle analogue of 33f was synthesised after a retrosynthetic analysis of target 
molecule 160 (scheme 7.1).
Scheme 7.1
Compound 160 can be synthesised reacting C-IDU 159 with pentylphenyl acetylene under 
Sonogashira conditions. C-IDU 159, instead, was obtained starting from the amino- 
cyclopentane derivative 161 in two steps reaction. However, the most challenge part of the 
synthesis was the preparation of the amino-cyclopentane derivative 161, which was obtained 
following two different routes.
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7.2 Synthesis of Carbosugar: Route I
As a first attempt for the synthesis of the carbosugar 161, a modified version of the method 
described by Bray11 was adopted, (scheme 7.2).
NH
162
BnO w
167
BnO
MeO
163
COPh
NH
MeO
164
COPh COPh COPh
NH NH
Bn HO MeO
166 165
V Bn HO
HC1
NH2
HO' 168 HO' 161
Schem e 7.2: i) MeOH, SOCl2. ii) BzCl, Pyr. iii) DBU, DCM. iv) A!Cl3, DIBAH, DCM, Toluene, v) BnBr, K2C03, 
BujN~HSO/, 'ButylMethyl Ether, vi) BH3mDimethylsulfide, 2-Methyl-2-Butene, THF, NaOH, H20 2. vii) Pd/C, 
PrOH, H20.
Starting from the commercially available Vince lactam 162, the amido bond was rapidly 
cleaved under strong acidic conditions converting substrate into methyl ester by methanolysis 
obtaining compound 163 in quantitative yield. The protection of the amino group with 
benzoyl chloride in pyridine was easily achieved, isolating in high yield compound 164. The 
isomerisation of 164 into 165 was performed in the presence of a strong base such as DBU. 
The proposed mechanism for the shifting of the double bond is showed in scheme 7.3. DBU 
removes the proton in a  to the carbonylic carbon, generating a carbanion, which is stabilised 
by resonance. The successive protonation occurs on the conjugated species forming the 
compound 165 in quantitative yield.
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MeO
COPh COPh
NH
MeO
MeO
COPh
MeO
COPh
Schem e 7.3
Reduction of the ester 165 using a wide variety of hydride based reducing agents (LiAlH,*, 
Red-Al, Vitride) led to complex mixtures of products as a result of competitive 1,2 vs 1,4 
reduction. 11 In addition, treatment of the substrate with DIBAH, although 1,2 selective, led to 
partial reduction of the amide. 11 The use of one eq. of AICI3 enhances significantly the 
chemoselectivity of DIBAH towards reduction of the ester. 11 Under these conditions, the 
target ally lie alcohol 166 was isolated without any detectable over-reduction. The benzylation 
of compound 166 led to compound 167, and enhanced the steric hindrance around the p face. 
The hydroboration was then achieved using the hindered disiamylborane providing the Bot­
hy droxy derivative 168. Under the same conditions hydroboration of 166 leads to a loss of 
selectivity. 11 Finally, palladium catalysed hydrogenolysis of the benzyl groups afforded the 
required amino diol 161 (41% overall yield).
7.3 Synthesis of Carbosugar: Route II
Even though the route I was found to be efficient, the work up of some reactions was 
laborious and complicated. A new route was then planned in order to simplify the synthesis of 
the carbosugar 161. Vince lactam 162 was protected with Boc group in order to obtain 169 in 
quantitative yield . 12 The introduction of Boc group in the amido function brings two main 
advantages.
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HO
HO 161
HN
/
Hoc * Bo
T /  
HN
vi
HO
v
TBDMSO'
172
Scheme 7.4: i) Boc anhydride, TEA, CH2C l2. ii) MCPBA, DCM. iii) NaBHj, M eOH. iv) TBDMS-Cl, Imia 
DCM. v) Red-Al, Toluene, vi) H20 .
First the successive epoxidation with 2 eq. o f MCPBA gave exclusively the exo epoxid< 
in excellent yield, according with K atagiri.13 This selectivity is given by the bulky natu 
Boc, in fact without the Boc the reaction led to a mixture o f exo and endo derivativ 
described by Dominguez (scheme 7.5).14
HN
endo
HN
MCPBA
HN
exo
Scheme 7.5
Secondly, the amido function o f the free lactam does not suffer reduction by so
borohydride, but when a carbonyl group like the Boc is introduced, the reduction o<
without affecting the epoxide ring, converting the amido bond into amino-alcohol 171.
11reaction is known as RAC reaction (Reductive Amido-bond Cleavage).
Treatment o f 171 with Red-Al gave a mixture o f the two regioisomers 173a and 173b 
ratio o f 3 :1 (scheme 7.6).14
In view o f the fact that the regioselectivity o f  the ring-opening o f epoxide 171 could be d 
in favour o f compound 173a, a bulky protecting group like TBDMS was introduc( 
position 5. Reaction o f 171 with ‘butyldimethylsilyl chloride followed by reduction with 
A1 gave compound 173 as the sole product.14 Although the silyl group is cleaved durin
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reduction, it is clearly in place at the stage of the ring-opening since total control of the 
regiochemistry is observed. Removing of Boc group in refluxing water afforded 161 in 
quantitative yield (64% overall yield).
HN'
HO
171
.Boc
Red-Al
.Boc
HN'
HO
HO 173a 
Schem e 7.6
HO
Boc
173b OH
7.4 Synthesis of C-IDU
The synthesis of C-IDU 159 was achieved reacting the amino-diol 161 with 
ethoxyacrylisocyanate 174 (scheme 7.8) in the presence of DBU affording the urea derivative 
175 in good yield . 15 Cyclisation of 175 in 2M H2 SO4 at reflux was completed in good yield 
(55% ) . 16 Iodination was performed with molecular iodine in the presence of one eq. of CAN 
in acetic acid obtaining C-IDU 159 in good yield (53%).17
o o
NH,
HO U
HO?  161 o*
*c*
O
HO
OEt
O
11
HN N*
H
HN
HO
I
HN
HO
'O'
HO* 159
Schem e 7.7: i) DBU, ethoxyacrylisocyanate 174, DMF. ii) H2S04. Hi) I2, CAN, AcOH.
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Compound 174 was synthesised according the scheme 7.8, adopting two possible routes.
In the first route ethyl-vinyl ether is reacted with oxalyl chloride to give an intermediate that 
is decarbonylated to compound 177 by heating at reflux. The acyl chloride thus obtained was 
purified by vacuum distillation.16 Although only one reaction was involved for the preparation 
of 177 decomposition problems were encountered during the distillation and an alternative 
route was followed.
In the second route, starting from the commercially available ethyl-ethoxyacrylate, the 
substrate was hydrolysed in basic condition in aqueous NaOH, and the resulting acid 178 was 
then converted into 177 by thionyl chloride.18 The final step was performed in the presence of 
silver isocyanate at reflux to obtain compound 176 needed for the synthesis of C-IDU.16
o
A .
'o
Scheme 7.8: i) Oxalyl chloride, ii) H20 , NaOH. iii) SOC l2, DCM. iv) AgNCO, Benzene.
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7.5 Synthesis ofC-BCNA
The synthesis of Carba-BCNA 160 was easily performed as described for the other BCNAs. 
In fact reacting C-IDU 159 with pentylphenyl acetylene under Sonogashira conditions 
followed by cyclisation gave in moderate yield (32%) the corresponding carbocyclic 
derivative 160 (scheme 7.9).
HN
HOHO
HOT 159
Scheme 7.9: i) DMF, 4-pentylethynylbenzene, Tetrakis Pd(P P h3) 4, Cul, DIPEA. ii) TEA, Cul.
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7.6 Biological results and NMR study
The C-BCNA 160 was evaluated for its ability to inhibit the replication of VZV in tissue 
culture. Table 7.2 contains data relating to two strains of thymidine kinase-competent (TK+) 
VZV and also two strains of thymidine kinase-deficient (TK') VZV, with data also given for 
ACV and 33f as reference compounds.
OKA YS TK 07 TK YS MCC CCS0 
160 0.28 - - - >100 >100
33f 0.0003 0.0001 >5 >5 >20 >200
ACV 2.9 1 74 125 >200 >200
Table 7.2
As it can be seen on table 7.2, the replacement of the furanose oxygen of the sugar with a 
methylene group led to a significant (c.a. 1000 fold) loss of activity, making the C-BCNA 
poorly active against VZV.
A possible explanation centres on a possible hydrogen bond in the active site that is 
eliminated on compound 160, but this hypothesis is not very strong as the carbocyclic 
analogue of BVdU exhibits the same activity as the corresponding nucleoside.
It was thought then that the interaction between the enzyme and the carbocycle was hindered 
somehow by several factors, like the conformation of the sugar or the base.
In fact it was demonstrated that the conformation of the sugar ring plays a critical role in 
determining the affinity of kinases and polymerases for nucleosides.19 An unrestricted 
furanose ring adopts a number of conformations that can be described by the value of P in a 
pseudorotation cycle (fig 7.2) that depends on the sugar torsion angles (v0-v4) of the furanose 
ring. By convention, a phase angle P = 0° corresponds to a North (N) conformation possessing 
a symmetrical twist form 3T2 , while an angle of P = 180° corresponds to the South (S) 
conformation [3T2]. Because nucleosides and nucleotides can crystallise in either N  or S 
conformation and in solution there is a dynamic equilibrium, the sugar does not show any 
preference for either state and the energy barrier for interconversion is quite low.19 When a 
nucleoside or nucleotide binds to an enzyme, it is expected an imposition of a specific 
conformation on the sugar ring (N  or S) for optimal fit that should affect energy binding 
and/or catalytic activity. In fact in the specific case of HSV-TK, it was found that the enzyme
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prefers nucleosides with the S  conformation where the N  nucleosides were found to be 
inactive or poorly active.20 Given the structural similarity of the VZV-TK with HSV-TK, it 
was assumed that also VZV-TK prefers the S  to the N  conformation.
HO — | B
Fig 7.2:
Thus a conformational study of 3 3 f  and 160  was carried out in order to investigate how the 
conformation of these two very similar analogues can affect the antiviral activity. After a 
conformational search based on a stochastic method a computational model was obtained. It 
was found that the two compounds adopt different conformations on the sugar: the parent 
compound 3 3 f  adopts the S conformation (fig 7.3) whereas the carbocycle derivative 160  
adopts the N  conformation (fig 7.4).
Fig 7.4: C-BCNA 160 in North conformation
N o rth
South
3
Pseudoration cycle o f the furanose ring in nucleosides
West
HO— i n  B
East
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<
Fig 7 3 :  B C N A  3 3 f  in South conform ation
The dominant sugar pucker can be identified based on J r .2 p and J3 4 coupling constants.21 The 
percentage of C3'-endo (S) versus C2’-endo (AO are calculated from the following equations:
^1',2’P J3',4*
% S =  -------------------- x 100 % N = --------------------  x 100
J 1 ',2’p+J 3’,4’ J 1 ',2’p+ J  3',4'
The NMR spectra of both compounds were analysed and the J values required were measured 
for some anti-herpetic nucleosides in order to obtain the wanted percentages (table 7.3).
%N %S K* (N/S) W
33f 39 61 0.64 6.1 3.9
160 82 18 8.22 1.6 7.4
IDU 32 68 0.47 6.6 3.1
BVdU 33 67 0.51 6.5 3.3
Table 7 3 :  Percentage o f  N vs S conform er and equilibrium  constant (N /S ) at 25°C
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It was also reported that these compounds do not undergo a significant temperature dependent 
conformational change,22 in fact when heated at 37 °C no significant change on J values was 
observed on compounds 33f and 160. As it can be seen, the experimental data show that for 
BCNA 33f the preferred conformation is South (K^ <1) supporting the hypothesis that VZV- 
TK prefers this conformation and that C-BCNA 160 adopts the North conformation (K^ >1) 
that is not tolerated by the VZV enzyme, giving a positive explanation why this compound 
exhibits lower activity than the parent analogue.
In order to further support these data, NOESY spectra were recorded determining also the syn 
/ anti conformations of the base for both compounds.
The parent 33f shows an anti conformation as the H-4 of the base presents strong interactions 
with the H-2’p. Moreover medium interactions were observed with the H-5’ and OH-5’, plus 
a medium-weak interaction with H-3’. From these data is clear that the H-4 faces above the 
sugar and that the strong interaction with the H-2’|3 and the weak interaction with the H-3’ 
indicates a predominant south conformation. Furthermore, the H -l’ shows a medium 
interaction with OH-3’ that supports the south conformation plus a very weak interaction with 
H-4 implying the anti conformation.
Regarding the carbocycle 160, the strong interaction of H-4 with H -l’ proves the syn 
conformation as no other relevant interactions with the rest of the sugar were detected, 
implying that the H-4 is faraway from the |3-face of the sugar. The H -l’ instead shows strong 
interactions with H-2’ and H-6’ as expected, plus other two: one strong with the H-4’ and one 
weak with the H-3’. The H-2’P does not show any interactions with H-4 confirming the syn 
conformation. The lack of interactions between H -l’ and OH-3’ means that these protons are 
very distant and this situation can occur only when the sugar is in north conformation. 
Concluding, it was though that a minor change like the replacement of the furanose oxygen of 
the sugar with a methylene would not affected the shape of the molecule and hence the 
biological activity. Instead it was found that this substitution deeply affects of the molecule 
inverting the preferred conformation of the sugar from south to north. Moreover, this switch 
changed also the conformation of the base from anti to syn conformation making of this 
compound a poor substrate for the VZV-TK.
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A
than 1,000,000. These encouraging b iological properties led to an extensive pre-cli 
programme, where several problem s w ere encountered. The m ajor issue encounterec 
represented by very low  absorption  and substantial enzym atic cleavage resulting 
bioavailability value less than  15%. The sam e problem  o f  poor availability emergec 
with A C V 1 that was solved synthesising am ino acid  prodrugs. In particular valacyc 
12 increased the bioavailability o f  A C V  from  20%  to 55% .' Different prodrugs o 
were synthesised in order to  im prove the pharm acokinetic properties (Fig 8.1).
Val-Pro-ValO
180179 NH HOHO
HO P O
OH
H c f  54
Fig 8.1: Prodrugs of BCNA
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Three kinds o f prodrugs o f the BCNA 33f were developed in collaboration with external 
labs: tripeptide (Val-Pro-Val) ester 179, valinyl ester 180 and monophosphate 54 (fig. 
8.1). After a preliminary study it was found that the antiviral activity of these compounds 
did not show any variation from the parent 33f. Regarding bioavailability, it was found 
that the tripeptide was the best compound, being 20 times better than the parent. The 
valinyl ester instead exhibited a lower bioavailability than tripeptide, but still 10 times 
higher than 33f. The phosphate 54 did not show any significant improvement in 
pharmacokinetic properties, and the problematic synthesis was an additional reason for 
discarding it. The tripeptide 179, although it shows an excellent bioavailability is 
expensive to synthesise, thus the Valinyl ester 180 emerged as excellent candidate also 
because it represents a good compromise between cost, synthesis and biological 
properties. The bioavailability results are summarised on table 8.1 and fig 8.2.
Time 33f MP* (54) Val (180) Val-Pro-Val (180)
15’ 0.43 1.72 2.61 8.25
30’ 0.62 2.1 1.93 11.9
45’ 0.85 3.4 7.5 17.3
60’ 0.68 2.57 4.46 10.3
120’ 1.25 2.22 3.19 2.38
180’ 0.79 1.1 1.42 0.86
Table 8.1: Concentrations vs time, *estimated values
■ 33f
■ MP
■ Val
■  Val-Pro-Val
Fig 8.2: AUC diagram
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8.2 Synthesis of Val-BCNA
The preparation of compound 180 was performed condensing the parent nucleoside 33f 
with Fmoc-L-Valine under Mitsunobu conditions (scheme 8.1). In these conditions the 
reaction was shown to be highly selective towards the 5’-OH as it is a primaiy alcohol, 
and the formation of the 3’-derivative and the 3’,5’-diester were observed on TLC but not 
isolated. Once coupled with the amino acid, the Fmoc group was readily removed by 
using two eq. of piperidine. The major problem encountered in this second step was the 
cleavage of the ester bond resulting in a difficult purification during the chromatographic 
process due to the similarilty of the r.f. o f the produg 180 and parent drug 33b. It was 
noticed that it is possible to isolate the Fmoc-intermediate after the first step and then 
remove the protecting group, but it was found more convenient to carry on the two steps 
in one pot, as only one chromatographic column was performed instead of two.
HO
n h 2 ho*' 180
Schem e 8.1: i) DMF, DBAB, TPP-PS,Fmoc-L-valine. ii) Piperidine.
33fHO
In order to increase the water solubility of this prodrug, the hydrochloric and succinate 
salts were synthesised reacting 180 with one eq. of the appropriate acid. Compound 180 
was found to be 20 times more soluble than parent nucleoside. Conversion of 180 into 
hydrochloric salt increased the solubility of 25 fold, becoming 500 times more soluble
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than parent nucleoside 33f. Instead the succinate salt resulted in a significant boost in 
solubility, 1500 times more soluble than 180 and 30,000 times than 33f (table 8.3). 
Furthermore it was found that formation of salts increased significantly the stability of 
this compound under “stressing” conditions in particular the hydrochloric salt resulted the 
most stable compound along the valyl series. The HC1 salt, called FV100, has been 
selected for clinical evaluation.
Solubility mg/ml Enhancement
33f OOOI ~
Val-BCNA (8.2) 0.020 20
Val-BCNA*HC1 0.490 490
Val-BCNA*Succ 30 30,000
Table 8.3
8.3 Cell Study
When irradiated in a range of wavelengths of 340-380 nm, 33b or 180 show an intense 
fluorescence clearly visible (fig 8.3). This phenomenon allowed us to start a biological 
study aiming to track the compound, in particular the distribution, inside the cell. 
Normally cells do not absorb in this range and thus they are virtually invisible.
Fig 83 : An irradiated crystal of 33b
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When HeLa cells (cervical carcinoma epithelial cells) are treated with an 8pM solution of 
33b for 1 hour, it can be seen that the compound is uniformly distributed in the 
cytoplasm, in particular it was observed that the derivative is localised in a structural 
component of the cell like the cytoskeleton. It was also noticed that the compound did not 
diffuse inside the nucleus (fig 8.4).
Fig 8.4: cells treated with 33b after 1 hour (HeLa)
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Treating the cells with 180 for 1 hour, it was observed a different distribution as fig 8.5 
clearly shows. The compound is trapped inside small vesicles scattered around the cell, 
which are probable lysosomes. This effect is due to the presence of the amino group in 
the compound that is protonated in the acidic environment of lysosome and therefore it 
cannot cross the membrane of the vesicle for passive diffusion getting trapped. Again the 
presence of the compound inside the nucleus was not detected.
Fig 8.5: cells treated with 180 after 1 hour (HeLa)
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In order to understand the mechanism of formation of these vesicles, more experiments 
were performed in different conditions.
Administering 180 to HeLa cells and observing after 2 minutes, it can be seen that the 
vesicles are not formed yet and that 180 is uniformly distributed in the cytoplasma like 
the parent drug 33b (fig 8.6). This fact implies that the formation of the vesicles is not an 
immediate process but it is time dependent.
Fig 8.6: cells treated with 180 after 2 minutes (HeLa)
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Carrying out the experiment at 0 °C for 1 hour, it was found that formation of the vesicles 
is significantly slowed. At this temperature the surface of the membrane is not fluid as at 
37 °C, but it is rather dense preventing the compound to cross efficiently the lipid bilayer. 
From this result it can hypothesised that the transport of 180 inside the vesicles is a 
passive phenomenon and not active. Further studies are still ongoing in order to clarify 
the global process.
Fig 8.7: cells treated with 180 after 1 hour at 0 °C (HeLa)
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In order to prove that the formation of vesicles is not dependent on the type of cells used, 
another cell line completely different from HeLa was used. The experiment was carried 
out exactly as for the HeLa cells using KG la cell line (acute myeloid leukaemia cells).
As fig 8.8 shows, the KG la cells present fluorescent vesicles, confirming that the cell 
line used does not affect the kind of distribution in the cytoplasma of 180.
Fig 8.8: cells treated with 180 after 1 hour (KGla)
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The same kind of vesicles can be observed on the cells where the anticancer drug 
daunorubicine 181 was administered. As for compound 180, daunorubicine is trapped 
inside the lysosomes and it cannot cross the membrane due to the positive charge on the 
amino group generated by the low pH of this organelle (fig 8.10).
o o h  o
'OH
OMe OH
rOH
181
Fig 8.9 : Daunorubicine
Fig 8.10: cells treated with daunorubicin after 1 hour (KGla)
Chapter 8
Administering the antibiotic nigericin 182 to KG la cells, the proton pump of the 
lysosomes is inhibited and thus the pH gradient between the vesicle and cytoplasma is 
nullified. In these conditions daunorubicin cannot be protonated and then trapped inside 
the lysosomes diffusing around the cytoplasma (fig 8.12). This experiment was used as a 
positive control.
OMe
HO OH
OH
182
Fig 8.11: Nigericin
Fig 8.12: Daunorubicine + Nigericine
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Carrying out the same experiment, KG la cells were treated first with nigericin and then 
with 180. It was observed that no vesicles were formed, and that the compound was well 
distributed in the cytosplasma, exactly like daunorubicine (Fig 8.13). To notice that also 
in this cell line compound 180 has never been detected inside the nucleus.
Fig 8.13: 180 + Nigericin (KIGa)
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Conclusions
This thesis is a report of a further development of BCNAs as inhibitors of VZV.
Given the high potency of the lead compound and the possibility that this compound could go 
into clinical trial, it was needed to have a substantial amount of nucleoside for pharmacological 
purposes. Therefore the chemistry of BCNAs was further improved, reducing time and removing 
any column chromatography from the synthesis. This new process was successfully used by 
external labs up to Kg scale.
In order to enhance the bioavailability of the lead compound a few strategies were used. The first 
one was the introduction of an ether side chain, with full retention of the antiviral activity but 
with no significant increase of water solubility. Then three prodrugs were synthesised, that 
include the monophosphate, the valinyl ester and a tripeptide ester. All of three were found to 
have a bioavailability better than lead with the order monophosphate, valinyl ester and finally 
tripeptide ester. The valinyl ester in particular represented a compromise between easy of 
synthesis access and biological properties making of this compound and its hydrochloric salt 
(FV-100) a good candidate for the clinical trial.
Then a series of mono-substituted phenyl derivatives was synthesised bearing electron- 
withdrawing and electron-donating groups in position ortho, meta and para. From the 
introduction of such groups it emerged that electron-withdrawing groups and meta substitution 
are damaging for biological activity while electron-donating groups group improve activity.
Given the general lack of activity of BCNAs against other viruses, the phosphoramidate protide 
approach was applied to this class of compounds resulting in loss of activity vs the lead. 
Moreover these derivatives were found not to be active against other viruses suggesting that VZV 
is the main target of BCNAs.
The L-enantiomer and the a-anomer of BCNA were synthesised in order to broaden the spectrum 
of activity, but these two derivatives were found to be poorly active against VZV, therefore the 
phosphoramidate technology was applied to them. Biological results for the other viruses are still 
awaited.
The replacement of the oxygen of the sugar ring with a methylene group led to the C-BCNA 
which was found to be chemically more stable then lead. This kind of substitution deeply affected
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1the biological activity in negative way. The explanation why this compound shows an activity 
1000 fold lesser than parent may be that the main conformation of the sugar of C-BCNA is North 
while the lead compound shows a predominant South conformation. Furthermore the 
conformation of the base of C-BCNA is syn while for BCNA is anti, making of this compound a 
poor substrate for VZV-TK as inhibition data suggest.
Finally a cell study was carried out in order to investigate of the distribution of the lead C l743 
and it prodrug FV-100 inside the cell. CF1743 was rapidaly uptaken and homogeneously 
distributed around the cytosol, while FV-100 was found to be segregated into vesicles, probably 
lysosomes. Interesting to notice that no compound was observed inside the nucleus, suggesting 
that the mechanism of action of BCNAs is more complex than it appears. Further studies on this 
field are still on going.
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Chapter 9
General experimental details 
Solvents and reagents
The following anhydrous solvents were bought from Aldrich® with sureseal stopper: 
Chloroform (CHC13), dichloromethane (DCM), diethyl ether (Et2 0), 1,4-dioxane, N,N- 
dimethylformamide (DMF), N-methylimidazole (NMI), pyridine (Pyr), tetrahydrofuran 
(THF), triethylamine (TEA). All reagents commercially available were used without further 
purification.
Thin Layer Chromatography (TLC)
Precoated, aluminium backed plates (60 F2 5 4 , 0.2 mm thickness, Merck) were visualised under 
both short (254 nm) and long wave (365 nm) ultraviolet light.
Preparitive TLC plates (20x20 cm, 500-2000 pm) were purchased from Merck.
Column Chromatography (CC)
Column chromatography processes were carried out using silica gel supplied by Fluka (silica 
gel 60, 35-70 pm, 220-440 mesh). Glass columns were slurry packed using the appropriate 
eluent and samples were applied either as a concentrated solution in the same eluent or pre­
adsorbed on silica gel.
High Performance Liquid Chromatography (HPLC)
Analytical procedures were run on a Varian ProStar instrument (LC work station, Varian 
Prostar 355 LC detector) using a Polaris C l 8 -A 10 u column; elution was performed using a 
mobile phase consisting of water / acetonitrile in gradient (Water 100->0 in 20 minutes).
Nuclear Magnetic Resonance (NMR)
'H-NMR (500 MHz), l3C-NMR (125 MHz), 3 IP-NMR (202 MHz), 19F-NMR (470 MHz) 
were recorder on a Bruker Avance 500 spectrometer at 25°C. Spectra were calibrated to the 
residual signal of the deuterated solvent used. I3 C-NMR, 3 1 P-NMR and 19F-NMR were
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proton-decoupled. Chemical shifts are given in parts per million (ppm) and coupling constants 
(J) in Hertz.
Abbreviations: s (singlet), d (doublet), t (triplet), q (quartet), qn (quintet), sx (sextet), m 
(multiplet), bs (broad signal), dd (doublet of doublets), dt (doublet of triplets), ddd (doublet of 
doublets of doublets).
Mass Spectroscopy (MS)
Mass spectra were recorded on a microTOFLC Bruker Daltonics spectrometer and/or 
performed as a service by the University of Birmingham.
Elemental Analysis (CHN)
CHN microanalysis was performed as a service by the School of Pharmacy at the University 
of London.
Optical Rotation
The optical rotation was measured on a Bellingham+Stanley Ltd. ADP-220 polarimeter. 
Molecular Modeling Studies
The computational studies were performed by using MOE 2006.08 Chemical Computing 
Group (Inc. Montreal, Quebec, Canada).
Standard Procedures and Synthesis
For convenience, standard procedures are given, since similar procedures were adopted for 
the synthesis of phosphorochloridates, phosphoramidates and BCNAs.
Standard Procedure A: synthesis of phosphorochloridates
Anhydrous TEA (2.8 ml, 2.0 eq.) was added dropwise at -78 °C to a stirred solution of phenyl 
dichlorophosphate (2.11 g, 1.0 eq.) and the appropriate amino acid ester salt (10 mmol) in 30 
ml of anhydrous DCM under an argon atmosphere. Following the addition, the reaction 
mixture was allowed to slowly warm to room temperature. Formation of desired compound 
was monitored by 3 1 P-NMR. The solvent was removed under reduced pressure and the 
residue was resuspended in anhydrous Et2 0  and filtered under nitrogen. The filtrate was
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reduced to dryness to give the crude product which was purified by flash column 
chromatography (Hexane / Ethyl Acetate 1:1).
Standard Procedure B: synthesis of phosphoramidates
To a stirring solution of 33f (0.2 g, 0.5 mmol) and the appropriate phosphorochloridate (4 eq.) 
in 5 ml of anhydrous Pyr at 0 °C was added dropwise over 1 minute NMI (0.4 ml, 10 eq.). 
After 5 minutes, the reaction was let to rise to room temperature and stirred for 2 hours. Water 
was added to quench the reaction. The solvent was removed under reduced pressure and the 
oil was dissolved in DCM, washed with HC1 0.5 M three times. The organic layer was dried 
over MgSC>4 , filtered, reduced to dryness and purified by column chromatography (CHCI3 / 
MeOH).
Standard Procedure C: synthesis of 3’-phosphoramidates
To a stirring solution of 127 (0.35 g, 0.5 mmol) and the appropriate phosphorochloridate (4 
eq.) in 5 ml of anhydrous THF at 0 °C was added dropwise over 1 minute NMI (0.4 ml, 10 
eq.). After 5 minutes, the reaction was allowed to rise to room temperature and stirred for 2 
hours. Water was added to quench the reaction and DOWEX 50Wx8-100 was added and the 
mixture was stirred for 30 minutes. The resin was filtered and the solvent was removed under 
reduced pressure and the oil was dissolved in DCM, washed with HC1 0.5 M three times. The 
organic layer was dried over MgSC>4 , filtered, reduced to dryness and purified by column 
chromatography (CHCI3 / MeOH).
Standard Procedure D: synthesis of BCNAs
To a stirred solution of IDU 1 (1.06 g, 3 mmol) in dry DMF (15 m) at room temperature, the 
appropriate acetylene (3 eq.), rerra/:/.s(triphenylphosphine)Pd0 (0.35 g, 0.1 eq.), copper(I) 
iodide (0.12 g, 0.2 eq.) and DIPEA (1 ml, 2 eq.) were added. The reaction mixture was stirred 
for 15 hours at room temperature, after which time TEA (15 ml) and further copper(I) iodide 
(0.12g 0.2 eq.) were added. The reaction mixture was then heated at 80 °C and stirred for 4-6 
hours. The solvent was removed under reduced pressure and the resulting residue was 
dissolved in DCM and left at 0 °C for 15 hours. The resulting precipitate was filtered and 
washed with DCM.
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Cell Cultures
HeLa cells, (cervical carcinoma epithelial cells, adherent cells) were cultured under 
standard conditions in 35mm MatTek live.
HeLa cells were maintained at 37 °C and 5% C 0 2 in a humidified incubator in D- 
MEM/lOOOg/ml glucose supplemented with 10% Foetal calf serum, 100 IU/mL penicillin and 
100 f4g/mL streptomycin. All cell culture reagents were from Invitrogen. For microscopy 
experiments, 1.2xl05 cells were plated on to 35mm glass bottomed culture dishes (MatTek 
Corporation, Ashland, USA) and incubated under tissue culture conditions for 16-20 hours. 
The cells were then washed 2x with D-MEM phenol red free medium and incubated for 1 
hour (2 minutes) at 37 °C (or 0 °C) with 8 ^iM of 180. The media was removed and the cells 
washed 2x in clear media prior to adding 1ml of clear medium containing 20mM HEPES 
buffer pH 7.4. The fluorescence of the compound in the living cells was then immediately 
analysed on a Leica DMIRB inverted fluorescent microscope equipped with a 340-380nm 
band pass filter and a 40x oil objective.
KGla cells, (acute myeloid leukaemia cells, non-adherent)
Cells were maintained at 37 °C in a humidified 5% C 0 2 incubator. KGla cells were 
maintained at a confluency of 0 .5 -lx l0 6 in RPMI 1640 media supplemented with 10% foetal 
calf serum (FCS), 100 IU/ml penicillin and 100/*g/ml streptomycin. 5x10s cells were 
centrifuged at incubated at 1500 x g and resuspended in 5-00/d media containing x 
compound. The cells were then centrifuged for 1 min at 4°C and resuspended in 1ml clear 
media (see above). This procedure was repeated 2x and finally the cell pellet was resuspended 
in 25/d clear media. 2/d aliquots of this was loaded on to Hendley slides and imaged as 
described above on the fluorescent microscope.
Nigericin
For experiments using nigericin the cells were pretreated with 20/<M nigericin for 30 min 
prior to the addition of the compound (Daunorubicine, 180). The cells were then processed 
for fluorescence microscopy as described.
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33f 3-(2-deoxy-P-D-ribofuranosyl)-6-(4-pentylphenyl)furo[2,3-rf]pyrimidm-2(3//)-one
[Cfl743]
Prepared according to Standard Procedure D using 4- 
ethynylpentylbenzene.
White solid: 1.02 g, 85%
'H-NMR (DMSO, 500 MHz) : 6  8.84 (1H, s, H-4), 7.75 
(2H, d, J 7.6 Hz, Phb), 7.33 (2H, d, J 7.6 Hz, Phc), 7.22 
(1H, s, H-5), 6.20 (1H, t, J 5.7 Hz, H -l’), 5.28 (1H, d, J
4.2 Hz, OH-3’), 5.15 (1H, t, J 5.1 Hz, OH-5’), 4.27 (1H, 
dq, J 6.1 Hz 4.2 Hz, H-3’), 3.94 (1H, q, J 3.8 Hz, H-4’), 
3.72 (1H, ddd, J 12.1 Hz 5.1 Hz 3.6 Hz, H-5’a), 3.65 (1H, 
ddd, J 12.1 Hz 5.1 Hz 4.2 Hz, H-5’b), 2.61 (2H, t, J 7.5 
Hz, CH2 a ), 2.42 (1H, ddd, J 13.5 Hz 6.3 Hz 4.1 Hz, H- 
2’,,), 2.11 (1H, dt, J 13.5 Hz 6.1 Hz, H-2’p), 1.59 (2H, qn, 
J 7.5 Hz, CH2 p), 1.35-1.24 (4H, m, CH2 6  + CH2y), 0.86 
(3H, t, J 7.1 Hz, CH 3 co)
°C-NMR (DMSO, 125 MHz): 6  171.02 (C7a), 153.90 (C6 ), 153.76 (C2), 144.02 (Ph-Cd),
137.77 (C4), 128.93 (Ph-Cc), 125.86 (Ph-C„), 124.50 (Ph-Cb), 106.88 (C4a), 98.62 (C5),
88.16 (C4’), 87.57 (C l’), 69.55 (C3’), 60.68 (C5’), 42.26 (C2’), 34.89 (Ca), 30.80 (Cy),
30.33 (CP), 21.89 (C6 ), 13.84 (Co)
Anal. Calcd for C2 2 H2 6N2 0 5 : C 66.32, H 6.58, N 7.03, O 20.08. Found C 66.28, H 6.60, N
6 .99 ,0  20.13 
MS: 421 (M+Na)
[ a ] d 2 0 : + 8 0 °  ( c 4 . 0 ,  D M S O )
HO
HO
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29g 3-(2-deoxy-p-D-ribofuranosyl)-6-octyl-furo[2,3-(/]pyrimidin-2(3/y)-one
[Cfl368]
White solid: 0.6 g 57%
‘H-NMR (DMSO, 500 MHz): 8 . 6 8  (1H, s, H-4), 6.43 (1H, s, H- 
5), 6.17 (1H, t, J 6.21 Hz, H - l’), 5.29 ( 1 H, d, J4.30 Hz, OH-3’),
5.12 (1H, t, J 5.24 Hz, OH-5’), 4.24 (1H, dq, J 5.91 Hz 4.09 Hz, 
H-3’), 3.91 (1H, q, J 3.82 Hz, H-4’), 3.68 (1H, ddd, J 12.07 Hz
5.42 Hz 3.70 Hz, H-5’), 3.62 (1H, ddd, J 12.07 Hz 5.30 Hz 4.06 
Hz, H-5’), 2.64 (2H, t, J 7.27 Hz, CH2a), 2.38 (1H, ddd, J 13.43 
Hz 6.06 Hz 4.20 Hz, H-2’a), 2.05 (1H, dt, J 13.43 Hz 6.15 Hz, H-2’„), 1.61 (2H, qn, J 7.32 
Hz, CH2 P), 1.33-1.24 (10H, m, 5x CH2), 0.85 (3H, t, J 6.58 Hz, CHjco) 
l3C-NMR (DMSO, 125 MHz): 171.03 (C7a), 158.27 (C 6 ), 153.75 (C2), 136.72 (C4), 106.33
(C4a), 99.72 (C5), 88.07 (C4’), 87.34 (C l’), 69.64 (C3’), 60.75 (C5’), 41.17 (C2’), 31.21
28.59 28.55 28.33 (4xCH2), 27.32 (Ca), 26.35 (CP), 22.04 (CH2), 13.91 (Cio)
Anal. Calcd for Ci9 H2 8N 2 0 5: C 62.62, H 7.74, N 7.69, O 21.95. Found C 62.60, H 7.78, N
7 .79 ,0  21.83 
MS: 387 (M+Na)
HO
HO
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44c 3-(2-deoxy-p-D-ribofuranosyl)-6-(4-propoxyphenyl)furo[2,3-<flpyrimidin-2(3//)-one
[Cfl948]
— Prepared according to Standard Procedure D 
using 4-ethynylpropoxybenzene.
White solid 0.71 g 61%
'H-NMR (DMSO, 500 MHz): 8.79 ( 1 H, s, H-4),
7.76 (2H, d J 8.85 Hz, Ph), 7.10 (1H, s, H-5), 
7.06 (2H, d J 8.85 Hz, Ph), 6.20 (1H, t, J 6.15 
Hz, H -l’), 5.29 (1H, d, J 4.35 Hz, OH-3’), 5.16 
(1H, t, J 5.25 Hz, OH-5’), 4.26 (1H, dq, J 5.95 
Hz 4.15 Hz, H-3’), 4.00 (2H, t, J 5.20 Hz, 
CH2 a), 3.94 (1H, q, J 3.60 Hz, H-4’), 3.71 (1H, 
ddd, J 12.04 Hz 5.24 Hz 3.69 Hz, H-5’), 3.64 
(1H, ddd, J 12.04 Hz 5.24 Hz 3.88 Hz, H-5’), 2.41 (1H, ddd, J 13.50 Hz 6.31 Hz 4.28 Hz, H-
2’), 2.10 (1H, dt, J 13.50 Hz 6.13 Hz, H-2’), 1.76 (2H, sx, J 7.46 Hz, CH2 0), 1.00 (3H, t, J
6.97 Hz, CH3y)
l3 C-NMR (DMSO, 125 MHz) : 171.03 (C7a), 159.64 (C6 ), 153.93 (Ph-Cd), 153.76 (C2), 
137.19 (C4), 126.22 (Ph-Cb), 120.77 (Ph-Ca), 115.02 (Ph-Cc), 107.11 (C4a), 97.24 (C5),
88.12 (C4’), 87.49 (C l’), 69.57 (C3’), 69.14 (Ca), 60.70 (C5’), 41.24 (C2’), 21.93 (Cp),
10.31 (Cy)
Anal. Calcd for C2 0 H2 2N2 O6: C 62.17, H 5.74, N 7.25, O 24.84. Found C 62.21, H 5.78, N 
7.32, O 24.69 
MS: 409 (M+Na)
HO
HO
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53 3-(2-deoxy-P-D-ribofuranosyl)-5-deutero-6-(4-pentylphenyl)furo[2,3-<flpyrimidin-2(3//)-
one
[Cf2572]
To a stirred solution of IDU 1 (1.06 g, 3 mmol) in dry 
DMF (15 m) at room temperature, 4- 
ethynyl pentyl benzene (1.55 g, 3 eq.),
tefraA/.y(triphenylphosphine)Pd0 (0.35 g, 0.1 eq.),
copper(I) iodide (0.12 g, 0.2 eq.) and DIPEA (1 ml, 2 eq.) 
were added. The reaction mixture was stirred for 15 hours 
at room temperature. The solvent was removed under 
reduced pressure and the resulting residue was dissolved 
in DCM and left at 0°C for 5 hours. The resulting 
precipitate was filtered and washed with DCM. The 
precipitate was the dissolved in anhydrous CH3OD stirred 
under argon for 30 minutes and then dried under reduced 
pressure. This operation was performed three times. The 
residue was then dissolved in anhydrous CH3OD (15 ml) 
and TEA (15 ml) plus copper(I) iodide (0.12g 0.2 eq.) were added. The reaction mixture was 
then heated at 60°C and stirred for 2 hours. The solvents were removed under reduced 
pressure and the resulting residue was suspended in MeOH and stirred for 15 minutes. The 
solvent was removed and the residue was washed with cold DCM to obtain the titled 
compound.
HO
HO
White solid: 0.60 g, 50%
‘H-NMR (DMSO, 500 MHz): 5 8.84 (1H, s, H-4), 7.75 (2H, d, J 7.6 Hz, H-Phb), 7.33 (2H, d, 
J 7.6 Hz, H-Phc), 6.20 (1H, t, J 5.7 Hz, H -l’), 5.28 (1H, d, J4.2 Hz, OH-3’), 5.15 (1H, t, J 5.1 
Hz, OH-5’), 4.27 (1H, dq, J 6.1 Hz 4.2 Hz, H-3’), 3.94 (1H, q, J 3.8 Hz, H-4’), 3.72 (1H, ddd, 
J 12.1 Hz 5.1 Hz 3.6 Hz, H-5’a), 3.65 (1H, ddd, J 12.1 Hz 5.1 Hz 4.2 Hz, H-5’b), 2.61 (2H, t, 
J 7.5 Hz, CH2cx), 2.42 (1H, ddd, J 13.5 Hz 6.3 Hz 4.1 Hz, H-2’„), 2.11 (1H, dt, J 13.5 Hz 6.1 
Hz, H-2’p), 1.59 (2H, qn, J 7.5 Hz, CH2 p), 1.35-1.24 (4H, m, CH2 6  + CH2y), 0.86 (3H, t, J 7.1 
Hz, CH3co)
2 H-NMR (DMSO, 76 MHz): 6  7.22 (ID, s, D-5)
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l3C-NMR (DMSO, 125 MHz): 6  171.02 (C7a), 153.90 (C6 ), 153.76 (C2), 144.02 (Ph-Cd),
137.77 (C4), 128.93 (Ph-Cc), 125.86 (Ph-Ca), 124.50 (Ph-C„), 106.88 (C4a), 98.62 (bs C5),
88.16 (C4’), 87.57 (C l’), 69.55 (C3’), 60.68 (C5’), 42.26 (C2’), 34.89 (Ca), 30.80 (Cy),
30.33 (Cp), 21.89 (C6 ), 13.84 (Co)
MS: 422 (M+Na)
54 3-(2-deoxy-fS-D-ribofuranosyl)-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-2(3tf)-one-5’-
monophosphate triethylammonium salt 
[Cf2359]
O)
Under an argon atmosphere, to a stirred 
y suspension of 33f (0.64g, 1.6 mmol) in 
triehyl phosphate (5 ml), POCl3 (0.22 ml, 
° 1.5 eq.) was added at 0°C, and the 
i reaction stirred at the same temperature
c
for 2 hours. After this time a
)
triethylammonium bicarbonate 1M 
solution was added until the 
effervescence stopped. The mixture was 
concentrated under reduced pressure, the 
residue was purified by column 
chromatography ('PrOH:TEA 9:1 to 
*PrOH:TEA:H20  9:1:2) to obtain the 
titled compound.
’H-NMR (DMSO, 500 MHz): 6  9.05 (1H, s, H-4), 7.64 (2H, d, J 7.6 Hz, H-Phb), 7.24 (2H, d, 
J 7.6 Hz, H-Phc), 7.22 (1H, s, H-5), 6.18 (1H, m, H -l’), 4.33-4.32 (1H, m, H-3’), 4.01 (2H, m, 
H-5’), 3.96-3.90 (1H, m, H-4’), 2.56 (2H, t, J 7.7 Hz, CH2 a), 2.42-2.34 (1H, m, H-2’a), 2.13-
2.05 (1H, m, H-2’p), 1.60-1.51 (2H, m, CH2 p), 1.33-1.24 (4H, m, CH2 6  + CH2y), 0.86 (3H, t, 
J 6 . 8  Hz, CH3 co)
White solid 0.44 g 40%
P-NMR (DMSO, 202 MHz): 6  -0.36
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55 3-(2-deoxy-|3-D-ribofuranosyl)-6-(4-pentylphenyl)furo[2,3-</]pyrimidin-2(3/7)-one-
5’-triophosphate ammonium salt
To a solution of 55 (0.14 g, 0.2 
mmol) in anhydrous DMF (3 
ml), 1 , 1 ’ -carbony limidazole
(0.16 g, 5 eq.) dissolved in 
anhydrous DMF (3 ml) was 
added. After 4 hours MeOH 
(2.5 ml) was added and the 
mixture was stirred for 30 
minutes. After this time 
tributylammonium 
pyrophosphate (0.78 g, 3 eq.) 
was added and the reaction was 
stirred for 24 hours. The solvent 
was removed under reduced 
pressure and the residue was 
dissolved in a minimum amount of ammonium bicarbonate 0.4M solution and the purified by 
column chromatography (‘PrOH:NH3 7:1:2 to 'Pr0H:NH3 :H20  6:1:3) to obtain the titled 
compound.
White solid: 0.10 g, 71%
3 lP-NMR (D20 , 202 MHz): 6  -23.1 (t, J 20 Hz, P|3), -11.6 (d, 19.9 Hz, Pa), -10.23 (d, J 20 Hz, 
Py)
'H-NMR(H2 0 , 500 MHz): 6  8.50 (1H, s, H-4), 7.44 (2H, d, J 7.6 Hz, H-Phb), 7.1 (2H, d, J 7.6 
Hz, H-Phc), 6.90 (1H, s, H-5), 6.03 (1H, m, H -l’), 4.51-4.41 (1H, m, H-3’), 4.25-4.04 (3H, m, 
H-4’+H-5’), 2.51-2.35 (3H, m, CH2 a+H-2’a), 2.20-2.15 (1H, m, H-2’p), 1.42 -1.37 (2H, m, 
CH2 p), 1.11-1.01 (4H, m, CH2 6  + CH2y), 0.72 (3H, t, J 7.1 Hz, CH3 w)
[Cf2423]
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30 minutes and then poured into ice. The solutic 
extracted with DCM, and then the orgain layer was v 
with a saturated solution of N aH C 03. The residue wj 
dissolved in a 10% solution of MeONa/MeOH (20n 
heated at 70°C for 2 hours. The solvent was removec 
reduce pressure and then dissolved in DCM and > 
with H20 . The solvent was then removed to 
compound 62. To a solution of 62 in TH F (100 ml), 
under argon atmosphere, was slowly added NaH (1.6 g, 2 eq. [60% dispersion]). / 
minutes stirring, hexyl methane sulfonate was added and the reaction was heated at 7(
4 hours. The reaction was quenched by addition of water and extracted with CHC
solvent was removed under reduce pressure to yield the crude compound 68.
To a stirred solution of crude 68 in dry DMF (30 m) at room temperature, TMS-acetyle 
ml, 2 eq.), tefra&/.s(triphenylphosphine)Pd0 (2.31 g, 0.1 eq.), copper(I) iodide (0.76 g, C 
and DIPEA (6.97 ml, 2 eq.) were added. The mixrure was stirred 15 hours at 
temperature, after which a 1M solution of TBAF (25 ml) was added and stirred at th< 
temperature for 1 hour. The solvent was removed under high vacuum and the residi 
purified by column chromatography (Hexane : Ethyl Acetate 9:1) to yield the title comf
Yellow oil: 1.38 g, 32%
'H-NM R (CDC13, 500 MHz): 6 7.49 (2H, d, J 7.6 Hz, Ph-H3), 7.30 (2H, d, J 7.6 Hz, I 
4.51 (2H, s, H-a), 3.49 (2H, t, J 7.0 Hz, H-b), 3.10 (1H, s, C=CH), 1.58-1.54 (2H, m 
1.45-1.30 (6H, m, H-d+H-e+H-f), 0.92 (3H, t, 6.7 Hz, H-g).
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76 4-ethynyl-(3-butoxypropyl)benzene
8  A mixture of glacial acetic acid (13.5 ml) and I2 (2.5 g 0.5 
eq.) was heated at 100°C. Concentrated sulphuric acid 
(1.4 ml) was added, followed by 3-phenyl-1-propanol 
(2.72 ml, 20 mmol). A solution of NaI0 3 (0.99 g, 0.25 
eq.) in HzO ( 6  ml) was added dropwise. The reaction was 
stirred at 100°C for 30 minutes and then poured into ice. 
The solution was extracted with DCM, and then the 
orgain layer was washed with a saturated solution of 
NaHC03. The residue was then dissolved in a 10% 
solution of MeONa/MeOH (20ml) and heated at 70°C for 2 hours. The solvent was removed 
under reduce pressure and then dissolved in DCM and washed with H20 . The solvent was 
then removed to obtain compound 64. To a solution of 64 in THF (100 ml), at 0°C under 
argon atmosphere, was slowly added NaH (1.6 g, 2 eq. [60% dispersion]). After 5 minutes 
stirring, butyl methane sulfonate was added and the reaction was heated at 70°C for 4 hours. 
The reaction was quenched by addition of water and extracted with CHC13. The solvent was 
removed under reduce pressure to yield the crude compound 70.
To a stirred solution of crude 70 in dry DMF (30 m) at room temperature, TMS-acetylene (5.6 
ml, 2 eq.), terra&/.s(triphenylphosphine)Pd0 (2.31 g, 0.1 eq.), copper(I) iodide (0.76 g, 0.2 eq.) 
and DIPEA (6.97 ml, 2 eq.) were added. The mixrure was stirred 15 hours at room 
temperature, after which a 1M solution of TBAF (25 ml) was added and stirred at the same 
temperature for 1 hour. The solvent was removed under high vacuum and the residue was 
purified by column chromatography (Hexane : Ethyl Acetate 9:1) to yield the title compound.
Yellow oil: 1.71 g, 39%
‘H-NMR (CDC13, 500 MHz): 6  7.48 (2H, d, J 7.7 Hz, Ph-H3), 7.22 (2H, d, J 7.7 Hz, Ph-H2), 
3.47-3.38 (4H, m, H-c+H-d), 3.10 (1H, s, C^CH), 2.70 (2H, t, J 7.4 Hz, H-a), 1.99-1.91 (2H, 
m, H-b), 1.67-1.63 (2H, m, H-e), 1.50-1.47 (2H, m, H-f), 1.02 (3H, t, 7.3 Hz, H-g).
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59 3-(2-deoxy-p-D-ribofuranosyl)-6-(4-hexoxymethylphenyl)furo[2,3-(/)pyrimidin-2(3H)-one
[Cf2522]
Prepared according to Standard Procedure D using 74.
White solid: 0.46 g, 35%
‘H-NMR (CD3 OD, 500 MHz): 5 9.00 (1H, s, H-4), 7.81 
(2H, d, J 7.8 Hz, H-Phb), 7.43 (2H, d, J 7.8 Hz, H-Phc), 7.12 
(1H, s, H-5), 6.32 (1H, t, J 5.5 Hz, H -l’), 4.52 (2H, s, H-a),
4.45-4.40 (1H, m, H-3’), 4.11-4.08 (1H, m, H-4’), 3.95-3.78 
(2H, m, H-5’), 3.52 (2H, t, J 6.78, H-b), 2.63 (1H, m, H- 
2’a), 2.23 (1H, m, H-2’p), 1.61 (2H, m, H-c), 1.49-1.25 (6 H, 
m, H-d+ H-e+H-f), 0.91 (3H, t, J 6.87 Hz, H-g) 
l3 C-NMR (CD3 OD, 125 MHz): 6  171.02 (C7a), 156.87 
(C6 ), 153.76 (C2), 141.97 (Ph), 139.45 (C4), 129.31 (Ph), 
128.96 (Ph), 125.94 (Ph), 109.87 (C4a), 99.72 (C5), 90.00 
(C4’), 89.77 (C l’), 73.30 (Ca), 71.75 (Cb), 71.37 (C3’),
62.31 (C5’), 42.90 (C2’), 32.83 (Cc), 30.76 (Cd), 26.98 
(Ce), 23.70 (Cf), 14.40 (Cg)
Anal. Calcd for C2 3 H2 8N20 6: C 64.47, H 6.59, N 6.54, O 22.40. Found C 64.40, H 6.60, N
6.70,0  22.30
HO
HO
MS: 451 (M+Na)
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61 3-(2-deoxy-P-D-ribofuranosyl)-6-(4-(butoxypropyl)phenyl)furo[2,3-rf]pyrimidin-2(3/f)-
one
(Cf2325]
Prepared according to Standard Procedure D using 76. 
White solid: 0.46 g, 35%
'H-NMR (CD3 OD, 500 MHz): 5 8.97 (1H, s, H-4), 7.75 
(2H, d, J 8.3 Hz, H-Phb), 7.34 (2H, d, J 8.3 Hz, H-Phc),
7.04 (1H, s, H-5), 6.34 (1H, t, J 5.9 Hz, H -l’), 4.45 
(1H, m, H-3’), 4.10 (1H, q, J 3.7 Hz, H-4’), 3.93 (1H, 
dd, J 12.1 Hz 3.3 Hz, H-5’a), 3.83 (1H, dd, J 12.1 hz
3.9 Hz, H-5’b), 3.48-3.43 (4H, m, H-c+H-d), 2.76 (2H, 
t, J 7.3 Hz, H-a), 2.64 (1H, ddd, J 13.6 Hz 6.4 Hz 4.6 
Hz, H-2’„), 2.25 (1H, dt, J 13.6 Hz 6.0 Hz, H-2’fi), 1.94-
1.87 (2H, m, H-b), 1.58 (2H, qn, J 6 . 6  Hz, H-e), 1.43 
(2H, sx, J 7.5 Hz, H-f), 0.96 (3H, t, J 7.3 Hz, H-g) 
l3C-NMR (CD 3OD, 125 MHz): 6  172.95 (C7a), 157.24 
(C6 ), 156.85 (C2), 145.59 (Ph), 139.11 (C4), 130.28 
(Ph), 127.52 (Ph), 126.01 (Ph), 109.97 (C4a), 99.00 (C5), 89.96 (C4’), 89.75 (C l’), 71.72
(Cc), 71.38 (C3’), 70.82 (Cd), 62.32 (C5’), 42.89 (C2’), 33.23 (Cc), 32.33 (Ce), 20.44
(Ca+Cf), 14.26 (Cg)
Anal. Calcd for C2 3 H28N2O6 : C 64.47, H 6.59, N 6.54, O 22.40. Found C 64.38, H 6.56, N
6.75 ,0  22.31 
MS: 451 (M+Na)
HO
HO
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85 3-(2-deoxy-p-D-ribofuranosyl)-6-(o-toluyl)furo[2,3-<flpyrimidin-2(3//)-one
[Cf2533]
To a stirred solution of IDU 1 (1.06 g, 3 mmol) in dry 
DMF (15 m) at room temperature, 2-ethynyl-toluene (3 
eq.), tefraA:/.s(triphenylphosphine)Pd0 (0.35 g, 0.1 eq.), 
copper(I) iodide (0.12 g, 0.2 eq.) and DIPEA (1 ml, 2 eq.) 
were added. The reaction mixture was stirred for 15 hours 
at room temperature. The solvent was removed under 
reduced pressure and the resulting residue was dissolved in 
DCM and left at 0°C for 1 hour. The resulting precipitate 
was filtered and washed with DCM. The precipitate was 
then dissolved in 1,4-dioxane (15 ml) and copper(I) iodide (0.60 g, 1 eq.) and TEA (15 ml) 
were added. The reaction was stirred at reflux for 3 hours, after which the solvents were 
removed under reduced pressure and the residue crystallized from MeOH to obtain the titled 
compound.
HO
HO
White solid: 0.39 g, 56%
’H-NMR (DMSO, 500 MHz): 6  8.87 (1H, s, H-4), 7.73 (1H, bs, Phf), 7.37 (3H, m, 
Phc+Phd+Pe), 7.01 (1H, s, H-5), 6.21 (1H, t, J 6.2 Hz, H - l’), 5.29 (1H, bs, OH-3’), 5.14 (1H, 
bs, OH-5’), 4.30-4.23 (1H, m, H-3’), 3.98-3.92 (1H, m, H-4’), 3.74-3.68 (1H, m, J 11.6 Hz, 
H-5’a), 3.68-3.62 (1H, m, J 11.6 Hz, H-5’b), 2.51 (3H, s, CH3), 2.47-2.40 (1H, m, H-2’a), 
2.11 (1H, dt, 12.5 Hz, H-2’p)
,3C-NMR (DMSO, 125 MHz): 6 170.62 (C7a), 153.81 (C6), 153.11 (C2), 144.02 (Ph-Cd),
138.42 (C4), 135.58, (Ph-Ca), 131.44 (Ph), 129.24 (Ph), 127.70 (Ph-Cb), 127.33 (Ph-Cf), 
126.37 (Ph-Cb), 106.78 (C4a), 103.2 (C5), 88.23 (C4’), 87.65 (C l’), 69.68 (C3’), 60.79 (C5’), 
41.27 (C2’), 21.45 (CH3)
Anal. Calcd for Ci8H,8N2 0 5 : C 63.15, H 5.30, N 8.18, O 23.37. Found C 63.08, H 5.40, N
8.00, O 23.52 
MS: 365 (M+Na)
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86 3-(2-deoxy-p-D-ribofuranosyl)-6-(m-toluyl)furo[2,3-<f]pyrimidin-2(3/f)-one
[Cf2534]
Prepared according to Standard Procedure D using 3- 
ethynyltoluene.
White solid: 0.76 g, 74%
‘H-NMR (DMSO, 500 Mhz): 5 8.87 (1H, s, H-4), 7.67 
(1H, s, Phb), 7.64 (1H, d, J 7.7 Hz, Phf), 7.39 (1H, t, J 7.7 
Hz, Ph,.), 7.26 (1H, d, J 9.3 Hz, Phd), 7.25 (1H, s, H-5),
6.20 (1H, t, J 6 . 1  Hz, H -l’), 5.29 (1H, d, J 4.3 Hz, 3’-
OH), 5.17 (1H, t, J 5.2 Hz, 5’-OH), 4.29-4.23 (1H, m, H- 
3’), 3.94 (1H, q, J 3.8 Hz, H-4’), 3.72 (1H, ddd, J 12.0 Hz
5.2 Hz 3.6 Hz, H-5’a), 3.65 (1H, ddd, J 12.0 Hz 5.2 Hz
3.6 Hz, H-5’b), 2.43 (1H, ddd, J 13.5 Hz 6.3 Hz 4.3 Hz, H-2’„), 2.39 (3H, s, CH3), 2.12 (1H, 
dt, J 13.5 Hz 6.0 Hz, H-2’p)
n C-NMR (DMSO) : 6  171.01 (C7a), 153.76 (C6 C2), 138.40 (Ph-Ca) 138.11(C4), 130.09 
(Ph-Co), 128.97 (Ph-Ce), 128.28 (Ph-Cc), 124.88 (Ph-Cb), 121.76 (Ph-Cf), 106.76 (C4a), 99.38 
(C5), 88.15 (C4’), 87.60 (C l’), 69.50 (C3’), 60.65 (C5’), 41.23 (C2’), 20.93 (CH3)
Anal. Calcd for Ci8H 18N2 0 5: C 63.15, H 5.30, N 8.18, O 23.37. Found C 63.10, H 5.42, N
8.05, O 23.43 
MS: 365 (M+Na)
HO
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87 3-(2-deoxy-P-D-ribofuranosyl)-6-(w-anisolyl)furo[2,3-<flpyrimidin-2(3/7)-one
[Cf2490]
Prepared according to Standard procedure D using 3- 
ethynylanisole.
White solid: 0.74 g, 69%
'H-NMR (DMSO, 500 Mhz): 6  8.90 (1H, s, H-4),
7.45-7.39 (2H, m, Ph), 7.39-7.35 (1H, m, Ph), 7.34 
(1H, s, H-5), 6.20 (1H, t, J 6.2 Hz, H -l’), 5.31 (1H, d, 
J 4.4 Hz, 3’-OH), 5.19 (1H, t, J 4.8 Hz, 5’-OH), 4.31- 
4.23 (1H, m, H-3’), 3.94 (1H, q, J 3.8 Hz, H-4’), 3.84 
(3H, s, OCH3), 3.78-3. 59 (2H, m, H-5’), 2.43 (1H, 
ddd, J 13.7 Hz 6.4 Hz 4.5 Hz, H-2’„), 2.12 (1H, dt, J
l3C-NMR (DMSO, 125 MHz): 6  171.35 (C7a), 160.03 (Ph-Cc), 154.12 (C2), 153.78 (C6 ), 
138.67 (C4), 130.66 (Ph-Ca), 130.03 (Ph-Ce), 117.27 (Ph-Cd), 115.70 (Ph-Cb), 109.95 (Ph-Cf),
107.06 (C4a), 99.38 (C5), 88.35 (C4’), 88.01 (C l’), 69.81 (C3’), 60.98 (C5’), 55.68 (OCH3),
41.62 (C2’)
Anal. Calcd for CisHigNjOs: C 60.33, H 5.06, N 7.82, O 26.79. Found C 60.01, H 5.24, N
8.09,0  26.66 
MS: 381 (M+Na)
d
HO
HO
13.7 Hz 5.9 Hz, H-2’p)
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8 8  3-(2-deoxy-P-D-ribofuranosyl)-6-(m-a,a,a-trifluorotoluyl)furo[2,3-d]pyrimidin-2(3//)-
one 
[Cf2488]
Prepared according to Standard procedure D using 3- 
ethynyl-a,a,a-trifluorotouene 
White solid: 0.63 g, 53%
‘H-NMR (DMSO, 500 MHz): 5 8.94 (1H, s, H-4),
8.19-8.08 (2H, m, Ph), 7.81-7.69 (2H, m, Ph), 7.54
(1H, s, H-5), 6.17 (1H, t, J 6.0 Hz, H -l’), 5.30 (1H, d, 
J 4.0 Hz, 3’-OH), 5.22 (1H, t, J 5.0 Hz, 5’-OH), 4.30-
4.21 (1H, m, H-3’), 3.98-3.90 (1H, m, H-4’), 3.78-
3.58 (2H, m, H-5’), 2.49-2.36 (1H, m, H-2’a), 2.18-
2.06 (lH ,m , H-2’„)
13C-NMR (DMSO, 125 MHz): 6  171.32 (C7a), 154.09 (Ph), 152.15 (C2), 139.53 (C4), 130.69
(Ph), 130.11 (Ph), 129.82 (Ph), 128.63 (Ph), 125.95 (q, J 270 Hz, CF3), 121.24 (Ph), 106.81
(4a), 102.07 (C5), 88.54 (C4’), 88.11 (C l’), 69.71 (C3’), 60.91 (C5’), 41.61 (C2’)
,9 F-NMR (DMSO, 482 MHz): 6  -61.76
Anal. Calcd for C 18H 15N2 O5 F3 : C 54.55, H 3.81, N 7.07, O 20.19. Found C 54.26, H 4.01, N
7.10
MS: 419 (M+Na)
HO
HO'
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89 3-(2-deoxy-P-D-ribofuranosyl)-6-0-a,a,a-trifluorotoluyl)furo[2,3-</]pyrimidin-2(3//)-one
[Cf2487]
c f 3 Prepared according to Standard procedure D using 4- 
ethy ny 1 -a  ,a  ,a-tri fluorotouene.
White solid: 0.75 g, 63%
‘H-NMR (DMSO, 500 MHz): 5 8.96 (1H, s, H-4), 8.03 
(2H, d, J 9.0 Hz, Ph), 7.84 (2H, d, J 9.0 Hz, Ph), 7.51 (1H, 
s, H-5), 6.19 (1H, t, J 6.0 Hz, H -l’), 5.32 (1H, d, J 4.0 Hz, 
3’-OH), 5.21 (1H, t, J 5.1 Hz, 5’-OH), 4.33-4.22 (1H, m, 
H-3’), 3.98-3.90 (1H, m, H-4’), 3.78-3.58 (2H, m, H-5’), 
2.51-2.36 (1H, m, H-2’„), 2.20-2.07 (1H, m, H-2’u) 
n C-NMR (DMSO, 125 MHz): 5 171.35 (C7a), 154.09 
(Ph), 152.15 (C2), 139.76 (C4), 132.51 (Ph), 129.8 (Ph), 126.37 (Ph), 126.16 (Ph), 125.42 (q, 
J 268 Hz, CF3), 106.76 (4a), 102.75 (C5), 88.59 (C4’), 88.17 (C l’), 69.79 (C3’), 60.96 (C5’),
41.62 (C2’)
l9 F-NMR (DMSO, 482 MHz): 6  -61.72
Anal. Calcd for C 18H 15N2 O5F3 : C 54.55, H 3.81, N 7.07, O 20.19. Found C 54.31, H 3.98, N
7.01
HO
H tf
MS: 419 (M+Na)
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96 5-ethynyl-2’-deoxyuridine
o
HN
HO
HO
To a stirred solution of IDU 1 (1.06 g, 3 mmol) in dry ACN (15 m) at room temperature, the 
TMS-acetylene (1.3 ml, 3 eq.), terra£fs(triphenylphosphine)Pd° (0.35 g, 0.1 eq.), copper(I) 
iodide (0.12 g, 0.2 eq.) and DIPEA (1 ml, 2 eq.) were added. The reaction mixture was stirred 
for 15 hours at room temperature, after which time a 1M solution of TBAF in THF (6 ml, 2 
eq.) was added. The solvent was removed under reduced pressure and the resulting residue 
was purified by column chromatography (CHC13: MeOH 95:5) to afford 0.57 g (76%) of the 
title compound.
'H-NMR (DMSO, 500 MHz): 6 11.64 (1H, bs, NH), 8.31 (1H, s, H-6), 6.11 (1H, dd, J 6.5 Hz 
3.9 Hz, H -l’), 5.27 (1H, d, J 3.8 Hz, 3’-OH), 5.18 (1H, t, J 4.5 Hz, 5’-OH), 4.24 (1H, m, H- 
3’), 4.10 (1H, s, CH), 3.80 (1H, m, H-4’), 3.60 (2H, m, H-5’), 2.20-2.10 (2H, m, H-2’) 
13C-NMR (DMSO, 125 MHz): 6 162.0 (C4), 150.0 (C2), 144.9 (C6), 98.0 (C5), 88.0 (C4’),
85.2 (C l’), 84.0 (C), 76.8 (CH), 70.3 (C3’), 61.2 (C5’), 40.6 (C2’)
99 4-ethynylnitrobenzene
To a stirred solution of 4-iodonitrobenzene (2.50 g, 10 mmol) in dry ACN (50 m) at room 
temperature, the TMS-acetylene (4.2 ml, 3 eq.), tetrakis(tr\phenylphosphine)Pd° (1.60 g, 0.1 
eq.), copper(I) iodide (0.38 g, 0.2 eq.) and DIPEA (2.6 ml, 2 eq.) were added. The reaction 
mixture was stirred for 15 hours at room temperature, after which time a 1M solution of
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TBAF in THF (20 ml, 2 eq.) was added. The solvent was removed under reduced pressure 
and the resulting residue was purified by column chromatography (Hexane : Ethyl Acetate 
8:3) to afford 1.35 g (92%) of the title compound.
MS: 148 (M+H)
To a stirred solution of 3-iodonitrobenzene (2.50 g, 10 mmol) in dry ACN (50 m) at room 
temperature, TMS-acetylene (4.2 ml, 3 eq.), r^ra^5(triphenylphosphine)Pd° (1.60 g, 0.1 eq.), 
copper(I) iodide (0.38 g, 0.2 eq.) and DIPEA (2.6 ml, 2 eq.) were added. The reaction mixture 
was stirred for 15 hours at room temperature, after which time a 1M solution of TBAF in 
THF (20 ml, 2 eq.) was added. The solvent was removed under reduced pressure and the 
resulting residue was purified by column chromatography (Hexane : Ethyl Acetate 8:3) to 
afford 1.09 g (74%) of the title compound.
MS: 148 (M+H)
90 3-(2-deoxy-P-D-ribofuranosyl)-6-(m-nitrophenyl)furo[2,3-c/]pyrimidin-2(3//)-one
[Cf2493]
1 0 0  3-ethynylnitrobenzene
n o 2
Prepared according to Standard Procedure D using 3-
NO; ethynylnitrobenzene 1 0 0 .
Yellow solid: 0.39 g, 35%
HO
'H-NMR (DMSO, 500 MHz): 5 8.99 (1H, s, H-4),
8.58 (1H, m, Ph), 8.28 (2H, m, Ph), 7.80 (1H, t, J 9.0 
Hz, Ph), 7.60 (1H, s, H-5), 6.19 (1H, t, J 6.0 Hz, H- 
1’), 5.32 (1H, d, J 4.0 Hz, 3’-OH), 5.21 (1H, t, J 5.1 
Hz, 5’-OH), 4.33-4.20 (1H, m, H-3’), 3.99-3.91 (1H, 
m, H-4’), 3.78-3.58 (2H, m, H-5’), 2.50-2.38 (1H, m, 
H-2’0), 2.20-2.07 (1H, m, H-2’„)
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l3C-NMR (DMSO, 125 MHz): 5 171.76 (C7a), 154.54 (C6 ), 151.90 (C2 ), 149.27 (Ph), 140.38 
(C4), 131.66 (Ph), 131.37 (Ph), 130.83 (Ph), 124.42 (Ph), 124.42 (Ph), 107.18 (4a), 103.35 
(C5), 89.05 (C4’), 88.64 (C l’), 70.18 (C3’), 61.37 (C 5 ’)s 42.07 (C2 ’)
Anal. Calcd for C 17H 15N3 O7 : C 54.69, H 4.05, N 11.26, O 30.00. Found C 54.38, H 3.98, N
11.53,0 30.11 
MS: 396 (M+Na)
91 3-(2-deoxy-j3-D-ribofuranosyl)-6-(/w-nitrophenyl)furo[2,3-flGpyrimidin-2(3//)-one
[Cf2492]
Nq 2 Prepared according to Standard Procedure D using 4- 
ethynylnitrobenzene 99.
Yellow solid: 0.47 g, 42%
'H-NMR (DMSO, 500 MHz): 6 9.01 (1H, s, H-4), 8.33 
(2H, d, J 9.0 Hz, Ph), 8.09 (2H, d, J 9.0 Hz, Ph), 7.63 (1H, 
s, H-5), 6.19 (1H, t, J 6.0 Hz, H -l’), 5.32 (1H, d, J 4.4 Hz, 
3’-OH), 5.21 (1H, t, J 6.0 Hz, 5’-OH), 4.35-4.20 (1H, m, 
H-3’), 3.99-3.91 (1H, m, H-4’), 3.78-3.58 (2H, m, H-5’), 
2.50-2.38 (1H, m, H-2’„), 2.20-2.07 (1H, m, H-2’p) 
l3C-NMR (DMSO, 125 MHz): 6 171.40 (C7a), 154.03 
(C6), 151.51 (C2), 147.42 (Ph), 140.43 (C4), 134.65 (Ph), 
125.73 (Ph), 124.76 (Ph), 106.69 (4a), 104.58 (C5), 88.62 (C4’), 88.27 (C l’), 69.73 (C3’), 
60.92 (C5’), 41.61 (C2’)
Anal. Calcd for Ci7Hi5N30 7: C 54.69, H 4.05, N 11.26, O 30.00. Found C 54.42, H 4.05, N
11.12,030.41
MS: 396 (M+Na)
HO
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98 3-(2-deoxy-P-D-ribofuranosyl)-6-(m-nitrophenyl)furo[2,3-cf]pyrimidin-2(3/f)-one
NO
n o 2
HO
HO
To a stirred solution of 96 (0.76 g, 3 mmol) in dry ACN (15 m) at room temperature, 4- 
iodonitrobenzene (2.24 g, 3 eq.), terra£/.s(triphenylphosphine)Pd0 (0.35 g, 0.1 eq.), copper(I) 
iodide (0.12 g, 0.2 eq.) and DIPEA (1 ml, 2 eq.) were added. The reaction mixture was stirred 
for 15 hours at room temperature, after which time TEA (15 ml) and further copper(I) iodide 
(0.12 g 0.2 eq.) were added. The reaction mixture was then heated at 80 °C and stirred for 4-6 
hours. The solvent was removed under reduced pressure and the resulting residue was 
dissolved in DCM and left at 0 °C for 15 hours. The resulting precipitate was filtered and
washed with DCM to obtain 1.08 g (73%) of the title compound.
'H-NMR (DMSO, 500 MHz): 6 9.22 (1H, s, H-4), 8.38 (2H, d, J 8.5 Hz, Ph), 8.27 (2H, d, J
9.0 Hz, Ph), 7.78 (2H, d, J 9.0 Hz, Ph), 7.77 (2H, d, 8.5 Hz, Ph), 6.15 (1H, dd, J 6.5 Hz 3.9 
Hz, H -l’), 5.32 (1H, d, J 4.8 Hz, 3’-OH), 5.23 (1H, t, J 4.1 Hz, 5’-OH), 4.34-4.24 (1H, m, H- 
3’), 3.88 (1H, dt, J 5.4 Hz 2.7 Hz, H-4’), 3.77-3.57 (2H, m, H-5’), 2.44 (1H, qn, J 6.7 Hz, H- 
2’a), 2.27-2.17 (1H, m, H-2’f)
13C-NMR (DMSO, 125 MHz): 5 170.20 (C7a), 154.03 (C6), 147.81 (C2), 147.7 (C4a), 146.9 
(C5), 140.43 (C4), 136.55, 134.42, 130.73, 128.36, 125.00, 124.78, 117.25, 107.21 (Ph),
88.12 (C4’), 87.97 (C l’), 69.93 (C3’), 59.62 (C5’), 41.51 (C2’)
Anal. Calcd for C 1 7 H 1 5 N 3 O 7 :  C 55.87, H 3.67, N 11.33, O 29.12. Found C 55.98, H 3.96, N
11.69.0 28.79 
MS: 517 (M+Na)
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104 2-ethyny 1 -N-trifluoroacetylani 1 ine
2-ethynylaniline (2.34 g, 20 mmol) was dissolved in 10 ml of THF, 
trifluoroacetic anhydride ( was added dropwise at 0 °C and the mixture 
was st'rred f°r 2 hours. The solvent was removed under vaccum and the 
f residue was washed with Hexane to afford 3.67 g (8 6 %)of 104 as 
3 yellow solid.
‘H-NMR (CDCI3 , 500 MHz): 6  8.63 (1H, bs, NH), 8.22 (1H, d, J 8.3 Hz, H-6 ), 7.40 (1H, dd, J 
7.8 Hz 1.6 Hz, H-3), 7.31 (1H, dt, J 8.0 Hz 1.6 Hz, H-4), 7.07 (1H, dt, J 7.7 Hz 1.0 Hz, H-5),
3.48 (1H, s, CH)
l3C-NMR (CDCIj, 500 MHz): 6  154.69 (CO, q, J 38.8 Hz), 136.79 (Cl), 132.38 (C3), 130.44 
(C4), 125.50 (C5), 119.74 (C6 ), 115.61 (CF3, q, J 288.8 Hz), 112.21 (C2), 85.74 (C), 77.87 
(CH)
i9 F-NMR (CDC13,470 MHz): 6  -75.75
105 3-ethynyl-N-trifluoroacetylaniline
3-ethynylaniline (2.34 g, 20 mmol) was dissolved in 10 ml of 
THF, trifluoroacetic anhydride ( was added dropwise at 0 °C and 
the mixture was stirred for 2 hours. The solvent was removed 
under vaccum and the residue was washed with Hexane to afford 3.67 g (8 6 %)of 104 as 
yellow solid.
'H-NMR (CDCI3 , 500 MHz): 6  8.01 (1H, bs, NH), 7.62 (2H, s, H-2), 7.50 (1H, d, J 7.2 Hz, 
H-6 ), 7.31-7.24 (2H, m, H-4+H-5), 3.13 (1H, s, CH)
,3 C-NMR (CDCI3 , 500 MHz): 6  155.25 (CO, q, J 37.6 Hz), 135.12 (Cl), 130.08 (C5), 129.35 
(C4), 124.22 (C2), 123.41 (C3), 121.20 (C6 ), 115.69 (CF3, q, J 288.0 Hz), 82.40 (C), 78.34 
(CH)
19F-NMR (CDC13, 470 MHz): 6  -75.75
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106 4-ethyny 1-N-trifluoroacetylaniline
N
H
O
A
4-ethynylaniline (2.34 g, 2 0  mmol) was dissolved in 1 0  ml of 
THF, trifluoroacetic anhydride ( was added dropwise at 0 °C 
and the mixture was stirred for 2 hours. The solvent was 
cf3 removed under vaccum and the residue was washed with 
Hexane to afford 3.67 g (8 6 %)of 104 as yellow solid.
'H-NMR (CDCIj, 500 MHz): 6  7.95 (1H, bs, NH), 7.58 (2H, d, J 8.4 Hz, H-3), 7.54 (1H, d, J
8.4 Hz, H-2), 3.13 (1H, s, CH)
l3 C-NMR (CDC13, 500 MHz): 6  155.05 (CO, q, J 38.1 Hz), 135.4 (Cl), 133.23 (C3), 120.19 
(C2), 120.14 (C4), 115.69 (CF3, q, J 287.8), 82.63 (C), 77.95 (CH) 
l9 F-NMR (CDCB, 470 MHz): 6  -75.71
92 3-(2-deoxy-P-D-ribofuranosyl)-6-(/?-N-trifluoroacetylanilinyl)furo[2,3-<7]pyrimidin-2(3T/)-
one
[Cf2541]
Prepared according to Standard Procedure D using
4-ethynyltrifluoroacetylaniline. 
c f3 White solid: 0.85 g, 65%
'H-NMR (DMSO, 500 MHz): 6  11.42 (1H, bs, NH), 
8 . 8 6  (1H, s, H-4), 7.89-7.77(4H, m, Ph), 7.23 (1H, s, 
H-5), 6.19 (1H, t, J 6.0 Hz, H -l’), 5.30 (1H, d, J 4.0 
Hz, 3’-OH), 5.17 (1H, t, J 5.0 Hz, 5’-OH), 4.29-4.25 
(1H, m, H-3’), 3.96-3.93 (1H, m, H-4’), 3.78-3.60 
(2H, m, H-5’), 2.48-2.38 (1H, m, H -2 'J , 2.16-2.07 
(1H, m, H-2’,,)
l3 C-NMR (DMSO, 125 MHz): 5 171.00 (C7a),
154.48 (q, J 37.6 Hz, NHCO), 153.74 (C6 ), 153.05 (C2), 138.12 (C4), 137.16 (Ph), 125.41 
(Ph), 125.26 (Ph), 121.20 (Ph), 115.63 (q, J 288.2 Hz, CF3), 106.78 (4a), 99.37 (C5), 88.16 
(C4’), 87.62 (C l’), 69.50 (C3’), 60.65 (C5’), 41.24 (C2’) 
l9 F-NMR (DMSO, 482 MHz): 6  -73.87
HO'
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Anal. Calcd for C 19H 16N3O6 F3 : C 51.94, H 3.67, N 9.56, O 21.85. Found C 51.80, H 4.00, N 
9.45
MS: 462 (M+Na)
93 3-(2-deoxy-P-D-ribofuranosyl)-6-(m-trifluoroacetylanilinyl)furo[2,3-<%yrimidin-2(3/7)- 
one
[Cf2559]
Prepared according to Standard Procedure D
r  ^ ^ ___ c f 3 u s i n g  3 -e th y n y ltr if lu o r o a c e ty la n ilin e .
White solid: 0.42 g, 32%
'H-NMR (DMSO, 500 MHz): 6  11.41 (1H, bs, 
NH), 8.90 (1H, s, H-4), 8.13 (1H, m, Ph), 7.68 
(2H, d, J 7.6 Hz, Ph), 7.55 (1H, t, 7.9 Hz, Ph), 
7.30 (1H, s, H-5), 6.19 (1H, t, J 6.0 Hz, H -l’), 
4.29-4.23 (1H, m, H-3’), 3.98-3.92 (1H, m, H- 
4’), 3.71 (1H, dd, J 12.2 Hz 3.5 Hz, H-5’a), 
3.65 (1H, dd, J 12.2 Hz 3.7 Hz, H-5’b), 2.46- 
2.40 (1H, m, H-2’„), 2.12 (1H, dt, J 13.8 Hz 6.2
Hz, H-2V
13C-NMR (DMSO, 125 MHz): 8  170.96 (C7a), 154.68 (q, J 36.25 Hz, CONH), 153.74 (C6 ),
152.76 (C2), 138.67 (C4), 137.05 (Ph), 130.03 (Ph), 129.07 (Ph), 122.50 (d, J 13.75 Hz, Ph), 
115.63 (q, J 288.2 Hz, CF3), 106.40 (4a), 100.4 (C5), 88.16 (C4’), 87.70 (C l’), 69.50 (C3’), 
60.65 (C5’), 41.22 (C2’)
19F-NMR (DMSO, 482 MHz): 8  -73.93
Anal. Calcd for C |9 H|6N3 0 6: C 51.94, H 3.67, N 9.56, O 21.85. Found C 51.78, H 3.50, N 
9.68
MS: 462 (M+Na)
HO
HO
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94 3-(2-deoxy-|3-D-ribofuranosyl)-6-(p-anilinyl)furo[2,3-</]pyrimidin-2(3//)'one
[2542]
Compound 92 (0.13 g, 0.3 mmol) was dissolved in a 
mixture MeOH / H20  (5:1) and K2C 0 3 (0.1 g , 2.5 eq.) 
was added. The mixture was stirred for 15 hours at room 
temperature.
The solvent was removed under reduced pressure and the 
residue was purified by column chromatography 
(CHC13:MeOH 9:1) to obtain the titled compound.
White solid: 0.08 g, 80%
'H-NMR (DMSO, 500 MHz): 6 8.74 (1H, s, H-4), 7.65- 
7.50 (4H, m, Ph), 6.99 (1H, s, H-5), 6.19 (1H, t, J 6.2 Hz, H -l’), 5.26 (2H, bs, OH-3’+ OH­
S’), 4.29-4.25 (1H, m, H-3’), 3.96-3.91 (1H, m, H-4’), 3.74-3.60 (2H, m, H-5’), 2.44-2.36 
(1H, m, H-2’„), 2.14-2.06 (1H, m, H-2’„)
l3C-NMR (DMSO, 125 MHz): 5 171.07 (C7a), 155.00 (C6), 153.85 (C2), 136.58 (C4),
127.16 (Ph), 124.60 (Ph), 123.81 (Ph), 119.20 (Ph), 107.45 (4a), 96.19 (C5), 88.08 (C4’)>
87.42 (C l’), 69.61 (C3’), 60.72 (C5’), 41.20 (C2’)
Anal. Calcd for C pH n ^O sF ,: C 59.47, H 4.99, N 12.24, O 23.30. Found C 59.50, H 4.87, N
12.00,0  23.63 
MS: 366 (M+Na)
NH,
HO
HO
181
Marco Migliore
114 2-ethynyl naphthalene
Chapter 9
To a stirred solution of 2-bromonaphthalene (4.14 g, 20 mmol) in dry ACN (100 m) at room 
temperature, TMS-acetylene (8.5 ml, 3 eq.), r^ra& 5 (triphenylphosphine)Pd° (3.2 g, 0.1 eq.), 
copper(I) iodide (0.76 g, 0.2 eq.) and DIPEA (5.2ml, 2 eq.) were added. The reaction mixture 
was stirred for 15 hours at room temperature, after which time a 1M solution of TBAF in 
THF (40 ml, 2 eq.) was added. The solvent was removed under reduced pressure and the 
resulting residue was purified by column chromatography (Hexane : Ethyl Acetate 8:3) to 
afford 2.65 g (87%) of the title compound.
MS: 153(M+H)
111 3-(2-deoxy-P-D-ribofuranosyl)-6-( 1 -naphthyl)furo[2,3-c/]pyrimidin-2(3//)-one
[2577]
To a stirred solution of IDU 1 (1.06 g, 3 mmol) in dry 
DMF (15 m) at room temperature, 1- 
ethynylnaphtalene (1.37 g, 3 eq.),
terra£/s(triphenylphosphine)Pd° (0.35 g, 0.1 eq.), 
copper(I) iodide (0.12 g, 0.2 eq.) and DIPEA (1 ml, 2 
eq.) were added. The reaction mixture was stirred for 
15 hours at room temperature. The solvent was 
removed under reduced pressure and the resulting 
residue was dissolved in DCM and left at 0°C for 5 
hours. The resulting precipitate was filtered and 
washed with DCM. The precipitate was then dissolved in anhydrous Acetone (15 ml) and 
TEA (15 ml) plus silver nitrate (0.5 lg, 1 eq.) were added. The reaction mixture was then 
heated at 60°C and stirred for 5 hours. The solvents were removed under reduced pressure 
and the resulting residue was purified by column chromatography to yield the titled 
compound.
HO
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White solid: 0.40 g, 35%
‘H-NMR (DMSO, 500 MHz): 6 8.94 (1H, s, H-4), 8.35 (1H, d, J 8.2 Hz, Naph), 8.11-8.04 
(2H, m, Naph), 7.90 (1H, d, J 7.2 Hz, Naph), 7.70-7.61 (3H, m, Naph), 7.23 (1H, s, H-5), 6.23 
(1H, t, J 6.1 Hz, H -l’), 5.31 (1H, d, J 4.3 Hz, OH-3’), 5.17 (1H, t, J 5.2 Hz, OH-5’), 4.32-4.26 
(1H, m, H-3’), 4.00-3.95 (1H, m, H-4’), 3.77-3.63 (2H, m, H-5’), 2.50-2.43 (1H, m, H-2’a), 
2 .14(lH ,d t, J 13.4 Hz 6.2 Hz, H-2’p)
13C-NMR (DMSO, 125 MHz): 5 171.06 (C7a), 153.80 (C6), 153.17 (C2), 138.62 (C4), 
133.46 (Naph), 130.29 (Naph), 129.532 (Naph), 128.81 (Naph), 127.42 (Naph), 127.25 
(Naph), 126.49 (Naph), 125.80 (Naph), 125.49 (Naph), 124.68 (Naph), 106.62 (C4a), 103.96 
(C5), 88.25 (C4’), 87.72 (C l’), 69.67 (C3’); 60.79 (C5’), 41.31
Anal. Calcd for C2 1 H 18N2 O5 : C 6 6 .6 6 , H 4.79, N 7.40, O 21.14. Found C 66.20, H 5.10, N
7.79,0  20.91 
MS: 401 (M+Na)
112 3-(2-deoxy-p-D-ribofuranosyl)-6-(2-naphthyl)furo[2,3-<flpyrimidin-2(3//)-one
[Cf2520]
Prepared according to Standard Procedure D using 2- 
ethynylnaphtalene.
Yellow solid: 0.84 g, 74%
'H-NMR (DMSO, 500 MHz) : 6  8.81 (1H, s, H-4),
8.33 (1H, s, Naph), 8.09-7.95 (4H, m, Naph), 7.60- 
7.56 (2H, m, Naph), 7.40 (1H, s, H-5), 6.20 (1H, t, J
5.7 Hz, H - l’), 5.28 (1H, d, J 4.0 Hz, OH-3’), 5.20 (1H, 
t, J 5.2 Hz, OH-5’), 4.29-4.25 (1H, m, H-3’), 3.96-3.92 
(1H, m, H-4’), 3.72 (1H, ddd, J 12.1 Hz 5.1 Hz 3.6 Hz, 
H-5’a), 3.65 (1H, ddd, J 12.1 Hz 5.1 Hz 4.2 Hz, H- 
5’b), 2.45 (1H, ddd, J 13.4 Hz 6.2 Hz 4.0 Hz, H-2’a),
2.11 (1H, dt, J 13.4 Hz 6.0 Hz, H-2’p)
l3C-NMR (DMSO, 125 MHz): 6  171.15 (C7a), 153.79 (C6 ), 153.63 (C2), 138.28 (C4),
133.01 (Naph), 132.81 (Naph), 128.75 (Naph), 128.47 (Naph), 127.70 (Naph), 127.05 (Naph),
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126.98 (Naph), 125.70 (Naph), 123.41 (Naph), 122.22 (Naph), 106.85 (C4a), 100.32 (C5), 
88.18 (C4’), 87.65 (C l’), 69.50 (C3’), 60.66 (C5’), 41.25
Anal. Calcd for C z iH ^ O j:  C 6 6 .6 6 , H 4.79, N 7.40, O 21.14. Found C 66.28, H 4.80, N
7 .69 ,0  21.23 
MS: 401 (M+Na)
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112 3-(2-deoxy-P-D-ribofuranosyl)-6-(2-naphthyl)furo[2,3-<^]pyrimidin-2(3//)-one
[Cf2523]
Prepared according to Standard Procedure D 
using 2 -ethynylnaphtalene.
Yellow solid: 0.81 g, 6 6 %
'H-NMR (DMSO, 500 MHz): 6  8.75 (1H, s, H-4), 
8.23 (1H, s, Naph), 7.98 (1H, d, J 9.3 Hz, Naph), 
7.88 (2H, s, Naph), 7.38 (1H, d, J 2.3 Hz, Naph), 
7.30 (1H, s, H-5), 7.21 (1H, dd, J 9.2 Hz 2.7, 
Naph), 6.21 (1H, t, J 6.0 Hz, H -l’), 5.28 (1H, d, J
4.0 Hz, OH-3’), 5.20 (1H, t, J 5.3 Hz, OH-5’),
4.29-4.25 (1H, m, H-3’), 3.96-3.92 (1H, m, H-4’), 
3.90 (3H, s, OCH3), 3.72 (1H, ddd, J 12.1 Hz 5.1 
Hz 3.6 Hz, H-5’a), 3.65 (1H, ddd, J 12.1 Hz 5.1 Hz 4.2 Hz, H-5’b), 2.45 (1H, ddd, J 13.1 Hz
6.0 Hz 4.1 Hz, H-2’„), 2.11 (1H, dt, J 13.1 Hz 6.0 Hz, H-2’„)
13C-NMR (DMSO, 125 MHz): 6  171.13 (C7a), 158.19 (Naph), 154.00 (C6 ), 153.80 (C2),
137.75 (C4), 134.56 (Naph), 130.05 (Naph), 128.13 (Naph), 127.59 (Naph), 123.43 (Naph),
123.39 (Naph), 122.71 (Naph), 119.41 (Naph), 106.99 (C4a), 106.23 (Naph), 99.11 (C5),
88.16 (C4’), 87.59(C l’), 69.54 (C3’), 60.69 (C5’), 55.30 (OCH3), 41.25
Anal. Calcd for C2 2 H2 0N2 O6 : C 64.70, H 4.94, N 6 .8 6 , O 23.51. Found C 64.46, H 4.80, N
6.80, O 23.94
MS: 431 (M+Na)
HO
HO
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125a Phenyl(methoxy-L-Alaninyl)phosphochloridate
V / o
NH
-Cl
Prepared according to standard procedure A using Alanine methylester 
hydrochloride.
Colourless oil: 1.66 g, 60%
]H-NMR (CDC13, 500 MHz): 6  7.40-7.18 (5H, m, Ph), 4.95-4.73 (1H, 
bs, NH), 4.32-4.10 (1H, m, Ala-CH), 3.82 3.78 (3H, 2 s, est CH3), 1.58- 
1.44 (3H, m, Ala-CH3).
31P-NMR ( C D C I 3 ,  202 MHz): 6  8.08, 7.88
125b Phenyl(ethoxy-L-Alaninyl)phosphochloridate
NH
Prepared according to standard procedure A using Alanine ethylester 
hydrochloride.
Colourless oil: 2.33 g, 80%
C 1 ‘H-NMR (CDCIj, 500 MHz): 6  7.30-7.18 (5H, m, Ph), 4.95-4.83 (1H, 
bs, NH), 4.22-4.01 (3H, m, Ala-CH, est CH2), 1.44-1.39 (3H, m, Ala- 
CH3), 1.22-1.10 (3H, m, est CH3)
3 1 P-NMR (CDC13, 202 MHz): 6  7.97, 7.60
125c Phenyl(n-propoxy-L-Alaninyl)phosphochloridate
Prepared according to standard procedure A using Alanine n- 
propylester hydrochloride 
Colourless oil: 1.98 g, 80%
‘H-NMR (CDCI3 , 500 MHz): 6  7.45-7.18 (5H, m, Ph), 5.32-5.15 
(1H, bs, NH), 4.22-4.07 (3H, m, Ala-CH, est CH2), 1.85-1.62, (2H, 
m, est CH2), 1.61-1.50 (3H, m, Ala-CH3), 0.98-0.85 (3H, m, est 
CH3)
3 ,P-NMR ( C D C I 3 ,  202 MHz): 6  7.80, 7.50
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125d Phenyl(i-propoxy-L-Alaninyl)phosphochloridate
Prepared according to standard procedure A using Alanine i- 
propylester hydrochloride 
j> Colourless oil: 2.17 g, 71% 
b — p— ci ‘H-NMR (CDCb, 500 MHz): 5 7.45-7.18 (5H, m, Ph), 5.32-5.10
'I,., .NH (1H, m, est CH), 4.72-4.57 (1H, bs, NH), 4.22-4.07 (1H, m, Ala-
'o
CH) 1.62-1.58, (3H, m, Ala-CH3), 1.39-1.28 (6 H, m, est CH3) 
3 IP-NMR (CDC13, 202 MHz): 5 7.90, 7.50
125e Phenyl(t-butyloxy-L-Alaninyl)phosphochloridate
W  O
Prepared according to standard procedure A using Alanine t- 
butylester hydrochloride 
Colourless oil: 1.73 g, 54% 
b — p— ci ‘H-NMR (CDCI3 , 500 MHz): 5 7.48-7.23 (5H, m, Ph), 4.65-4.48 (1H, 
" V / NH bs, NH), 4.22-4.00 (1H, m, Ala-CH) 1.60-1.57, (12H, m, est CH3, 
Ala-CH3)
■ o ^ ^ o  3 1 p-NMR (CDC13, 202 MHz): 5 8.08, 7.79
125f Phenyl(benzyloxy-L-Alaninyl)phosphochloridate
W  O
Prepared according to standard procedure A using Alanine 
benzylester hydrochloride 
Colourless oil: 2.40 g, 6 8 % 
o — p— ci 1 H-NMR (CDC13, 500 MHz): b 7.42-7.20 (10H, m, Ph+Bn), 5.30-
V . ^ NH 5.21(2H, m, Bn-CH2), 4.50-4.35 (1H, m, NH), 4.35-4.20 (1H, m, 
Ala-CH) 1.61-1.53 (3H, m, Ala-CH3)
3 1 p-NMR (CDC13, 202 MHz): 6  7.97, 7.60
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125g Phenyl(methoxy-dimethylglycinyl)phosphochloridate
\  / 0
i
-P  Cl
1
,NH
Prepared according to standard procedure A using Dimethylglycine 
methylester hydrochloride.
Colourless oil: 1.57 g, 54%
'H-NMR (CDC13, 500 MHz): 5 7.41-7.19 (5H, m, Ph), 4.97 (1H, d, J
10.0 Hz, NH), 3.79 (3H, s, est CH3), 1.70 (3H, s, DMG-CH3), 1.68 (3H, 
s, DMG-CH3).
3 1P-NMR (CDCI3 , 202 MHz): 6  6.97
125h Phenyl(ethoxy-dimethylglycinyl)phosphochloridate
\  /
Prepared according to standard procedure A using Dimethylglycine 
ethylester hydrochloride, 
jj Colourless oil: 1.37 g, 45% 
o — P— ci 'H-NMR (CDCI3 , 500 MHz): 5 7.38-7.16 (5H, m, Ph), 5.04 ( 1 H, d, J 
J / NH 10.3 Hz, NH), 4.21 (2H, q, J 7.3 Hz, est CH2), 1.67 (3H, s, DMG-CH3), 
1.66 (3H, s, DMG-CH3), 1.27 (3H, t, J 7.1 Hz, est CH3)
3 1 P-NMR (CDCI3 , 202 MHz): 5 7.050 ^ 0
125i Phenyl(ethoxy-dimethylglycinyl)phosphochloridate
\  /
Ph'
Prepared according to standard procedure A using Dimethylglycine 
benzylester hydrochloride, 
jj Colourless oil: 2.83 g, 77%
p— ci >H-NMR (CDC13, 500 MHz): 6  7.51-7.26 (10H, m, Ph+ Bn), 5.30 
(2H, s, Bn-CH2), 5.08 (1H, d, J 9.8 Hz, NH), 1.80 (3H, s, DMG- 
CH3), 1.78 (3H, s, DMG-CH3)
3 1 P-NMR (CDC13, 202 MHz): 6  6.98
.NH
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125j Phenyl(methoxy-phenylalaninyl)phosphochloridate
Prepared according to standard procedure A using phenylalanine 
methylester hydrochloride.
Colourless oil: 2.23 g, 63%
'H-NMR (CDC13> 500 MHz): 6  7.46-7.16 (10H, m, Phe-Ph+Ph), 4.68- 
4.38 (2H, m, Phe-CH+NH), 3.78 3.75 (3H, 2s, est CH3), 3.21-3.16 (2H, 
m, Phe-CH2)
3 1 P-NMR (CDCb, 202 MHz): 6  9.43, 9.25
125k Phenyl(ethoxy-phenylalaninyl)phosphochloridate
Prepared according to standard procedure A using phenylalanine 
ethylester hydrochloride.
Colourless oil: 2.13 g, 58% 
o — p— ci ‘H-NMR (CDC13, 500 MHz): 6  7.41-7.12 (10H, m, Phe-Ph+Ph), 4.50- 
ph/ V . ^ NH 4.24 (2H, m, Phe-CH+NH), 4.24-4.07 (2H, m, est CH2), 3.18-3.11 (2H, 
m, Phe-CH2), 1.30-1.18 (3H, m, est CH3)
^ 0 - ^ 0  3 IP-NMR (CDC13, 202 MHz): 6  9.36, 9.26
125j Phenyl(benzyloxy-phenylalaninyl)phosphochloridate
Prepared according to standard procedure A using phenylalanine 
benzylester hydrochloride.
White solid: 2.13 g, 46% 
o — p— ci jH-NMR (CDC13, 500 MHz): 6  7.41-7.01 (15H, m, Phe-Ph+Ph+Bn), 
/ NH 5.21-5.15 (2H, m, Bn-CH2), 4.62-4.39 (1H, m, Phe-CH), 4.33-4.15
Ph 'Y
(1H, m, NH), 3.24-3.07 (2H, m, Phe-CH2)
3 1 P-NMR (CDCls, 202 MHz): 6  9.10, 9.07
V / o
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126a 3-(2-deoxy-p-D-ribofuranosyl-5-[phenyl-(methoxy-L-alaninyl)]phosphate)-6-(4-
penty lpheny l)furo [2,3 -^pyrimidin-2(3/y)-one
[Cf2451]
CeH,, Prepared according to Standard Procedure B 
using 125a
White foam: 0.04 g, 12%
'H-NMR (CDCI3, 500 MHz): 6  8.60 8.55 (1H, 
2s, H-4), 7.69-7.62 (2H, m, BCNA-Ph), 7.40-
7.10 (7H, m, BCNA-Ph+Ph), 6.60 6.58 (1H, 
2s, H-5), 6.43-6.30 (1H, m, H -l’), 4.62-3.89 
(5H, m, H-3’+H-4’+ Ala-CH+ H-5’), 3.76 
3.70 (3H, 2s, est CH3), 2.90-2.74 (1H, m, H- 
2 ’„), 2.71-2.60 (2H, m, CH2a), 2.20-2.06 (1H, 
m, H-2’,,), 1.74-1.59 (2H, m, CH2§), 1.49-1.22 
(7H, m, CH2Y+CH26 +Ala+CH3), 0.97-0.84 
(3H, m, CH3 co)
,3 C-NMR (CDC13, 125 MHz): 6  173.1 173.0 (Ala-CO), 170.6 (C2), 154.8 (C7a), 153.7 (C6 ),
149.3 149.2 (Ph), 144.0 (C4a), 134.9 (C5), 128.8 128.0, 124.9, 124.3, 123.8, 119.1, 119.0,
107.4 (Ph), 96.2 96.1 (C4), 87.2 (C l’), 84.4 84.3 (C4’), 68.9 (C3’), 64.5 (C5’), 51.7 (est CH3),
49.4 49.2 (Ala-CH), 40.5 (C2’), 34.8 (CH2 a), 30.4 (CH2y), 29.9 (CH2 (3), 21.5 (CH2 6 ), 19.9
19.8 (Ala-CH3), 13.0 (CH3 u>)
3 1 P-NMR (CDCb, 202 MHz): S 4.41, 4.17
Anal. Calcd for C3 2 H3 8N3 C>9 P: C 60.09, H 5.99, N 6.57, O 22.51. Found C 60.46, H 5.67, N
6.80
MS: 662 (M+Na)
PhO P O
NH
HO
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126b 3-(2-deoxy-P-D-ribofuranosyl-5-[phenyl-(ethoxy-L-alaninyl)]phosphate)-6-(4-
penty lpheny l)furo [2,3 -o]py rimidin-2(3//)-one
[Cf2452]
CcH., Prepared according to Standard Procedure B 
using 125b
White foam: 0.02 g, 6 %
‘H-NMR (CDClj, 500 MHz): 5 8.60 8.59 (1H, 
2s, H-4), 7.69-7.58 (2H, m, BCNA-Ph), 7.40-
7.07 (7H, m, BCNA-Ph+Ph), 6.72 6.59 (1H, 
2s, H-5), 6.43-6.30 (1H, m, H -l’), 4.60-3.65 
(7H, H-3’+H-4’+ Ala-CH+ H-5’+est CH2), 
2.90-2.74 (1H, m, H-2’„), 2.71-2.60 (2H, m, 
CH2a ), 2.20-2.06 (1H, m, H-2’„), 1.78-1.55 
(2H, m, CH2 P), 1.49-1.12 (10H, m,
CH2Y+CH25+Ala-CH3+est CH3), 1.01-0.81
(3H , m, (JH3to)
UC-NMR (CDCh, 125 MHz): 6  172.6 172.5 (Ala-CO), 170.5 (C2), 154.9 154.7 (C7 a), 153.9 
(C6 ), 149.5 149.4 149.3 (Ph), 143.9 (C4a), 135.2 135.0 (C5), 128.9 128.0, 127.8, 124.9,
124.8, 124.3, 124.2, 123.8, 119.2, 119.1, 107.4 (Ph), 96.4 96.2 (C4), 87.4 (C l’), 84.7 84.6 
(C4’), 69.1 69.0 (C3’), 65.0 64.8 64.7 (C5’), 60.8 60.7 (est CH2), 49.5 49.3 (Ala-CH), 40.6 
(C2’), 34.8 (CH2 a), 30.4 (CH2Y), 29.9 (CH2 p), 21.5 (CH2 S), 19.9 19.8 (Ala-CHj), 13.1 13.0 
(CHjto), 9.9 (est CH3)
3 1 P-NMR (CDC13, 202 MHz): 6  4.45 4.36
Anal. Calcd for C3 3 H4oN3 0 9 P: C 60.64, H 6.17, N 6.43, O 22.03. Found C 60.65, H 6.47, N
6.85
MS: 676 (M+Na)
PhO P O
NH
HO
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126c 3-(2-deoxy-p-D-ribofuranosyl-5-[phenyl-(n-propoxy-L-alaninyl)]phosphate)-6-(4-
pentylphenyl)furo[2,3-</]pyrimidin-2(3/f)-one
[Cf2453]
o
PhO— P
NH
HO
using 125c
White foam: 0.04 g, 11%
'H-NMR (CDC13, 500 MHz): 6  8.49 8.47 
(1H, 2s, H-4), 7.56-7.46 (2H, m, BCNA-Ph),
7.29-6.95 (7H, m, BCNA-Ph+Ph), 6.50 6.45 
(1H, 2s, H-5), 6.35-6.20 ( 1 H, m, H -l’), 4.61- 
3.20 (8 H, H-3’+H-4’+ Ala-CH+ H-5’+est 
CH2+ NH), 2.80-2.62 (1H, m, H-2’J ,  2.60-
2.40 (2H, m, CH2<x), 2.10-1.90 (1H, m, H-
2 ’p), 1.65-1.40 (4H, m, CH2 p+ est CH2),
1.40-1.12 (7H, m, CH2Y+CH26 +Ala-CH3), 
0.91-0.65 (6 H, m, CH3o>+est CH3)
l3C-NMR (CDCI3 , 125 MHz): 6  174.2 (Ala-CO), 172.0 (C2), 156.3 (C7a), 155.1 (C6 ), 150.5 
(Ph), 145.4 (C4a), 136.5 (C5), 130.3, 129.4, 126.7, 125.8, 125.7, 120.6, 120.5, 109.0 (Ph),
9 7 . 8  97.6 (C4), 88.7 8 8 . 6  (C l’), 8 6 . 0  (C4’), 70.1 (C3’), 67.8 67.7 (est CH2), 6 6 . 0  (C5’), 51.0
50.9 (Ala-CH), 42.5 (C2’), 36.2 (CH2 a ), 31.9 (CH2y), 31.3 (CH2 p), 22.9 (CH2 6 ), 22.2 (est
CH2), 21.3 (Ala-CHj), 14.4 (CH3 w), 10.6 (est CH3)
3 1 P-NMR (CDCI3 , 202 MHz): 6  4.61 4.43
Anal. Calcd for C3 4 H4 2N 3 0 9 P: C 61.16, H 6.34, N 6.29, O 21.57. Found C 60.86, H 6.43, N
6.01
MS: 690 (M+Na)
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126d 3 -(2 -deoxy-p-D-ribofuranosyl-5 -[phenyl-(i-propoxy-L-alaninyl)]phosphate)-6 -(4 - 
pentylphenyl)furo[2,3-<flpyrimidin-2(3.tf)-one 
[CK454]
c 5h u  Prepared according to Standard Procedure B 
using 125d
White foam: 0.05 g, 15%
‘H-NMR (CDC13, 500 MHz): 6  8.60 8.55 (1H, 
2s, H-4), 7.69-7.62 (2H, m, BCNA-Ph), 7.40-
7.10 (7H, m, BCNA-Ph+Ph), 6.60 6.58 (1H, 
2s, H-5), 6.43-6.30 (1H, m, H 1’), 5.10-4.88 
(1H, m, est CH), 4.62-3.89 (5H, H-3’+H-4’+ 
Ala-CH+ H-5’), 2.88-2.70 (1H, m, H-2’„), 
2.70-2.53 (2H, m, CH2oc), 2.18-2.00 (1H, m, 
H-2'p), 1.74-1.51 (2H, m, CH2), 1.49-1.05 
(13H, m, CH2y+CH2 6 +Ala-CH3+ est CH3), 
1.01-0.81 (3H, m, CH3)
l3C-NMR (CDCI3 , 125 MHz): 6  173.5 173.4 (Ala-CO), 172.0 (C2), 156.2 156.1 (C7a), 155.3 
(C6 ), 150.7 150.8 (Ph), 145.3 (C4a), 136.6 136.4 (C5), 130.2, 129.4, 126.3, 125.6, 125.2, 
120.7, 120.6, 108.9 (Ph), 97.8 97.7 (C4), 8 8 . 8  88.7 (C l’), 86.1 (C4’), 70.4 70.3 (est CH), 69.9
69.8 (C3’), 66.2 (C5’), 51.0 50.8 (Ala-CH), 42.0 (C2 ’), 36.2 (CH2a), 31.9 (CH2y), 31.3 
(CH2 P), 22.9 (CH2 5), 22.2 22.1 (est CH3), 21.3 (Ala-CHj), 14.4 (CH3co)
3 1 P-NMR (CDC13, 202 MHz): 6  4.49 4.43
Anal. Calcd for C34 H42N 3 0 9P: C 61.16, H 6.34, N 6.29, O 21.57. Found C 60.06, H 6.33, N
6.41
MS: 690 (M+Na)
PhO P O
NH
HO
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126e 3-(2-deoxy-|3-D-ribofuranosyl-5-[phenyl-(t-butoxy-L-alaninyl)]phosphate)-6-(4-
penty lpheny l)furo [2,3 -</]pyrimidin-2(3 H )-ouq
[Cf2455]
c 5h „  Prepared according to Standard Procedure B 
using 125e
White foam: 0.06 g, 17%
'H-NMR (CDC13, 500 MHz): 6  8.60 8.55 (1H, 
2s, H-4), 7.69-7.62 (2H, m, BCNA-Ph), 7.40-
7.10 (7H, m, BCNA-Ph+Ph), 6.60 6.58 (1H, 
2s, H-5), 6.43-6.30 (1H, m, H -P), 4.62-3.89 
(6 H, H -3’+H-4’+ Ala-CH+ H-5’+NH), 2.90- 
2.74 (1H, m, H-2’a), 2.71-2.60 (2H, m, CH2a), 
2.20-2.06 (1H, m, H-2’p , 1.74-1.59 (2H, m, 
CH2), 1.49-1.22 (16H, m, CH2y+CH2d+Ala- 
CH3+ est CH3), 0.97-0.84 (3H, m, CH3) 
l3C-NMR (CDC13, 125 MHz): 6 171.7 171.6 (Ala-CO), 170.6 (C2), 154.9 154.7 (C7a), 153.8 
(C6 ), 149.5 149.4 149.3 (Ph), 143.9 (C4a), 135.0 134.8 (C5), 128.8, 128.0, 124.9, 124.3,
124.2, 123.9, 119.2, 119.1, 107.5 (Ph), 96.4 96.2 (C4), 87.3 87.1 (C P ), 84.6 84.5 (C4’), 81.4
81.3 (est C), 69.0 68.8 (C3’)s 64.7 (C5’), 49.9 49.8 49.7 (Ala-CH), 40.7 40.5 (C2’), 34.8 
(CH2a), 30.4 (CH2y), 29.9 (CH2p), 26.9 (est CH3), 21.5 (CH25), 20.1 20.0 (Ala-CHj), 13.0 
(CH3co)
31P-NMR (CDCI3, 202 MHz): 6  4.59 4.52
Anal. Calcd for C35H44N 3O9P: C 61.66, H 6.51, N 6.16, O 21.12. Found C 61.70, H 6.48, N 
6.10
MS: 704 (M+Na)
PhO----
NH
HO
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126f 3-(2-deoxy-p-D-ribofuranosyl-5-[phenyl-(benzyloxy-L-alaninyl)]phosphate)-6-(4-
penty lpheny l)furo [2,3 -<flpyrimidin-2(3//)-one
[Cf2300]
CcH,, Prepared according to Standard Procedure B 
using 125f
White foam: 0.09 g, 24%
'H-NMR (CDC13, 500 MHz): 5 8.45 8.34 (1H, 
2s, H-4), 7.56-7.48 (2H, m, BCNA-Ph), 7.27-
7.00 (12H, m, BCNA-Ph+Ph+Bn), 6.47 6.45 
(1H, 2s, H-5), 6.27-6.21 (1H, m, H -l’), 5.07-
4.98 (2H, m, Bn-CH2), 4.44-3.88 (6 H, m, H- 
3’+H-4’+Ala-CH+H-5’+NH), 2.73-2.60 (1H, 
m, H-2’„), 2.59-2.50 (2H, m, CH2ct), 2.05-1.85 
(1H, m, H-2’p), 1.60-1.50 (2H, m, CH2P), 
1.36-1.09 (7H, m, CH2Y+CH2d+Ala+CH3), 
0.87-0.80 (3H, m, CH3w)
13C-NMR (CDC13, 125 MHz): 6  172.9 172.8 (Ala-CO), 170.6 (C2), 154.8 (C7a), 153.7 (C6 ),
146.4 146.3 (C4a), 138.7 138.5 (C5), 130.9, 130.8, 130.2, 129.6, 129.4, 129.3, 129.2, 126.3,
125.9, 125.8, 1 2 1 .6 , 121.5, 121.3, 1 2 1 .2 , 104.7, 104.5 (Ph), 99.2 99.1 (C4), 90.3 90.2 (C l’),
87.8 87.7 87.6 (C4’), 71.7 71.6 (C3’), 68.1 68.0 (Bn-CH2), 67.5 67.4 67.3 67.2 (C5’), 51.9
51.7 (Ala-CH), 42.8 42.7 (C2’), 36.7 (CH2 a), 32.6 (CH2y), 32.2 (CH2 p), 23.6 (CH2 8 ), 20.3 
(Ala-CHj), 14.4 (CH3w)
3 IP-NMR (CDCIj, 202 MHz): 6  4.22, 3.49
Anal. Calcd for C3 8H4 2N3 0 9 P: C 63.77, H 5.91, N 5.57, O 20.12. Found C 63.80, H 5.90, N
5.85
MS: 738 (M+Na)
PhO P O
NH
HO
Ph
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126g 3-(2-deoxy-p-D-ribofuranosyl-5-[phenyl-(methoxy-dimethylglycinyl)]phosphate)-6-(4-
pentylphenyl)furo[2,3-rf]pyrimidin-2(3//)-one
[Cf2481]
jCjH,, Prepared according to Standard Procedure B 
using 125g
White foam: 0.07 g, 22%
'H-NMR (CDClj, 500 MHz): 6  8.63 8.55 
(1H, 2s, H-4), 7.72-7.59 (2H, m, BCNA-Ph),
7.41-7.20 (7H, m, BCNA-Ph+Ph), 6.61 6.59 
(1H, 2s, H-5), 6.48-6.37 (1H, m, H -l’), 4.84- 
4.73 (1H, bs, NH), 4.64-4.42 (2H, m, H- 
3 ’+H-4’), 4.41-4.29 (2H, m, H-5’), 3.76 (3H, 
2, est CH3), 2.94-2.76 (1H, m, H-2’„), 2.73-
2.61 (2H, m, CH2a), 2.18-2.02 (1H, m, H- 
2’p), 1.75-1.56 (8 H, m, CH2 p+ DMG-CH3), 
1.47-1.32 (4H, m, CH2y+CH2), 0.95-0.84 (3H, m, CH3co)
n C-NMR (CDCb, 125 MHz): 5 176.4 176.2 176.1 (DMG-CO), 172.0 (C2), 156.3 156.1 
(C7a), 155.2 (C6 ), 151.1 151.0 150.9 (Ph), 145.4 145.3 (C4a), 136.6 136.3 (C5), 130.2, 130.1,
129.4, 126.3, 125.6, 125.3, 120.7, 120.6, 108.9 (Ph), 97.8 97.6 (C4), 8 8 . 8  8 8 . 6  (C l’), 86.1
86.0 (C4’), 70.6 70.4 (C3’), 66.4 66.3 (C5’), 57.7 57.6 (DMG-C), 53.4 (est CH3), 42.1 42.0 
(C2’)> 36.2 (CH2 a), 31.9 (CH2y), 31.4 (CH2 p), 27.5 27.4 (DMG-CH3), 22.9 (CH2 6 ), 14.4 
(CHjco)
3 IP-NMR (CDCb, 202 MHz): 6  3.01,2.93
Anal. Calcd for C3 3H4oN3 0 9 P: C 60.64, H 6.17, N 6.43, O 22.03. Found C 60.58, H 6.20, N
6.80
MS: 676 (M+Na)
PhO-----
NH
HO
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126h 3-(2-deoxy-|3-D-ribofuranosyl-5-[phenyl-(ethoxy-dimethylglycinyl)]phosphate)-6-(4-
pentylphenyl)furo[2,3-c/]pyrimidin-2(3//)-one
[Cf2482]
c . h „ Prepared according to Standard Procedure B 
using 125h
White foam: 0.06 g, 19%
‘H-NMR (CDClj, 500 MHz): 6  8.51 8.40 (1H, 
2s, H-4), 7.61-7.53 (2H, m, BCNA-Ph), 7.22-
6.99 (7H, m, BCNA-Ph+Ph), 6.50 (1H, 2s, H- 
5), 6.35-6.26 ( 1 H, m, H -l’), 4.52-4.04 (7H, m, 
NH+H-3’+H-4’+H-5’+est CH2), 2.85-2.62 
(1H, m, H-2’a), 2.62-2.49 (2H, m, CH2a), 
2.06-1.82 (1H, m, H-2’p), 1.65-1.41 (8 H, m, 
CH2 (3+ DMG-CHj), 1.40-1.09 (7H, m, 
CH2y+CH2 6 +est CH3), 0.95-0.91 (3H, m,
“ C-NMR (CDCb, 125 MHz): 5 175.9 175.7 175.6 (DMG-CO), 172.0 171.9 (C2), 156.2
156.1 (C7a), 155.3 155.2 (C6 ), 151.1 151.0 150.9 (Ph), 145.4 145.3 (C4a), 136.7 136.4 (C5),
130.2, 130.1, 130.0, 129.4, 126.3, 125.5, 125.2, 120.7, 120.6, 120.5, 108.9 108.8 (Ph), 97.8
97.6 (C4), 8 8 . 8  88.7 (C l’), 86.2 86.1 (C4’), 70.6 70.4 (C3’), 66.4 (C5’), 62.4 (est CH2), 57.5 
(DMG-C), 42.1 42.0 (C2’), 36.2 (CH2a ), 31.9 (CH2y), 31.4 (CH2 p), 27.4 27.3 (DMG-CH3),
22.9 (CH2 5), 14.5 14.4 (CH3co), 14.3 (est CH3)
3 1 P-NMR (CDCb, 202 MHz): 6  3.01,2.87
Anal. Calcd for C3 4 H4 2N3 0 9P: C 61.16, H 6.34, N 6.29, O 21.57. Found C 60.98, H 6.30, N
6.09
MS: 690 (M+Na)
PhO P O
NH
HO
CH3 o>)
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126i 3-(2-deoxy-p-D-ribofuranosyl-5-[phenyl-(benzyloxy-dimethylglycinyl)]phosphate)-6-(4-
penty lpheny l)furo [2,3 -^0 pyrimidin-2(3/i)-one
[Cf2483]
CcH,, Prepared according to Standard Procedure B 
using 125i
White foam: 0.05 g, 15%
'H-NMR (CDC13, 500 MHz): 6  8.54 8.46 (1H, 
2s, H-4), 7.62-7.51 (2H, m, BCNA-Ph), 7.37-
6.99 (12H, m, BCNA-Ph+Ph+Bn), 6.52 6.49 
(1H, 2s, H-5), 6.40-6.25 (1H, m, H -l’), 4.92-
4.72 (2H, m, Bn-CH2), 4.54-4.17 (5H, m, 
NH+H-3’+H-4’+H-5’). 2.86-2.65 ( 1 H, m, H- 
2 ’„), 2.65-2.53 (2H, m, CH2ct), 2.08-1.90 (1H, 
m, H-2'p), 1.68-1.49 (8 H, m, CH2p+ DMG- 
CH3), 1.40-1.22 (4H, m, CH2y+CH2 6 ), 0.96- 
0.80 (3H, m, CH3co)
l3C-NMR (CDCb, 125 MHz): 6  174.3 174.2 (DMG-CO), 170.5 (C2), 154.9 154.7 (C7a),
153.9 (C6 ), 149.5 (Ph), 143.9 (C4a), 135.3 135.0 (C5), 134.3, 134.2, 128.8, 128.7, 127.9, 
127.6, 127.4, 127.0, 126.9, 124.8, 124.7, 124.2, 123.8, 119.3, 119.2, 107.6 (Ph), 96.4 96.2 
(C4), 87.3 87.1 (C l’), 84.6 (C4’), 68.7 68.4 (C3’), 6 6 . 6  (C5’), 64.7 (Bn-CH2), 56.2 (DMG-C),
40.5 40.3 (C2’), 34.8 (CH2a), 30.4 (CH2y), 29.9 (CH2 p), 26.1 26.0 25.9 (DMG-CH3), 21.5 
(CH2 6 ), 13.0 (CH3<u)
3 ,P-NMR (CDCb, 202 MHz): 6  3.16, 3.10
Anal. Calcd for C3 9 H4 4N3O9 P: C 64.19, H 6.08, N 5.57, O 19.73. Found C 64.35, H 6.38, N 
5.15
MS: 752 (M+Na)
PhO P
NH
HO
Ph
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126j 3-(2-deoxy-(3-D-ribofuranosyl-5-[phenyl-(methoxy-phenylalaninyl)]phosphate)-6-(4-
pentylphenyl)furo[2,3-rf]pyrimidin-2(3/f)-one
[Cf2484]
c.n,, Prepared according to Standard Procedure 
B using 125j 
White foam: 0.04 g, 12%
'H-NMR (CDClj, 500 MHz): 6  8.54 8.51 
(1H, 2s, H-4), 7.70-7.56 (2H, m, BCNA- 
Ph), 7.32-7.04 (12H, m, BCNA-
Ph+Ph+Phe-Ph), 6.60 6.50 (1H, 2s, H-5),
6.44-6.29 ( 1 H, m, H -l’), 4.54-3.89 (6 H, 
m, NH+H-3 ’+H-4’+H-5’+Phe-CH), 3.68 
3.65 (3H, 2s, est CH3), 3.17-2.60 (5H, m, 
Phe-CH+H-2’„+CH2a ), 2.15-1.89 ( 1 H, m, 
H-2'p), 1.77-1.59 (2H, m, CH2), 1.46-1.30
I3C-NMR(CDC13, 125 MHz): 8  173.4 173.2 173.1 (Phe-CO), 171.9 (C2), 156.2 156.1 (C7a),
155.3 (C6 ), 150.9 150.7 (Ph), 145.4 145.3 (C4a), 136.5 136.3 (C5), 130.2, 130.1, 129.9,
129.5, 129.4, 129.1, 127.6, 127.5, 126.3, 125.6, 125.5, 125.3, 120.7, 120.6, 120.5, 120.4,
108.9 (Ph), 97.9 97.7 (C4), 89.0 (C l’), 86.2 (C4’), 70.6 70.4 (C3’), 66.3 (C5’), 56.7 56.3 
(Phe-CH), 52.8 (est CH3), 42.0 (C2’), 40.6 (Phe-CH2), 36.2 (CH2 a), 31.9 (CH2y), 31.4 
(CH2 p), 22.9 (CH2 6 ), 14.4 (CH3to)
3 IP-NMR (CDC13, 202 MHz): 8  4.34,4.15
Anal. Calcd for C3 8 H4 2N30 9P: C 63.77, H 5.91, N 5.87, O 20.12. Found C 63.58, H 5.96, N
6.12
MS: 738 (M+Na)
o
PhO P
HO
(4H, m, CH2y+CH2), 1.03-0.90 (3H, m, CH3 co)
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126k 3-(2-deoxy-fl-D-ribofuranosyl-5-[phenyl-(ethoxy-dimethylglycinyl)]phosphate)-6-(4-
pentylphenyl)furo[2,3-<|pyrimidm-2(3fl)-one
[Cf2485]
c «h ,, Prepared according to Standard Procedure 
B using 125k 
White foam: 0.05 g, 13%
'H-NMR (CDCI3 , 500 MHz): 6  8.57 8.53 
(1H, 2s, H-4), 7.69-7.56 (2H, m, BCNA- 
Ph), 7.36-6.93 (12H, m, BCNA-
Ph+Ph+Phe-Ph), 6.60 6.51 (1H, 2s, H-5),
6.45-6.32 (1H, m, H -l’), 4.57-3.97 (8 H, 
m, NH+H-3’+H-4’+H-5’+Phe-CH+est 
CH2), 3.24-2.53 (5H, m, Phe-CH+H- 
2 ’a+CH2a), 2.17-1.84 (1H, m, H-2’p), 
1.80-1.51 (2H, m, CH2 |3), 1.48-1.28 (4H, 
m, CH2y+CH2 6 ), 1.25-1.12 (3H, m, est CH3), 1.03-0.88 (3H, m, CH3to)
13C-NMR (CDCI3 , 125 MHz): 6  173.0 172.9 172.8 (Phe-CO), 171.9 (C2), 156.2 156.0 (C7a),
155.3 (C6 ), 150.8 (Ph), 145.3 (C4a), 136.7 136.5 136.4 (C5), 130.2, 130.1, 129.9, 129.4,
129.0, 127.6, 127.5, 126.3, 125.6, 125.5, 125.3, 120.7, 120.6, 120.5, 120.4, 108.9 (Ph), 97.9
97.8 (C4), 88.9 (C l’), 86.3 86.2 86.1 (C4’), 70.6 70.4 (C3’), 66.2 (C5’), 62.0 (est CH2), 56.7
56.3 (Phe-CH), 42.1 42.0 (C2’), 40.7 (Phe-CH2), 36.2 (CH2 a), 31.9 (CH2Y), 31.3 (CH2 p),
22.9 (CH2S), 14.4 (est CH3), 14.2 (CH3co)
3 1 P-NMR (CDCI3 , 202 MHz): 6  4.44,4.19
Anal. Calcd for C39H44N3O9P: C 64.19, H 6.08, N 5.76, O 19.73. Found C 64.43, H 6.10, N
5.42
MS: 752 (M+Na)
PhO P
HO
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1 2 6 j 3 -(2 -deoxy-(3 -D-ribofuranosyl-5 -[phenyl-(benzyloxy-phenylalaninyl)]phosphate)-6 -(4 - 
pentylphenyl)furo[2,3-</]pyrimidin-2(3//)-one
[Cf2484]
c 5Hn Prepared according to Standard 
Procedure B using 125j 
White foam: 0.07 g, 17%
‘H-NMR (CDC13, 500 MHz): 6  8.54 
8.52 (1H, 2s, H-4), 7.69-7.57 (2H, m, 
BCNA-Ph), 7.43-7.00 (17H, m, BCNA- 
Ph+Ph+Phe-Ph+Bn), 6.58 6.51 (1H, 2s, 
H-5), 6.45-6.31 (1H, m, H -l’), 5.20-5.01 
(2H, m, Bn-CH2), 4.51-4.01 (6 H, m, 
NH+H-3’+H-4’+H-5’+Phe-CH), 3.10-
2.87 (2H, m, Phe-CH), 2.81-2.63 (3H, 
m, H-2’a+CH2a), 2.00-1.84 (1H, m, H- 
2’p), 1.67-1.51 (2H, m, CH2 P), 1.38-1.19 (4H, m, CH2y+CH2S), 0.94-0.80 (3H, m, CH3 ca) 
13C-NMR (CDCI3 , 125 MHz): 6  171.3 171.2 (Phe-CO), 170.5 (C2), 154.8 154.6 (C7a), 153.8 
(C6 ), 149.4 (Ph), 143.8 (C4a), 134.6 134.5 (C5), 133.9, 128.8, 128.7, 128.5, 127.9, 127.6,
127.5, 127.4, 126.1, 124.8, 124.2, 124.1, 123.8, 119.2, 119.1, 119.0, 107.4 (Ph), 96.4 96.3 
(C4), 87.4 (C l’), 84.6 84.5 (C4’), 69.1 69.0 (C3’)> 66.3 (C5’), 64.8 (Bn-CH2), 55.2 54.8 (Phe- 
CH), 40.5 (Phe-CH2), 39.2 (C2’), 34.8 (CH2 a), 30.4 (CH2y), 29.9 (CH2 p), 21.5 (CH2 6 ), 13.0 
(CH3 co)
3 ,P-NMR (CDCI3 , 202 MHz): 6  4.40, 4.28
Anal. Calcd for C4 4 H46N 3O9 P: C 66.74, H 5.86, N 5.31, O 18.19. Found C 6 6 .6 8 , H 5.96, N
5.01
MS: 814 (M+Na)
PhO----
HO
Ph
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127 3-(2’-Deoxy-|3-D-ribofuranosyl-5’-[bis(4-methoxyphenyl)-phenyl]-6-(4-pentylphenyl)-
2 ,3 -di hy drof u ro [2 ,3 -af] py ri mi di n-2 -one
c 5h u  33b (0.5 g, 1.25 mmol) was dissolved in 
pyridine ( 1 0  ml),
dimethoxytrirylchlorode (0.51 g, 1 . 2  eq.) 
was added at 0°C and the solution was 
stirred overnight at room temperature. 
The solvents were evaporated under high 
vacuum and the residue was purified by 
column chromatography pre-washed with 
TEA (CHC13 : MeOH: Et3N 95:5) to 
obtain 0.56 g (64%) as orange solid.
‘H-NMR (DMSO, 500 Mhz): 6  9.05 (1H, 
s, H-4), 7.58-6.87 (13H, m, Trityl), 6.25 
(1H, dd, J 6.7 Hz 3.6 Hz, H -l’), 5.80 (1H, s, H-5), 4.72 (1H, q, J 6.7 Hz, H-3’), 4.12 (1H, dt, J
5.7 Hz 2.9 Hz, H-4’), 3.76 (3H, s, OCH3), 3.73 (3H, s, OCH3), 3.59 (1H, dd, J 11.0 Hz 3.0 Hz, 
H-5’), 3.53 (1H, dd, J 11.0 Hz 2.7 Hz, H-5’), 2.70-2.63 (3H, m, CH2a  + H-2’a), 2.46 (1H, 
ddd, J 13.8 Hz 6.5 Hz 3.7 Hz, H-2’), 1.66 (2H, qn, J 7.5 Hz, CH2 |3), 1.41-1.33 (4H, m, CH2y + 
CH26 ), 0.93 (3H, t J 6 . 8  Hz, CH3w)
13C-NMR (DMSO, 125 MHz) : 172.73 (C7a), 160.33 (C), 160.26 (Ph), 156.70 (Ph), 156.57 
(Ph), 153.89 (C=0), 153.75 (C6 ), 146.21 (Ph), 145.61 (C4a), 138.84 (C4), 137.18, 136.72, 
131.58, 131.38, 130.17, 129.70, 129.26, 128.31, 127.14, 125.82, 125.59, 114.53, 114.51,
109.55 (Ph), 98.75 (C5), 89.59 (C l’), 88.45 (Ph-Cq), 87.85 (C4’), 69.89 (C3’), 63.14 (C5’), 
55.89 (OCH3), 55.87 (OCH3), 42.93 (C2’), 36.81 (CH2a), 32.66 (CH2y), 32.15 (CH2 |3), 23.65 
(CH2 6 ), 14.64 (CH3 co)
MS: 723 (M+Na)
OMe
HO
OMe
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128a 3-(2-deoxy-P-D-ribofuranosyl-3-[phenyl-(methoxy-L-alaninyl)]phosphate)-6-(4- 
pentylphenyl)furo[2,3-^Jpyrimidin-2(3//)-one 
[Cf2511]
c 5h u Prepared according to Standard Procedure C 
using 125a
White foam: 0.08 g, 25%
'H-NMR (CDC13, 500 MHz): d 8.74-8.69 (1H, 
2s, H-4), 7.54-6.66 (10H, m, BCNA-Ph+Ph+H- 
5), 6.24-6.20 (1H, m, H -l’), 5.12-5.05(1H, m, 
H-3’), 4.20-3.49 (8H, m. H-4’+ H-5’+Ala- 
CH+est CH3+NH), 2.85-2.27 (4H, m, H- 
2’„+CH2a), 1.54-1.43 (2H, m, CH2p), 1.30-
1.11 (7H, m, CH2Y+CH26+Ala-CH3), 0.82-0.80 
(3H, m, CH3co)
13C-NMR (CDC13s 125 MHz): 6 173.1 173.0
172.9 172.8 (Ala-CO), 170.5 (C2), 155.1 155.0 
(C7a), 163.8 (C6), 149.3 149.2 (Ph), 144.1 144.0 (C4a), 135.7 135.5 (C5), 128.9, 128.8,
128.5, 128.4 127.96,124.77, 124.3 123.9, 119.6 119.3, 119.2, 119.0, 118.9, 114.4, 107.8,
107.7 (Ph), 96.3 (C4), 87.1 86.9 (C l’), 85.4 (C4’), 75.8 75.3 73.9 73.1 (C3’), 60.2 59.8 (C5’),
51.7 51.3 (est CH3), 49.4 49.1 (Ala-CH), 39.2 39.1 39.0 (C2’), 34.8 (CH2a), 30.4 (CH2y),
29.9 (CH2p), 21.5 (CH26), 19.6 19.5(Ala-CH3), 12.9 (CH3<d).
31P-NMR (CDCb, 202 MHz): 5 3.14, 3.21
Anal. Calcd for C32H38N30 9P: C 60.09, H 5.99, N 6.57, O 22.51. Found C 60.10, H 5.80, N
6.42
MS: 662 (M+Na)
HO
O
O. HN P OPh
-O
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128b 3-(2-deoxy-j3-D-ribofuranosyl-3-[phenyl-(ethoxy-L-alaninyl)]phosphate)-6-(4-
pentylphenyl)furo[2,3-tfGpyrimidin-2(3//)-one
[Cf2510]
CcH,, Prepared according to Standard Procedure C 
using 125b
White foam: 0.10 g, 32%
'H-NMR (CDCls, 500 MHz): 5 8.66-8.61 
(1H, 2s, H-4), 7.56-7.06 (9H, m, BCNA- 
Ph+Ph), 6.60-6.59 (1H, 2s, H-5), 6.28-6.22 
(1H, m, H - l’), 5.14-5.09 (1H, m, H-3’), 4.17-
3.40 (7H, m. H-4’+ H-5’+Ala-CH+est
CH2 +NH), 2.83-2.22 (4H, m, H-2’a+CH2 a), 
1.59-1.41 (2H, ra, CH2 (3 ), 1.36-1.11 (10H, m, 
CH2y+CH2 6 +Ala-CH3+est CH3), 0.86-0.81 
(3H, m, CH3 io)
n C-NMR (CDCb, 125 MHz): 6  173.8 173.7
173.5 173.4 (Ala-CO), 171.8 171.7 (C2), 155.9 155.8 (C7a), 154.8 (C6 ), 150.4, 150.3, 145.0,
144.9, 136.4, 136.3,129.9, 129.8, 128.9, 125.9, 125.8, 125.3, 125.2, 124.9, 120.4, 120.3,
120.0, 119.9, 108.5, 108.4 (Ph), 97.17 (C4), 87.9 87.8 (C l’), 86.4 86.3 86.2 86.1 (C4’), 76.1
76.0 74.4 74.3 (C3’), 61.8 61.7 61.2 60.7 (C5’ + est CH2), 50.4 50.2 (Ala-CH), 40.3 40.0 
(C2’), 35.8 (CH2a), 31.4 (CH2y), 30.9 (CH2 p), 22.5 (CH2 6 ), 20.7 20.6 (Ala-CH3), 14.1 
(CH3 w), 14.0 (est CH3)
3 IP-NMR (CDCb, 202 MHz): 5 3.13, 2.05
Anal. Calcd for C3 3 H4oN3 0 9 P: C 60.64, H 6.17, N 6.43, O 22.03. Found C 60.45, H 6.15, N
6.12
MS: 676 (M+Na)
HO
I
Ov HN P
x _ K ‘
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128f 3-(2-deoxy-P-D-ribofuranosyl-3-[phenyl-(benzyloxy-L-alaninyl)]phosphate)-6-(4-
pentylphenyl)furo[2,3-^pyrimidin-2(3/f)-one
[Cf2512]
128.3 128.2 128.1 125.9 125.8 125.3 124.9 120.4 120.3 120.0 119.9 108.5 108.4 (Ph), 97.2
(Ala-CH3), 14.0 (CH3co)
3 1 P-NMR (CDC13, 202 MHz): 6  3.00, 1.92
Anal. Calcd for C38H42N30 9P: C 63.77, H 5.91, N 5.87, O 20.12. Found C 63.90, H 6.05, N 
5.59
MS: 738 (M+Na)
- /  using 125f
y  White foam: 0.20 g, 56%
‘H-NMR (CDCI3 , 500 MHz): 6  8.66-8.61
c sh „ Prepared according to Standard Procedure C
O HN-----P-----OPh
i *
a
(1H, 2s, H-4), 7.54-7.04 (14H, m, BCNA- 
Ph+ Phe-Ph+Bn), 6.59-6.57 (1H, 2s, H-5), 
6.25-6.21 (1H, m, H -l’), 5.15-4.98 (3H, m, 
H-3’+Bn-CH2), 4.27-3.75 (5H, m, H- 
4’+H5’+Ala-CH+NH), 2.82-2.20 (4H, m, 
H-2’+CH2 a), 1.57-1.51 (2H, m, CH2 p), 
1.30-1.13 (7H, m, CH2v+CH2 6 +Ala-CH3), 
0.83-0.77 (3H, m, CH3 cd)
n C-NMR (CDC13, 125 MHz): 5 173.6
173.5 173.4 (Ala-CO), 171.7 171.6 (C2), 155.9 (C6 ), 154.90 154.83, 150.37, 150.32 (Ph), 
145.0 144.9 (C4a), 136.5 136.4 (C5), 135.2, 135.1, 129.9 129.7 128.9 128.7 128.6 128.4
(C4), 87.8 (C l’), 86.3 (C4’), 76.1 76.0 74.8 74.7 (C3’), 67.4 67.2 (Bn-CH2), 50.5 50.2 (Ala- 
CH), 40.3 40.1 (C2’), 35.8 (CH2a), 31.5 (CH2y), 30.9 (CH2 p), 22.5 (CH2 5), 20.6 20.5 20.4
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128j 3-(2-deoxy-p-D-ribofuranosyl-3-[phenyl-(methoxy-L-phenylalaninyl)]phosphate)-6-(4-
pentylphenyl)furo[2,3-<flpyrimidin-2(3//)-one
[Cf2513]
o.
-o
HO
c sh u Prepared according to Standard Procedure C 
using 125j
White foam: 0.18 g, 52%
'H-NMR (CDCI3 , 500 MHz): 6  8.59-8.56 (1H, 
2s, H-4), 7.70-7.07 (14H, m, BCNA-
Ph+Ph+Phe-Ph), 6.70-6.69 (1H, 2s, H-5), 6.30- 
6.22 (1H, m, H -l’), 5.06-4.86 (1H, m, H-3’),
4.29-3.51 (8 H, m, H-4’+H-5’+Phe-CH+est
CH3 +NH), 3.14-2.17 (6 H, m, H-2’+CH2 a+Phe- 
CH2), 1.69-1.62 (2H, m, CH2 0), 1.40-1.32 (4H, 
m, CH2y+CH2), 0.94-0.91 (3H, m, CH3 co) 
l3 C-NMR (CDC13, 125 MHz): 6  172.8 (Phe- 
CO), 171.8 (C2), 156.1 156.0 (C7a), 154.6 
(C6 ), 150.3 (Ph), 145.1 (C4a), 135.9 135.8 
(C5), 135.5, 129.8, 129.4, 129.0, 128.7, 127.4, 124.3, 125.9, 125.4, 125.3, 125.0, 124.9,
120.3, 120.2, 120.0, 108.4, 108.2 (Ph), 96.9 (C4), 87.8 87.5 (C l’), 85.7 (C4’), 75.1 73.8
(C3’>, 61.0 60.6 (C5’), 56.0 55.6 (Phe-C), 52.5 52.4 (est CH3), 40.3 40.2 (Phe-CH2), 40.2 40.1
39.8 39.5 (C2’), 34.8 (CH2 a), 31.4 (CH2y), 30.9 (CH2 p), 22.5 (CH2 6 ), 14.0 (CH3 co)
3 1 P-NMR (CDC13, 202 MHz): 5 3.19, 2.49
Anal. Calcd for C3 8H4 2 N3 0 9 P: C 63.77, H 5.91, N 5.87, O 20.12. Found C 63.85, H 5.69, N
5.55
MS: 738 (M+Na)
-OPh
Ph
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128k 3-(2-deoxy-p-D-ribofuranosyl-3-[phenyl-(ethoxy-L-phenylalaninyl)]phosphate)-6-(4-
pentylphenyl)furo[2,3-aT]pyrimidin-2(3W)-one
[Cf2514]
c«H„ Prepared according to Standard Procedure C 
using 125k
White foam: 0.21 g, 58%
'H-NMR (CDCI3 , 500 MHz): 6  8.52-8.50 
(1H, 2s, H-4), 7.59-6.98 (14H, m, BCNA- 
Ph+Ph+Phe-Ph), 6.60-6.59 (1H, 2s, H-5 ), 
6.22-6.12 ( 1 H, m, H -l’), 5.00-4.77 ( 1 H, m, 
H-3’), 4.16-3.58 (7H, m, H-4’+H-5’+Phe- 
CH+est CH2 +NH), 3.30-2.06 (6 H, m, H- 
2’+CH2 a+Phe-CH2), 1.60-1.53 (2H, m,
CH2 p), 1.31-1.00 (7H, m, CH2y+CH2+est 
CH3), 0.86-0.81 (3H, m, CH3 co) 
l3 C-NMR (CDC13, 125 MHz): 6  172.4 172.3 
(Phe-CO), 171.8 (C l), 156.1 156.0 (C7a),
154.7 154.6 (C6 ), 150.3 (Ph), 145.1 145.0 (C4a), 136.0, 135.9, 135.7, 135.4, 129.8, 129.5,
129.0, 128.6, 127.3, 127.2, 125.9, 125.4, 125.3, 124.3, 120.3, 120.2, 120.0, 119.9, 108.4,
108.2 (Ph), 97.0 (C4), 87.8 87.5 (C l’), 85.9 85.8 85.7 (C4’), 75.3 73.8 (C3’), 61.8 60.7 (C5’),
61.1 60.6 (est CH2), 56.1 55.6 (Phe-C), 40.4 40.3 (Phe-CH2), 40.2 40.1 39.9 39.5 (C2’), 35.8 
(CH2a), 31.4 (CH2y), 30.9 (CH2 P), 22.5 (CH2 6 ), 14.0 14.0 (CH3 w)
3 IP-NMR (CDCb, 202 MHz): 6  3.23, 2.46
Anal. Calcd for C3 9 H4 4 N3 O.jP: C 64.19, H 6.08, N 5.76, O 19.73. Found C 64.00, H 6.09, N 
5.95
MS: 752 (M+Na)
o.
o
0
1
HN P OPh
IIO
Ph
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134 1 -0-Benzyl-|3-L-Arabinopyranoside
Ph,
HO
Benzyl alcohol (50 mL) was saturated with hydrogen chloride 
for 40 min at 0°C, L-arabinose (10 g, 6 6 . 6  mmol) was added,
''"oh an<^  m x^ u^re was sliced at room temperature overnight. The 
solution was concentrated and Ethyl Acetate was slowly added 
while stirring for precipitation. Filtration of the resulting solid, 
washing with Ethyl Acetate, and drying under nitrogen air gave 16.00 g (100%) of desired 
compound as a white precipitate, which was used for the next step without further 
purification.
OH
'H-NMR (DMSO, 500 MHz): 5 7.40-7.27 (5H, m, Ph), 4.76 (1H, d, J 2.3 Hz, H-l), 4.66 (1H, 
d, J 12.4 Hz, Bn-CH2), 4.46 (1H, d, J 12.4 Hz, Bn-CH2), 4.25 (3H, bs, OH - 2  + OH-3+ OH-4),
3.73 (1H, m, H-4), 3.68 (1H, dd, J 11.8 Hz 1.8 Hz, H-5), 3.64-3.63 (2H, m, H-2 + H-3), 3.47 
(1H, dd, J 11.8 Hz 2.9 Hz, H-5’)
13C-NMR (DMSO, 125 MHz): 6  138.18 (Ph-Cl), 128.13 (Ph-C4), 127.40 (Ph-C3), 127.27 
(Ph-C2), 98.90 (Cl), 69.06 (C2), 68.62 (C3), 68.40 (Bn-CH2), 68.25 (C4), 63.27 (C5)
135 l-0-Benzyl-3,4-O-isopropylidene-|3-L-Arabinopiranoside
Ph. .Om ,o . A mixture of 134 (2.0 g, 8.3 mmol), 2,2-dimethoxypropane (2.6 
mL, 2.5 eq.) and /?-TsOH*H20  (0.1 g, 0.05 eq.) in acetone (20 
mL) was stirred for 1 h. The reaction mixture was then 
/  neutralized with Et3N and evaporated under reduced pressure to 
give the wanted compound as a yellow syrup, which was filtered 
through a short silica gel pad and washing with Hexane : Ethyl Acetate 3:1 to obtain 2.2 g 
(95%) of titled compound as white solid.
o-
’H-NMR (DMSO, 500 MJz): 6  7.41-7.28 (5H, m, Ph), 5.12 (1H, d, J 6 . 6  Hz, OH-2), 4.74 
(1H, d, J 3.3, H-l), 4.68 (1H, d, J 12.3 Hz, Bn-CH2), 4.47 (1H, d, J 12.3 Hz, Bn-CH2), 4.23 
(1H, dd, J 5.6 Hz 1.8 Hz, H-4), 4.05 (1H, dd, J 7.7 Hz 5.7 Hz, H-3), 3.88 (1H, dd, J 13.3 Hz 
2.8 Hz, H-5), 3.83 (1H, dd, 13.3 Hz 1.2 Hz, H-5), 3.51 (1H, ddd, J 7.7 Hz 6 . 6  Hz 3.3 Hz, H- 
2), 1.41 (3H, s, CH3), 1.28 (3H, s, CH3)
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,3 C-NMR (DMSO, 125 MHz): 6  137.75 (Ph-C l’), 128.18 (Ph-C4’) , 127.49 (Ph-C3’), 127.42 
(Ph-C2’), 107.63 (C ), 98.09 (C l), 75.59 (C3), 72.72 (C4), 69.78 (C2), 68.56 (Bn-CH2), 58.56 
(C5), 28.16 (CH3), 26.22 (CH3)
136 l-0-Benzyl-3,4-0-isopropylidene-2-0-phenoxythiocarbonyl-j3-L-Arabinopiranoside
To a stirred solution of 135 (2 g, 7.1 mmol) and pyridine (2.5 ml,
4.3 eq.) in anhydrous DCM (60 ml), O- 
phenylchlorothionoformate (1.4 ml, 2.3 eq.) was added at room 
temperature. The resulting yellow solution was stirred overnight 
at room temperature under argon atmosphere. After evaporation 
of the solvent, the residue was purified by column chromatography using Hexane : Ethyl 
Acetate 10:1 as eluent to give 2.85 g (96%) of pure compound as yellow oil.
‘H-NMR (CDC13, 500 MHz): 6  7.45-7.29 ( 8 H, m, Bn-Ph +CSO-Ph), 7.12-7.09 (2H, m, CSO- 
Ph), 5.48 (1H, dd, J 8.1 Hz 3.4 Hz, H-2), 5.28 (1H, d, J 3.4, H-l), 4.81 (1H, d, J 12.3 Hz, Bn- 
CH2), 4.62 (1H, d, J  12.3 Hz, Bn-CH2), 4.60 (1H, dd, J 8.1 Hz 5.6 Hz, H-3), 4.35 (1H, dt, J
5.6 Hz 1.8 Hz, H-4), 4.09 (2H, m, H-5), 1.61 (3H, s, CH3), 1.42 (3H, s, CH3)
13C-NMR (CDC13, 125 MHz): 6  194.83 (C=S), 153.45 (PhOCS-Cl), 137.75 (Bn-Cl), 129.47 
128.53 127.96 127.64 126.57 121.86 (Bn-Ph + PhO), 109.67 (C), 94.21 (Cl), 81.19 (C2), 
73.71 (C4), 72.64 (C3), 69.56 (Bn-CH2), 58.94 (C5), 28.01 (CH3), 26.39 (CH3)
137 1 -O-Benzyl-3,4-0-isopropy lidene-2-deoxy-(3-L-Arabinopiranoside
To a stirred solution of 136 (2.85 g, 6 . 8  mmol) in anhydrous and 
degassed toluene (30 ml), a solution of «Bu3SnH (4.3 ml, 2.3 
eq.) and ACCN (0.33 g, 0.2 eq.) were added over 1 hour. After 
the addiction the solution was stirred at reflux for 1 hour. The 
resulting clear solution was evaporated and purified by column 
chromatography Hexane : Ethy lAcetate 6:1 to give 1.46 g (81%) of the desired compound as 
a colourless oil.
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‘H-NMR (CDCb): 5 7.29-6.73 (5H, m, Ph), 4.92 (1H, dd, J 6.0 Hz 4.6 Hz, H-l), 4.70 (1H, d, 
J 11.9 Hz,Bn-CH2), 4.43 (1H, d, J 11.9 Hz, Bn-CH2), 4.40 (1H, dt, J 6.5 Hz 4.9 Hz , H-3),
4.09 (1H, dt, J 6.4 Hz 2.5 Hz, H-4), 3.83 (1H, dd, J 13.0 Hz 2.8 Hz, H-5) 3.71 (1H, dd, J 13.0 
Hz 2.4 Hz, H-5), 2.11 (1H, dt, J 14.8 Hz 4.8 Hz, H-2), 1.80 (1H, ddd, 14.8 Hz 6.1 Hz, 4.6 Hz, 
H-2), 1.44 (3H, s, CH3), 1.27 (3H, s, CH3)
i3C-NMR (CDCb, 125 MHz): 6  137.78 (Bn-Cl), 129.64 (Bn-C4), 128.47 (Bn-C3), 127.75 
(Bn-C2), 108.84 (C ), 95.78 (C l), 72.06 (C4), 69.96 (C3), 69.41 (Bn-CH2), 61.24 (C5), 31.49 
(C2), 27.25 (CH3), 25.45 (CH3)
131 2-deoxy-L-ribose 
A mixture of 137 (1.46 g, 5.5 mmol) in 4% of trifluoroacetic acid 
was stirred at 40°C overnight. The reaction mixture was poured into 
a separatory funnel and washed with Ethyl Acetate three times. The 
aqueous layer was filtered through Amberlite Ira400 (HCO3 ') and 
evaporated to dryness. The remaining syrup was co-evaporated with toluene twice to give 
0.44 g (60%) of 2-Deoxy-L-Ribose.
'H-NMR (DMSO, 500 MHz): 6  6.10 (1H, d J 4.9 Hz, OH-1), 4.97 (1H, dt, J 4.9 Hz 2.8 Hz, 
H-l), 4.47 (1H, br, OH-5), 4.45 (1H, br, OH-3), 3.83 (1H, dt, J 7.4 Hz 3.6 Hz, H-3), 3.63 (1H, 
dd, 11.0 Hz 2.9 Hz, H-5), 3.50 (1H, m, H-4), 3.44 (1H, dd, J 11.0 Hz 6.0 Hz, H-5), 1.78 (1H, 
ddd, J 12.6 Hz 7.9 Hz 2.8 Hz), 1.47 (1H, ddd, J 12.6 Hz 5.4 Hz 3.8 Hz)
13C-NMR (DMSO, 125 MHz): 6  91.25 (Cl), 67.35 (C4), 65.05 (C3), 63.05 (C5), 35.56 (C2)
138 1,3,5-Tri-0-benzoyl-2-deoxy-L-ribose
A mixture of 1 3 1  (°’5°  S’ 3  7  mmol) and benzoyl chloride (2 . 1  g,
\  j  OBz 4.0 eq.) in dry dichloromethane (10 cm3) was stirred for 30
\> B z  minutes at -15°C. Then pyridine (4 ml) in dry DCM (8  ml) was
added dropwise over a period of 1 hour at 15°C. After the addition, the mixture was stirred for 
1 h over the same temperature range, washed twice with water, dried over MgSO and filtered. 
After removing the solvent under reduced pressure the residue was purified by column 
chromatography Hexane : Ethyl Acetate 1:1.
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'H-NMR (CDCI3 , 500 MHz): 5 8.10-7.16 (15H, m, Bz), 6.62-6.59 (1H, m, H -l’), 5.78-5.72 
( 1 H, m, H-3’)> 5.65-5.48 (1H, m, H-4’), 4.28-4.20 ( 1 H, m, H-5’), 4.13-4.07 ( 1 H, m, H-5’), 
2.62-2.54 (1H, m, H-2’), 2.33-2.25 (1H, m, H-2’)
13C-NMR (CDC13, 125 MHz): 6  165. 82, 164.85, 162.37 (Bz-CO), 136.13, 134.52, 133.61, 
133.36, 133.28, 130.58, 130.04, 129.89, 129.82, 129.70, 129.57, 129.54, 128.88, 128.63, 
128.54, 128.41, 128.34, 123.79 (Bz-Ph), 92.53 (C l’), 68.00 (C4’), 66.34 (C3’), 63.42 (C5’),
30.39 (C2’)
NH,
N '  JD
139 2-amino-P-L-arabinofuranof 1 ’ ,2 ’ :4,5]oxazoline
A mixture of L-arabinose (17g, 113 mmol), cyanamide (10 g, 2 eq.), 
M e O H  (30 ml) and 6 M N H 4 O H  (5 ml) was stirred at room temperature 
for 48 hours and then kept at —10°C for 15 hours. The product was 
collected by filtration, washed with M e O H  and Et2 0  and dried under
''oh vacuum to obtain 14.75 g (75%) of white solid.
1 H-NMR (DMSO, 500 MHz): 6  6.27 (2H, bs, NH2), 5.67 (1H, d, J 5.5 Hz, H -l’), 5.39 (1H, 
bs, OH-3’), 4.68 ( 1 H, bs, OH-5’), 4.53 ( 1 H, d, J 5.5 Hz, H-2’), 4.02-3.99 ( 1 H, m, H-3’), 3.67-
3.62 (1H, m, H-4’), 3.31-3.23 (2H, m, H-5’)
13C-NMR (DMSO, 125 MHz): 6  162.18 (C-NH2), 99.95 (C l’), 88.04 (C2’), 84.58 (C4’),
75.62 (C3’), 61.55 (C5’)
o
N JO
140 O ’ -Anhydro-L-uridine
A solution of 139 (12g, 69 mmol) and methyl propiolate (12 ml, 2 
eq.) in 50% aqueous ethanol (180 ml) was refluxed for 5 hours and 
then dried under reduced pressure to obtain a residue that was taken 
with acetone and left at 0°C for 2 hours. The resulting white 
precipitate filtrated and washed with acetone to afford 10 g (65%) of 
o h  the titled compound.
*H-NMR (DMSO, 500 MHz): 6  7.83 (1H, d, J 7.4 Hz, H-5), 6.31 (1H, d, J 5.8 Hz, H -l’), 5.87 
(1H, d, J 4.3 Hz, OH-3’), 5.84 (1H, d, J 7.4 Hz, H-6 ), 5.20 (1H, d, J 5.5 Hz, H-2’), 4.97 (1H, t,
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J 5.0 Hz, OH-5’), 4.41-4.37 (1H, m, H-3’), 4.08 (1H, t, J 4.1 Hz, H-4’), 3.31-3.25 (1H, m, H- 
5’), 3.23-3.16 (1H, m, H-5’)
13C-NMR (DMSO, 125 MHz): 5 171.10 (C4), 159.76 (C2), 136.77 (C5), 108.59 (C6 ), 89.97 
(C l’), 89.16 (C4’), 88.71 (C2’), 74.71 (C3’), 60.81 (C5’)
141 3’, 5 ’-diacetyl-2’-bromo-2’-deoxy-L-uridine
Compound 140 (2.26 g, 10 mmol) was suspended in ACN (50 ml) 
and heated at reflux. AcBr (6.7 ml, 9 eq.) was added dropwise. The 
mixture was stirred at reflux for 1 hours, then the sovent was 
removed under reduced pressure and the residue was washed with
OAc
Et20  to obtain the titled compound as orange solid 3.90 g (100%).
B* %Ac
‘H-NMR (DMSO, 500 MHz): 6  11.52 (1H, bs, NH), 7.70 (1H, d, J 8.2 Hz, H-5), 6.15 (1H, d,
7.2 Hz, H -l’), 5.78 (1H, d, J 8.2 Hz, H-6 ), 5.28-5.23 (1H, m, H-3’), 5.01 (1H, t, 6.5 Hz, H-2’), 
4.36-4.23 (3H, m, H-4’+H-5’), 2.14 (3H, s, CH3), 2.08 (3H, s, CH3)
13C-NMR (DMSO, 125 MHz): b 170.10 (Ac-CO), 169.24 (Ac-CO), 162.74 (C4), 150.46 
(C2), 140.04(C5), 102.86 (C6 ), 88.81 (C l’), 79.64 (C4’), 71.09 (C3’), 62.78 (C5’), 47.48 
(C2’), 20.51 (Ac-CH3), 20.50 (Ac-CH3)
142 3’, 5 ’-diacetyl-2’-deoxy-L-uridine
OAc
To a stirred solution of 141 (3.90 g , 10 mmol) in anhydrous and 
degassed toluene (30 ml), a solution of ^BusSnH (4.3 ml, 2.3 eq.) 
and AIBN (0.33 g , 0.2 eq.) were added. After the addiction the 
solution was stirred at reflux for 2 hours. The resulting clear solution 
was evaporated and Et2 0  was slowly added to obtain a precipitate. 
The solid was filtered and dried to obtain 2.99 g (96%) of the titled 
compound.OAc
‘H-NMR (DMSO, 500 MHz): 6  11.52 (1H, bs, NH), 7.70 (1H, d, J 8.2 Hz, H-5), 6.15 (1H, d,
7.2 Hz, H -l’), 5.78 (1H, d, J 8.2 Hz, H-6 ), 5.17-5.19 (1H, m, H-3’), 4.29-4.20 (1H, m, H-4’), 
4.19-4.08 (2H, m, H-5’), 2.29-2.48 (2H, m, H-2’), 2.11 (3H, S, CH3), 2.02 (3H, s, CH3)
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l3C-NMR (DMSO, 125 MHz): 8  170.20 (Ac-CO), 169.56 (Ac-CO), 161.74 (C4), 151.56 
(C2), 139.34(C5), 103.86 (C6 ), 85.12 (C l’), 81.76(C4’), 75.23 (C3’), 63.12(C5’) ,42.12 
(C2’), 21.10 (Ac-CH3), 20.76 (Ac-CH3)
143 3’, 5 ’-diacety!-2’-deoxy-5-iodo-L-uridine
To solution of 142 (2.99 g, 9.60 mmol) in glacial AcOH was 
added I2 (1.22 g, 0.5 eq.) and CAN (2.63 g, 0.5 eq.) and the 
mixture was then stirred at 80°C for 1 hours. The solvent was 
removed under reduced pressure and the residue was dissolved in 
DCM and washed with HzO and brine. The organic layer was 
dried over M gS0 4 and evaporated to afford 4.00 g (95%) of the 
titled compound.
‘H-NMR (DMSO, 500 MHz): 6  11.74 (1H, bs, NH), 8.05 (1H, s, H-6 ), 6.11 (1H, t, J = 7.1 Hz, 
H-l’), 5.17-5.19 (1H, m, H-3’), 4.20-4.29 (3H, m, H-4’+H-5’), 2.29-2.48 (2H, m, H-2’), 2.10 
(3H, s, CH3), 2.04 (3H, s, CH3)
13C-NMR (DMSO, 125 MHz): 6  170.30 (Ac-CO), 170.10 (Ac-CO), 159.64 (C4), 149.79 
(C2), 143.70 (C6 ), 85.42 (C4’), 82.36 (C l’), 74.54 (C3’), 68.93 (C5), 63.78 (C5’), 38.38 
(C2’), 21.11 (Ac-CH3), 20.96 (Ac-CH3)
144 2 ’-deoxy-5-iodo-L-uridine
Compound 143 (4.00 g, 9.1 mmol) was dissolved in 1M MeONa / 
MeOH solution (100 ml) and then stirred for 2 hours. The 
solution was concentrated under reduced pressure and diluited 
with HzO (100 ml). DOWEX H+ was added and the solution was 
stirred for 30 minutes. The resin was filtered and washed with 
H20 , then the solution was dried under reduced pressure to obtain
2 . 7 5  g (85%) of the titled compound.
‘H-NMR (DMSO, 500 MHz): 6  11.67 (1H, bs, NH), 8.40 (1H, s, H-6 ), 6.10 (1H, t, J 6 . 6  Hz, 
H -l’), 5.24 (1H, d, J 4.4 Hz, OH-3’), 5.13 (1H, t, J 4.9 Hz, OH-5’), 4.26-4.22 (1H, m, H-3’),
o
i
NH
OH
OH
O
I
NH
OAc
OAc
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3.80 (1H, q, J 3.3 Hz, H-4’), 3.63 (1H, ddd, J 11.9 Hz 4.9 Hz, 3.3 Hz, H-5’), 3.57 (1H, ddd,J
11.9 Hz 4.9 Hz 3.3 Hz, H-5’), 2.17-2.08 (2H, m, H-2’)
l3C-NMR (DMSO, 125 MHz): 5 160.46 (C4), 150.08 (C2), 145.03 (C6 ), 87.51 (C4’), 84.64 
(C l’), 70.00 (C3’), 69.18 (C5), 60.81 (C5’), 40.16 (C2’)
129f 3-(2-deoxy-(3-L-ribofuranosyl)-6-(4-pentylphenyl)furo[2,3-rf]pyrimidin-2(3/7)-one
[Cf2543]
Prepared according to Standard Procedure D (144 instead of IDU) 
using 4-ethynylpentylbenzene. Even if the compound was pure on 
NMR, the solid was purified by column chromatography (CHCI3 : 
MeOH 8:2).
White solid: 0.54 g, 45%
'H-NMR (DMSO, 500 MHz): 6  8.84 (1H, s, H-4), 7.75 (2H, d, J
7.6 Hz, Phb), 7.33 (2H, d, J 7.6 Hz, Plu), 7.22 (1H, s, H-5), 6.20 
(1H, t, J 5.7 Hz, H - l’), 5.28 (1H, d, J 4.2 Hz, OH-3’), 5.15 (1H, t, J
5.1 Hz, OH-5’), 4.27 (1H, dq, J 6.1 Hz 4.2 Hz, H-3’), 3.94 (1H, q, J
3.8 Hz, H-4’), 3.72 (1H, ddd, J 12.1 Hz 5.1 Hz 3.6 Hz, H-5’a), 3.65 
(1H, ddd, J 12.1 Hz 5.1 Hz 4.2 Hz, H-5’b), 2.61 (2H, t, J 7.5 Hz, 
CH2 a), 2.42 (1H, ddd, J 13.5 Hz 6.3 Hz 4.1 Hz, H-2’„), 2.11 (1H,
dt, J 13.5 Hz 6.1 Hz, H-2’,,), 1.59 (2H, qn, J 7.5 Hz, CH2 p), 1.35-
1.24 (4H, m, CH2 6  + CH2y), 0.86 (3H, t, J 7.1 Hz, CH3co)
13C-NMR (DMSO, 125 MHz): 5 171.02 (C7a), 153.90 (C6 ), 153.76 (C2), 144.02 (Ph-Cd),
137.77 (C4), 128.93 (Ph-Cc), 125.86 (Ph-Ca), 124.50 (Ph-Cb), 106.88 (C4a), 98.62 (C5),
88.16 (C4’), 87.57 (C l’), 69.55 (C3’), 60.68 (C5’), 42.26 (C2’)s 34.89 (Ca), 30.80 (Cy),
30.33 (CP), 21.89 (C6 ), 13.84 (Cco)
Anal. Calcd for C2 2 H2 6N2 Os: C 66.32, H 6.58, N 7.03, O 20.08. Found C 66.30, H 6.56, N
7.10 ,0  20.25 
MS: 421 (M+Na)
[a]d20: -80° (c 4.0 , DMSO)
OH
OH
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129f 3-(2-deoxy-P-L-ribofuranosyl-5-[phenyl-(benzyloxy-L-alaninyl)]phosphate)-6-(4-
penty lpheny 1) furo [2,3-d \ py r imidin-2 (3 //)-one
[Cf2552]
Prepared according to Standard Procedure C (129 
instead of 33f) using 125f 
White foam: 0.07 g, 20%
'H-NMR (CDC13, 500 MHz): 5 8.45 8.34 (1H, 2s, H- 
4), 7.56-7.48 (2H, m, BCNA-Ph), 7.27-7.00 (12H, m, 
BCNA-Ph+Ph+Bn), 6.47 6.45 (1H, 2 s, H-5), 6.27-6.21 
(1H, m, H -l’), 5.07-4.98 (2H, m, Bn-CH2), 4.44-3.88 
(6 H, m, H-3’ +H-4’ +Ala-CH+H-5’ +NH), 2.73-2.60 
(1H, m, H-2’a), 2.59-2.50 (2H, m, CH2a), 2.05-1.85
(1H, m, H-2’p), 1.60-1.50 (2H, m, CH2 P), 1.36-1.09
(7H, m, CH2y+CH2 6 +Ala+CH3), 0.87-0.80 (3H, m,
CH3co)
l3 C-NMR (CDC13, 125 MHz): 6  172.9 172.8 (Ala-CO),
170.6 (C2), 154.8 (C7a), 153.7 (C6 ), 146.4 146.3 
(C4a), 138.7 138.5 (C5), 130.9, 130.8, 130.2, 129.6, 
129.4, 129.3, 129.2, 126.3, 125.9, 125.8, 121.6, 121.5, 121.3, 121.2, 104.7, 104.5 (Ph), 99.2
9 9 . 1  (C4), 90.3 90.2 (C l’), 87.8 87.7 87.6 (C4’), 71.7 71.6 (C3’), 6 8 . 1  6 8 . 0  (Bn-Ofe), 67.5
67.4 67.3 67.2 (C5’), 51.9 51.7 (Ala-CH), 42.8 42.7 (C2’), 36.7 (CH2 a), 32.6 (CH2y), 32.2
(CH2 P), 23.6 (CH2 6 ), 20.3 (Ala-CH3), 14.4 (CH3 co)
3 IP-NMR (CDC13, 202 MHz): 5 4.23, 3.50
Anal. Calcd for C3 8H4 2N3 0 9 P: C 63.77, H 5.91, N 5.57, O 20.12. Found C 63.65, H 5.82, N 
5.97
MS: 738 (M+Na)
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151 2-amino-a-D-ribofuranof 1 ’ ,2 ’ :4,5]oxazoline
A mixture of D-ribose (17g, 113 mmol), cyanamide (10 g, 2 eq.), MeOH 
(30 ml) and 6 M NH4 OH (5 ml) was stirred at room temperature for 72 
hours and then kept at -10°C for 15 hours. The product was collected by 
OH filtration, washed with MeOH and Et2 0  and dried under vacuum to obtain
17.00 g (8 6 %) of white solid.
NH,
to
Os
‘H-NMR (DMSO, 500 MHz): 6  6.25 (2H, bs, NH2), 5.78 (1H, d, J 3.4 Hz, H -l’), 5.15 (1H, 
bs, OH-3’), 4.63-4.52 (2H, bs, OH-5’+H-2’), 3.76-3.68 (1H, m, H-3’), 3.68-3.61 (1H, m, H- 
5’), 3.44-3.36 (1H, m, H-5’), 3.30-3.25 (1H, m, H-4’)
13C-NMR (DMSO, 125 MHz): 6  163.74 (C-NH2), 98.16 (C l’), 80.69 (C2 ’), 77.70 (C4’),
71.09 (C3’), 60.35 (C5’)
152 O2 2  -Anhydro-a-D-uridine
OH
OH
A solution of 151 (12g, 69 mmol) and methyl propiolate (12 ml, 2 eq.) 
in 50% aqueous ethanol (180 ml) was refluxed for 5 hours and then 
dried under reduced pressure to obtain a residue that was taken with 
acetone and left at 0°C for 2 hours. The resulting white precipitate 
filtrated and washed with acetone to afford 11.53 g (75%) of the titled 
compound.
‘H-NMR (DMSO, 500 MHz): 6  7.85 (1H, d, J 7.0 Hz, H-5), 6.20 (1H, d, J 5.0 Hz, H -l’), 5.89 
(1H, d, J 7.0 Hz, H-6 ), 5.74 (1H, d, J 6.5 Hz, OH-3’), 5.24 (1H, t, J 5.4 Hz, H-2’), 4.85 (1H, t, 
J 5.5 Hz, OH-5’), 4.06 (1H, q, J 6.5 Hz, H-3’), 3.73-3.67 (1H, m, H-5’), 3.60-3.54 (1H, m, H- 
4 ’), 3.51-3.44 (1H, m, H-5’)
13C-NMR (DMSO, 125 MHz): 6  171.03 (C4), 160.68 (C2), 136.82 (C5), 108.78 (C6 ), 88.57 
(C l’), 81.43 (C2’), 80.76 (C4’), 69.82 (C3’), 59.48 (C5’)
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153 3’, 5 ’-diacetyl-2’-bromo-2’-deoxy-a-D-uridine
Compound 152 (2.26 g, 10 mmol) was suspended in ACN (50 ml) and 
heated at reflux. AcBr (6.7 ml, 9 eq.) was added dropwise. The mixture 
was stirred at reflux for 1 hours, then the sovent was removed under 
reduced pressure and the residue was washed with Et^O to obtain the 
\ / 'OAc titled compound as orange solid 3.90 g (100%).
Br  ^ T>Ac
1 H-NMR (DMSO, 500 MHz): 5 11.46 (1H, bs, NH), 7.80 (1H, d, J 8.0 Hz, H-5), 6.22 (1H, d,
5.3 Hz, H -l’), 5.67 (1H, d, J 8.0 Hz, H-6 ), 5.43 (1H, t, J 5.0 Hz, H-3’), 4.85 (1H, t, 5.2 Hz, H- 
2’), 4.62 (1H, q, J 6.0 Hz, H-4’), 4.33-4.25 (2H, m, H-5’), 2.06 (6 H, s, CH3) 
l3C-NMR (DMSO, 125 MHz): 6  169.99 (Ac-CO), 169.46 (Ac-CO), 162.97 (C4), 150.40 
(C2), 140.47 (C5), 101.95 (C6 ), 90.32 (C l’), 81.19 (C4’), 77.46 (C3’), 63.69 (C5’), 48.60 
(C2’), 20.54 (Ac-CHj), 20.50 (Ac-CH3)
154 3’, 5 ’-diacetyl-2’-deoxy-a-D-uridine
To a stirred solution of 153 (3.90 g , 10 mmol) in anhydrous and 
degassed toluene (30 ml), a solution of «Bu3 SnH (4.3 ml, 2.3 eq.) and 
AIBN (0.33 g , 0.2 eq.) were added. After the addiction the solution 
was stirred at reflux for 2 hours. The resulting clear solution was 
evaporated and Et2 0  was slowly added to obtain a precipitate. The 
solid was filtered and dried to obtain 2.99 g (96%) of the titled 
compound.
‘H-NMR (DMSO, 500 MHz): 6  11.29 (1H, bs, NH), 7.68 (1H, d, J 7.7 Hz, H-5), 6.12 (1H, d,
6.1 Hz, H -l’), 5.62 (1H, d, J 7.7 Hz, H-6 ), 5.14 (1H, d, J 6 . 6  Hz, H-3’), 4.67 (1H, t, J 5.1 Hz, 
H-4’), 4.16-4.07 (2H, m, H-5’), 2.77 (1H, dt, J 14.8 Hz 6.9 Hz, H-2’), 2.16 (1H, d, J 14.8 Hz, 
H-2’), 2.06 (3H, s, CH3), 1.99 (3H, s, CH3)
13C-NMR (DMSO, 125 MHz): 6  170.10 (Ac-CO), 169.82 (Ac-CO), 163.26 (C4), 150.31 
(C2), 140.47 (C5), 100.87 (C6 ), 86.31 (C l’), 83.42 (C3’), 73.83 (C4’), 63.42 (C5’), 37.16 
(C2’), 20.77 (Ac-CH3), 20.55 (Ac-CH3)
o
NH
OAc
OAc
Marco Migliore
o
NH
,o,
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155 3’, 5 ’-diacetyl-2’-deoxy-5-iodo-a-D-uridine
0  To solution of 154 (2.99 g, 9.60 mmol) in glacial AcOH was
added I2 (1.22 g, 0.5 eq.) and CAN (2.63 g, 0.5 eq.) and the 
mixture was then stirred at 80°C for 1 hours. The solvent was 
removed under reduced pressure and the residue was dissolved in 
DCM and washed with HzO and brine. The organic layer was
OAc , . ,
dried over M gS0 4 and evaporated to afford 4.00 g (95%) of the 
titled compound.
i
NH
OAc
1 H-NMR (DMSO, 500 MHz): 6  11.68 (1H, bs, NH), 8.05 (1H, s, H-6 ), 6.15 (1H, t, J = 7.1 Hz, 
H-l’), 5.17 (1H, d, J 5.5 Hz, H-3’), 4.77 (1H, t, J 4.6 Hz, H-4’), 4.15-4.03 (2H, m, H-5’), 2.77 
(1H, dt, J 14.8 Hz 6 . 8  Hz, H-2’), 2.22 (1H, d, J 14.8 Hz, H-2’), 2.06 (3H, s, CH3), 2.04 (3H, s, 
CH3)
13C-NMR (DMSO, 125 MHz): 6  170.08 (Ac-CO), 169.49 (Ac-CO), 160.58 (C4), 150.03 
(C2), 144.88 (C6 ), 86.47 (C l’), 83.55 (C4’), 73.85 (C3’), 68.50 (C5), 63.37 (C5’), 37.08 
(C21), 20.92 (Ac-CH3), 20.56 (Ac-CH3)
156 2’-deoxy-5-iodo-a-D-uridine
o Compound 155 (4.00 g, 9.1 mmol) was dissolved in 1M MeONa /
MeOH solution (100 ml) and then stirred for 2 hours. The solution 
was concentrated under reduced pressure and diluited with H20  
(100 ml). DOWEX H+ was added and the solution was stirred for 
30 minutes. The resin was filtered and washed with HzO, then the 
solution was dried under reduced pressure to obtain 2.75 g (85%) 
of the titled compound.
'H-NMR (DMSO, 500 MHz): 6  11.62 (1H, bs, NH), 8.31 (1H, s, H-6 ), 6.10 (1H, t, J 7.0 Hz, 
H -l’), 5.40 (1H, bs, OH-3’), 4.81 (1H, bs, OH-5’), 4.24 (1H, d, J 4.8 Hz, H-3’), 4.21-4.16 
(1H, m, H-4’), 3.40-3.34 (2H, m, H-5’), 2.57 (1H, dt, J 14.3 Hz 6.4 Hz, H-2’), 1.92 (1H, d, J
14.3 Hz, H-2’)
13C-NMR (DMSO, 125 MHz): 6  160.57 (C4), 150.20 (C2), 146.03 (C6 ), 89.67 (C4’), 86.19 
(C l’), 70.51 (C3’), 68.32 (C5), 61.68 (C5’), 39.99 (C2’)
i
NH
...
OH
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149 3-(2-deoxy-a-D-ribofuranosyl)-6-(4-pentylphenyl)furo[2,3-df]pyrimidin-2(3//)-one
[Cf2553]
Prepared according to Standard Procedure D (155 instead of 
I DU) using 4-ethynylpentylbenzene. Even if the compound was 
pure on NMR, the solid was purified by column chromatography 
(CHC13 : MeOH 8:2).
White solid: 0.42 g, 35%
'H-NMR (DMSO, 500 MHz): 5 8.63 (1H, s, H-4), 7.73 (2H, d, J 
6.9 Hz, Phb), 7.33 (2H, d, J 6.9 Hz, Phc), 7.21 (1H, s, H-5), 6.11 
(1H, d, J 6 . 8  Hz, H - l’), 5.10 (1H, d, J 2.6 Hz, OH-3’), 4.92 (1H, 
t, J 5.7 Hz, OH-5’), 4.43 (1H, t, J 4.6 Hz, H-4’), 4.28-4.24 (1H, 
m, H-3’), 3.52-3.42 (2H, m, H-5’), 2.67-2.59 (3H, m, H- 
2’(t+CH2 a), 2.07 (1H, d, J 14.5 Hz, H-2’„), 1.60 (2H, qn, J 7.4
Hz, CH2 p), 1.37-1.22 (4H, m, CH25 + CH2y), 0.87 (3 H, t, J 6 . 8
Hz, CH3 C0 )
1 3C-NMR (DMSO, 125 MHz): 6  171.03 (C7a), 153.83 (C6 ), 
153.50 (C2 ), 143.94 (Ph-Cd), 138.84 (C4), 128.99 (Ph-Cc), 125.96 (Ph-Ca), 124.45 (Ph-Cb), 
106.13 (C4a), 98.84 (C5), 90.65 (C4’), 89.57 (C l’), 70.61 (C3’), 61.68 (C5’), 40.75 (C2’),
34.88 (Ca), 30.80 (Cy), 30.36 (C(3), 21.89 (C6 ), 13.87 (Cco)
Anal. Calcd for C2 2 H2 6N2 Os: C 66.32, H 6.58, N 7.03, O 20.08. Found C 66.21, H 6.36, N
7.26, O 20.38 
MS: 421 (M+Na)
...
OH
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149f 3-(2-deoxy-a-D-ribofuranosyl-5-[phenyl-(benzyloxy-L-alaninyl)]phosphate)-6-(4-
penty lpheny l)furo [2,3 -d \ pyrimidin-2(3//)-one
[Cf2552]
Prepared according to Standard Procedure C (149 
instead of 33f) using 125f 
White foam: 0.08 g, 23%
'H-NMR (CDC13, 500 MHz): 5 8.22 8.19 (1H, 2s, H-4), 
7.43-7.38 (2H, m, BCNA-Ph), 7.31-7.05 (12H, m, 
BCNA-Ph+Ph+Bn), 6.45 6.43 (1H, 2s, H-5), 6.14-6.01 
(1H, m, H - l’), 5.14-5.04 (2H, m, Bn-CH2), 4.64-4.57 
(1H, m, H-4’), 4.43-4.35 (1H, m, H-3’), 4.16-3.94 (3H, 
m, Ala-CH+H-5’), 3.73-3.55 (1H, m, NH), 2.62-2.45
(4H, m, CH2a+H -2’), 1.62-1.50 (2H, m, CH2p), 1.35- 
1.31 (3H, m, Ala-CH3), 1.31-1.22 (4H, m, CH25+ 
CH2y), 0.86-0.79 (3H, m, CH3co) 
l3 C-NMR (CDCI3 , 125 MHz): S 173.34 173.30 173.28
173.24 (Ala-CO), 171.45 (C2), 155.63 155.60 (C7a), 
154.66 154.62 (C6 ), 150.61 150.53 150.48 (C4a),
144.77 136.88, 135.21 135.20 129.82, 129.80, 128.81, 128.69, 128.66, 128.57, 128.53,
128.28, 128.22, 125.76, 125.21, 125.17, 124.75, 120.22, 120.18, 120.12, 120.08, 107.65,
107.59 (Ph), 96.93 (C4), 91.02 91.00 (C l’), 88.34 88.28 88.23 (C4’); 71.92 71.87 (C3’)s
67.40 67.65 (Bn-CH2), 66.58 66.53 66.51 66.47 (C5’), 50.45 50.34 (Ala-CH), 40.98 40.90 
(C2’), 35.83 (CH2a), 31.48 (CH2y), 30.94 (CH2 (3), 22.53 (CH2 S), 20.92 20.88 (Ala-CH3),
14.02 (CH3C0 )
3 IP-NMR (CDCI3 , 202 MHz): 8  2.62,2.36
Anal. Calcd for CbsH^NsOsP: C 63.77, H 5.91, N 5.57, O 20.12. Found C 63.82, H 5.96, N
5.47
MS: 738 (M+Na)
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163 cis-4-amino-2-cycIopentenecarboxilic acid methyl ester hydrochloride
o
NH3 Cl
SOCl2 (8 ml) was slowly added to MeOH (50 ml) at 0°C, then 5.45 g (50 mmol) of Vince 
lactame 162 was added and the mixture was stirred for 2 hours at the same temperature. The 
solvent was removed under reduced pressure to obtain 8.88 g (100%) of the titled compound 
as white solid.
13C-NMR (DMSO, 125 MHz): 6 172.68 (C-5), 134.18 (C-2), 130.44 (C-3), 55.18 (C-l), 51.89 
(OCH3), 48.93 (C-4), 31.21 (C6)
Compound 163 (8.8 g, 50 mmol) was dissolved in Pyr (50 ml) and benzoyl chloride (6.4 ml,
1.1 eq.) was added dropwise at 0°C. The mixture was then stirred at room temperature for 3 
hours after which it was poured in ice. When the ice complete melted the precipitate was 
filtered, washed with water and dried under vaccum to obtain 11.04 g (90%) of the title 
compound as a white solid.
‘H-NMR (DMSO, 500 MHz): 6 8.44 (3H, bs, NH3), 6.07 (1H, dd, J 5.5 Hz 2.2 Hz, H-2), 5.90 
(1H, dd, J 5.5 Hz 2.4 Hz, H-3), 4.21-4.12 (1H, m, H-l), 3.72-3.67 (1H, m, H-4), 3.65 (3H, s, 
OCH3), 2.60-2.52 (1H, m, H-6), 2.00-1.92 (1H, m, H-6)
164 cis-4-benzoylamino-2-cyclopentenecarboxilic acid methyl ester
'H-NMR (DMSO, 500 MHz): 5 8.53 (1H, d, J 7.0 Hz, NH), 7.88 (2H, d, J 7.5 Hz, Ph-H2),
7.52 (1H, t, 7.5 Hz, Ph-H„), 7.45 (2H, t, 7.5 Hz, Ph-H,), 5.94-5.90 (1H, m, H-2), 5.90-5.85
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(1H, m, H-3), 5.03 (1H, q, J 7.8 Hz, H -l), 3.66 (3H, s, OCH3), 3.64-3.59 (1H, m, H-4), 2.58 
(1H, dt, J 13.0 Hz 7.8 Hz, H-6 ), 1.94 (1H, dt, J 13.0 Hz 7.8 Hz, H-6 )
13C-NMR (DMSO, 125 MHz): 6  173.59 (C-5), 165.80 (CON), 134.47 (C-3), 134.24 (Ph-C), 
131.12 (Ph-C4), 130.60 (C-2), 128.14 (Ph-H3), 127.31 (Ph-C2), 54.91 (C-l), 51.69 (OCH3),
48.46 (C-4), 33.64 (C-6 )
165 4-(benzoylamino)-l-cyclopentenecarboxilic acid methyl ester
NH
Compound 164 (11.04 g, 45 mmol) was dissolved in DCM (55 ml) and DBU (9.6 ml, 1.45 
eq.) was added. The mixture was stirred at room temperature for 15 hours after which it was 
cooled at 0°C and ice (17 g), HzO (11 ml) and H2 S 0 4(C) (3.3 ml) were added. The organic 
phase was separated and washed with water. The organic layer was evaporated under reduced 
pressure and the solid was triturated with Et20  filtered and dried to obtain 11 g (100%) of the 
title compound as a yellow solid.
*H-NMR (DMSO, 500 MHz): 6  8.60 (1H, d, J 6.2 Hz, NH), 7.86 (2H, d, J 7.5 Hz, Ph-H2),
7.52 (1H, t, 7.5 Hz, Ph-H4), 7.45 (2H, t, 7.5 Hz, Ph-H3), 6.76-6.70 (1H, m, H-3), 4.66-4.58 
(1H, m, H-l), 3.69 (3H, s, OCH3), 2.95-2.84 (2H, m, H-2+H-6), 2.61-2.49 (2H, m, H-2+H-6) 
13C-NMR (DMSO, 125 MHz): 6  165.98 (CON), 164.45 (C-5), 141.82 (C-3), 134.39 (Ph-C), 
133.83 (C-4), 131.07 (Ph-C4), 128.12 (Ph-H3), 127.27 (Ph-C2), 51.29 (OCH3), 48.83 (C-l),
40.10 (C6 ), 33.64 (C2)
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166 N-[3-(Hydroxymethyl)-3-cyclopentenyl]-benzamide
NH
HO'
Compound 165 (11 g, 45 mmol) was suspended in a mixture of DCM (50 ml) and Toluene 
(25 ml) and the suspension was colled at 0°C. A1C13 ( 6  g, 1 eq.) was added and the reaction 
was mixture was stirred for 20 minutes to give a cloudy solution. The resultant mixture was 
then cooled to 0°C and a 25% solution of DIBAH in toluene (69 ml, 2 eq.) was added at a rate 
such that the reaction mixture remained in the temperature range of 0°C-10°C. Upon 
completion of the additionof DIBAH the reaction mixture was stirred for 10 minutes at 0°C. 
After this time the mixture was slowly added to a solution of 4M HC1 at room temperature. 
Toluene was added and stirring continued for a further 30 minutes. The reaction mixture was 
the cooled to 0°C and stirred at this temperature for 1 hour. The product was harvested by 
filtration and washed with toluene, 2M HC1 and H20 and dried under vacuum to yield the title 
compound (8.9 g, 90%).
‘H-NMR (DMSO, 500 MHz): 6  8.50 (1H, d, J 6 . 8  Hz, NH), 7.85 (2H, d, J 7.8 Hz, Ph-H2), 
7.51 (1H, t, 7.8 Hz, Ph-H4), 7.45 (2H, t, 7.8 Hz, Ph-H3), 5.52-5.48(lH, m, H-3), 4.58 (1H, sx, 
J 6 . 8  Hz, H-l), 4.02-3.93 (2H, m, H-5), 2.72-2.57 (2H, m, H-2+H-6), 2.39-2.25 (2H, m, H- 
2+H-6)
13C-NMR (DMSO, 125 MHz): 6  165.99 (CO), 143.66 (C-4), 134.60 (Ph-C), 130.95 (Ph-C4),
128.10 (Ph-H3), 127.25 (Ph-C2), 121.38 (C-3), 59.99 (C-5), 49.45 (C-l), 39.14 (C2), 38.76 
(C6 )
223
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Compound 166 (8.9 g, 41 mmol) was added to t-butyl methyl ether (90 ml) and the resu 
suspension stirred at room tem perature while potassium carbonate (34 g), teti 
butylammonium hydrogen sulphate (2.1 g) and sodium hydroxide (11.5 g) were a< 
sequentially. Stirring was continued while the internal tem perature was raised to reflux ' 
hot water bath. Reflux was continued for a further 25 minutes and then benzyl bromide ( 
ml, 2.2 eq.) was added dropwise to the refluxing suspension. Reflux was continued f 
further 160 minutes. Heating was discontinued and methanol (1 ml) added over 30 secc 
The mixture was then cooled and distilled water (5 times 18 ml) added over 4  minutes, 
mixture was further cooled with a cold w ater bath, transferred to a glass separating flask 
the lower aqueous phase removed. The aqueous phase was extracted with t-butyl methyl € 
and the organic phases combined and washed with distilled water. The organic phase 
dried and the residue was purified by column chromatography (Hexane Ethyl Acetate 9 : 
obtain the title compound (14.05 g, 86%) as a yellow oil.
'H-NM R (DMSO, 500 MHz): 6 7.55-7.21 (15H, m, Ph+2xBn), 5.53 (1H, bs, H-3), 4.62 i 
Bs, Bn+H-1), 4.38 (2H, s, Bn), 3.90 (2H, s, H-5), 2.40 (4H, bs, H-2+H-6) 
l3C-NMR (DMSO, 125 MHz): 6 172.21 (CO), 141.74 (C-4), 140.26, 138.98, 131.14, 131 
130.43, 130.21, 130.10, 129.59, 129.37, 129.18, 128.49, 128.16 (Ar), 126.59 (C-3), 7: 
(Bn-CH2), 69 .%  (C-5), 60 .00(bs, C -l), 46.62 (Bn-CH2), 38.86 (bs, C2), 38.42 (bs, C6)
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168 4-benzylamino-2-Benzyloxymethyl-l-cyclopentanol
Bn
HO
2-methyl-2-butene (25 ml) was added to tetrahydrofuran (25 ml) and the resulting solution 
stirred under nitrogen and cooled to 0°C. Borane dimethylsulphide complex (10.6 ml) was 
then added at a rate such that the temperature of the mixture did not exceed 24°C. This 
solution was then stirred and treated with a solution of 167 (14.05 g, 3 5  mmol) in 
tetrahydrofuran (28 ml) over 40 minutes. Stirring was continued for 24 h at room temperature 
and then the reaction quenched by cooling the solution to 0°C and adding dropwise a mixture 
of water (1.5 ml) and tetrahydrofuran (14 ml). The solution was re-cooled to 0°C and then 3M 
sodium hydroxide (35 ml) added over 12 minutes. The solution/emulsion obtained was cooled 
to -20°C and hydrogen peroxide (30%, 36 ml) added dropwise over ca 2 hours such that an 
internal temperature of <30°C was maintained. After 20 minutes a solution of sodium sulphite 
(7 g) in water (28 ml) was added over 70 minutes. Following the final addition of hydrogen 
peroxide the mixture was left under nitrogen overnight. The mixture was then stirred and 
methyl isobutyl ketone (70 ml) was added. The phases were separated and the aqueous phase 
was extracted with methyl isobutyl ketone. The combined organic phases were washed with 
water and the organic phase reduced to ca 70 ml volume. The resulting yellow solution was 
stirred and cooled to 4°C and then concentrated hydrochloric acid (3 ml) was added. The 
cooling bath was removed and after 30 minutes t-butyl methyl ether (70 ml) was added 
dropwise. The pH was lowered to 1-2 during the addition of t-butyl methyl ether by further 
addition of concentrated hydrochloric acid. The resulting suspension was stirred for ca 1 hour 
with ice/water cooling and then filtered. The residual white solid was washed with t-butyl 
methyl ether and then dried to give the title compound (7.5 g, 63%).
‘H-NMR (DMSO, 500 MHz): 9.6 (2H, broad, NH2), 1.1-12 (10H, m, 2xBn), 4.90 (1H, broad, 
OH-3), 4.48 (2H, m, Bn), 4.10 (2H, m, Bn), 3.98 (1H, m, H-3), 3.62-3.53 (1H, m, H-l), 3.53- 
3.35 (2H, m, H-5), 2.30-2.20 (1H, m, H-6 ), 2.10-.1.82 (3H, m, H-2+H-4), 1.54-1.47 (1H, m, 
H-6 )
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13C-NMR (DMSO, 125 MHz): 6  138.52 (Bn-C), 132.17 (Bn-C), 130.00, 128.78, 128.56, 
128.22, 127.43, 127.36 (Bn), 72.05 (Bn-CH2), 71.32 (C-5), 71.17 (C-3), 55.35 (C-l), 48.85 
(Bn-CH2), 46.56 (C-4), 37.24 (C2), 31.01 (C6 )
169 N-Boc-2-azabicyclo [2.2.1 Jhept-5-en-3-one
A solution of Boc anhydride (14.4 g, 1.1 eq.) in THF (10 ml) was added dropwise to a stirred 
solution of Vince lactam 162 ( 6  g, 55 mmol), TEA (12 ml) and DMAP (0.67 g, 0.1 eq.) in 
THF (50 ml) at room temperature. The reaction was stirred for 4 hours and the solvent was 
then removed under reduced pressure. The residue was dissolved in Ethyl Acetate and washed 
with H20 and brine. The organic layer was separated dried over M gS04 and evaporated under 
reduced pressure to give 11.5 g (100%) of the title compound as an orange solid.
lH-NMR (DSMO, 500 MHz): 6  6.98 (1H, dd, J 5.1 Hz 1.9 Hz, H-2), 6.75 (1H, dt, J 3.5 Hz
1.8 Hz, H-3), 4.91-4.89 (1H, m, H-l), 3.32 (1H, bs, H-4), 2.30 (1H, bs, H-6 ), 2.08-2.05 (1H, 
m, H-6 ), 1.42 (9H, s, Boc)
13C-NMR (DMSO, 125 MHz): 6  175.42 (C-5), 149.82 (Boc-CO), 140.40 (C-2), 138.15 (C-3),
81.47 (Boc-C), 62.10 (C-l), 54.29 (C-6 ), 53.89 (C-4), 27.61 (Boc-CH3)
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170 N-Boc-2-azabicyclo f2.2.1]hept-5-an-3-one-2,3-epoxide
Chapter 9
Compound 169 (11.5 g, 55 mmol) was dissolved in 100 ml of DCM and MCPBA 60% (32 g, 
2 eq.), was addedand the mixture was stirred for 48 hours. The precipitate formed was filtered 
and the resulting solution was washed with a saturated solution of NaHC03 until complete 
remotion of the perbenzoic acid. The solvent was removed under reduced pressure to obtain 
10.53 g (85%) of the title compound as a white solid.
‘H-NMR (DSMO, 500 MHz): 6  4.64-4.62 (1H, m, H-l), 3.95 (1H, dd, J 3.6 Hz 1.2 Hz, H-2), 
3.82 (1H, dd, J 3.6 Hz 1.5 Hz, H-3), 3.07 (1H, qn, J 1.5 Hz, H-4), 1.70 (1H, dt, J 10.3 Hz 1.8 
Hz, H-6 ), 1.62 (1H, dt, J 10.3 Hz 1.6 Hz, H-6 ), 1.49 (9H, s, Boc)
13C-NMR (DMSO, 125 MHz): 6  172.90 (C-5), 149.14 (Boc-CO), 82.02 (Boc-C), 58.02 (C-l),
52.46 (C-2), 49.35 (C-3), 47.60 (C-4), 27.60 (Boc-CH3), 26.22 (C-6 )
171 N-Boc-4-hydroxymethyl-cyclopentylamine-2,3-epoxide
HN
HO
Compound 171 (9.00 g, 40 mmol), was dissolved in MeOH (100 ml) and NaBH4 (4.54 g, 3 
eq.) was added at 0°C. the mixture was stirred at the same temperature for 2 hours after which 
the excess of NaBH4 was neutralised by addition of NH4 C1 solution. The solvent was removed
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under vaccum and dissolved in DCM, washed with H20 and dried to obtain the title compound 
as colourless crystals (9.17 g, 100%).
'H-NMR (DSMO, 500 MHz): 6  6.70 (1H, d, J 6.7 Hz, NH), 5.03 (1H, bs, OH-5), 3.92 (1H, t, 
J 7.9 Hz, H-l), 3.53-3.36 (3H, m, H-5+H-2), 3.34-3.30 (1H, m, H-3), 2.24 (1H, dt, J 8 . 8  Hz
5.0 Hz, H- 4), 1.80 (1H, dt, J 13.9 Hz 8 . 8  Hz, H-6 ), 1.39 (9H, s, Boc), 1.29 (1H, d, J 13.9 Hz, 
H-6 )
13C-NMR (DMSO, 125 MHz): 6  154.79 (Boc-CO), 77.98 (Boc-C), 61.53 (C-5), 59.30 (C-2), 
58.15 (C-3), 49.79 (C-l), 40.86 (C-4), 31.64 (C-6 ), 27.62 (Boc-CH3)
172 N-Boc^-'butyldimethylsilyloxymethyl-cyclopentylamine^,3-epoxide
To a solution of 171 (9.17 g, 40 mmol) in DCM (100 ml), imidazole (2.73 g, 40 mmol) and 
TBDMS-C1 were added. The mixture was stirred for 15 hours at room temperature. The 
solution was then washed with 0.5M solution of citric acid and the organic layer was dried 
over MgS04, evaporated to give the title compound as clear oil (13.74 g, 100%).
'H-NMR (DSMO, 500 MHz): 6  6.49 (1H, d, J 7.2 Hz, NH), 3.92 (1H, t, J 7.2 Hz, H-l), 3.70- 
3.60 (2H, m, H-5), 3.43-3.41 (1H, m, H-2), 3.34 (1H, bs, H-3), 2.31-2.25 (1H, m, H- 4), 1.85-
1.75 (1H, dt, J 13.9 Hz 8.7 Hz, H-6 ), 1.39 (9H, s, Boc), 1.30 (1H, d, J 13.9 Hz, H-6 ), 0.89 
(9H, s, TBDMS), 0.09 (3H, s, TBDMS), 0.08 (3H, s, TBDMS)
13C-NMR (DMSO, 125 MHz): 6  154.72 (Boc-CO), 77.98 (Boc-C), 63.85 (C-5), 59.10 (C-2),
58.03 (C-3), 49.85 (C-l), 40.97 (C-4), 31.74 (C-6 ), 27.62 (Boc-CH3), 25.85 (TBDMS-CH3), 
18.07 (TBDMS-C), -5.46 (TBDMS-CH3)
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173 N-Boc-4-hydroxymethyl-3-hydroxy-l-cyclopentylamine
HN
HO
HO
Compound 172 (13.74 g, 40 mmol) was dissolved in toluene (50 ml) and 65 % RED-A1 (25 
ml, 2 eq.) was added at 0°C. The mixture was stirred for 2 hour and then a saturated solution 
of NH4C1 was added and stirred for 30 minutes. The precipate was filtred and the solvents 
were removed under reduced pressure to give the title compound as a white solid (7.03 g, 
76%).
‘H-NMR (DSMO, 500 MHz): 6  6.75 (1H, d, J 7.2 Hz, NH), 4.55, (2H, bs, OH-3+OH-5), 
3.92-3.68 (2H, m, H-l+H-3), 3.49-3.21 (2H, m, H-5), 2.05-1.93 (1H, m, H-2), 1.79-1.71 (1H, 
m, H-4), 1.71-1.63 (1H, m, H-6 ), 1.54-1.49 (1H, m, H-6 ), 1.35 (9H, s, Boc), 1.07-0.99 (1H, 
m, H-2)
13C-NMR (DMSO, 125 MHz): 6  154.99 (Boc-CO), 77.26 (Boc-C), 71.75 (C-3), 63.10 (C-5),
49.19 (C-4), 48.91 (C-l), 41.07 (C-6 ), 38.44 (C-2), 25.84
161 4-Amino-2-hydroxymethyl-1 -cyctopentanol
HO
HO
METHOD A: Compound 168 (5 g, 16 mmol) was dissolved in isopropanol (12.5 mL) and 
water (4 mL). Charcoal (2.5 g) was added and the mixture stirred for 30 minutes. After this 
time celite (1.25 g) was added and the mixture filtered through a bed of celite. The filter bed 
was washed with a mixture of isopropanol ( 6  mL) and water (2 mL) twice. The filtrate and 
washes were combined. 5% Palladium on charcoal (5 g) was charged into a dry flask. The 
flask was purged with nitrogen and the combined filtrate and washes from above were added.
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The resulting mixture was stirred and heated to 50°C under an atmosphere of hydrogen for 3 
hours. After this time the reaction mixture was allowed to cool and then filtered through a pad 
of celite. The filter pad was then washed with mixtures of isopropanol and water. The 
combined filtrate and washings were evaporated to approximately 20 mL. n-Butanol (10 mL) 
was added and the mixture re-evaporated under reduced pressure to 3 mL. Methanol (2 mL) 
containing concentrated hydrochloric acid (2 mL) was added followed by n-butanol (10 mL). 
The solvent was removed under reduced pressure to yield a gum. This was taken up in 
methanol and the volume reduced under pressure to the point at which crystallisation had just 
begun. Acetone (10 mL) was added slowly and filtration followed by washing with n- 
butanol/acetone ( 1 :1 ) and acetone yielded after drying, under reduced pressure, the title 
compound (2 g, 95%).
METHOD B: Compound 173 (7.03 g, 30 mmol) was dissolved in 100 ml of H20  and the 
solution was refluxed for 24 hours. The solvent was removed under vaccum to yield 3.98 g 
( 1 0 0 %) of the title compound as brown crystals.
1H-NMR (DMSO, 500 MHz): 6  8.20 (3H, bs, NH3), 4.90-4.50 (2H, bs, OH-3+OH-5), 3.94 
(1H, bs, H-3); 3.55-3.48 (1H, m, H-l), 3.48-3.21 (2H, m, H-5), 2.17-2.09 (1H, m, H-6 ); 1.95-
1.70 (3H, m, H-2+H-4), 1.34-1.27 (1H, m, H-6 )
13C-NMR (DMSO, 125 MHz): 6  71.44 (C-3), 62.40 (C-5), 49.20 (C-4), 48.71 (C-l), 39.00 
(C2), 32.32 (C6 )
177 Ethoxy-acryloyl chloride
o
METHOD A: Ethyl vinyl ether (9.6 ml, 100 ml) was slowly added to oxalyl chloride (12.9 
ml, 1.5 eq.) at 0°C. The reaction mixture was maintaned for 2 hours at )°C and then warmed at 
room temperature for 12 hours. Excess of oxalyl chloride was distilled off, and the residue 
was heated at 120°C for 30 minutes and then purified by vaccum distillation, affording 177 
(7.53 g, 53%).
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METHOD B: 178 (7 g, 60 mmol) was dissolved in 50 ml of DCM and SOCl2 (8.7 ml, 120 
mmol) was added dropwise. The mixture was then stirred at reflux for 2 hours. The solution 
was concentreated under reduced pressure to obtain the title compound 177 ( 8  g, 1 0 0 %).
'H-NMR (CDC13, 500 MHz): 6  7.76 (1H, d, J 12.1 Hz, H-3), 5.49 (1H, d, J 12.1 Hz, H-2),
4.05 (2H, q, J 7.2 Hz, CH2), 1.38 (3H, t, J 7.2 Hz, CH3)
13C-NMR (CDCI3, 125 MHz): 6  168.25 (C-3), 164.51 (C-l), 102.80 (C-2), 68.89 (CH2), 14.35 
(CH3)
178 Ethoxy-acrylic acid
o
A mixture of ethoxyethyl acrylate (10 g, 52 mmol), H20 (20 ml) and NaOH (2.8 g, 1.1 eq.) 
was stirred at 110°C for 30 minutes. The resulting clear solution was cooled to room 
temperature and acidified by careful addition of HC1(C) (5 ml). The product was extracted with 
Wthyl Acetate and H20 and the combined extracts were dried over M gS04 and concentrated 
under reduced pressure to yield 7.00 g (87%) of the title acid.
'H-NMR (DMSO, 500 MHz): 6  11.82 (1H, bs, OH), 7.52 (1H, d, J 12.6 Hz, H-3), 5.14 (1H, 
d, J 12.6 Hz, H-2), 3.94 (2H, q, J 6.7 Hz, CH2), 1.24 (3H, t, J 6.7 Hz, CH3)
13C-NMR (DMSO, 125 MHz): 6  168.17 (C-3), 166.22 (C-l), 96.71 (C-2), 66.58 (CH2), 14.30 
(CH3)
174 Ethoxy-acryloyl isocyanate
o
Dry silver cyanate (16.27 g, 108 mmol) was refluxed in dry benzene (80 ml) for 30 minutes, 
and a solution of 177 (7.3 g, 0.5 eq.) in dry benzene (20 ml) was added dropwise. After
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addition of 177 was complete, the mixture was stirred under reflux for 30 minutes before 
allowing the solid to settle out The supernatant was then decanted and used directly in the 
next reaction.
'H-NMR (CDClj, 500 MHz): 6  7.87 (1H, d, J 12.3 Hz, H-3), 5.50 (1H, d, J 12.3 Hz, H-2),
4.05 (2H, q, J 7.1 Hz, CH2), 1.51 (3H, t, J 7.1 Hz, CH3)
,3C-NMR (CDCIj, 125 MHz): 6  166.89 (C-3), 164.31 (C-l), 128.90 (NCO), 100.92 (C-2),
67.70 (CH2), 14.48 (CH3)
176 1 -(3-hydroxy-4-(hydroxymethyl)cyclopentyl)uracil
o
HO
HO
To a solution of 161 (2.01 g, 12 mmol) in dimethylformamide (15 mL) containing DBU (2 
mL, 1 2  mmol) and 4-A molecular sieves (3 g) at - 2 0  °C was added a 0.5M benzenic solution 
of 176 (37 ml, 1.7 eq.). The mixture was stirred at -15 °C for 1 h and then left to warm to 
room temperature. After 18 hours the mixture was filtered and the filtrate evaporated. The 
residue was purified by column chromatography on silica gel, eluting with chloroform- 
methanol (9: 1) to give the intermediate acryloylurea 174 (2.48 g, 76%) as a brown solid. A 
solution of the acryloylurea 174 (2.48 g, 9.1 mmol) in 5% sulfuric acid (50 mL) was refluxed 
for 3 hours. The mixture was cooled to room temperature and adjusted to pH 7 with 2N 
sodium hydroxide. The solution was evaporated under reduced pressure and the residue dried 
and then extracted with ethanol. The combined ethanolic solution was evaporated under 
reduced pressure and purified by column chromatography (CHC13 MeOH 9:1) to give 1.48 g 
(72%) of the title compound.
‘H-NMR (DMSO, 500 MHz): 6  10.30 (1H, bs, NH), 7.70 (1H, d, J 7.9 Hz, H-5), 5.56 (1H, d, 
J 7.9 Hz, H-6 ), 4.94 (1H, qn, J 8.9 Hz, H -l’), 4.83 (1H, bs, OH-3’), 4.71 (1H, bs, OH-5’),
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4.09-4.02 (1H, m, H-3’), 3.51-3.35 (2H, m, H-5’), 2.12-2.00 (1H, m, H-2’), 1.95-1.72 (3H, m, 
H+4’+H-6’), 1.43-1.34 (1H, m, H-2’)
,3C-NMR (DMSO, 125 MHz):S 163.11 (C-2), 151.00 (C-4), 142.29 (C-5), 101.33 (C-6 ), 
71.37 (C-3’), 62.57 (C-5’), 53.61 (C -l’), 48.85 (C-4’), 38.92 (C-2’), 32.32 (C-6 ’)
159 1 -(3-hydroxy-4-(hydroxymethyl)cyclopentyl)-5-iodo-uracil
o
HN
HO
HO
To solution of 174 (1.48 g, 6.5 mmol) in glacial AcOH was added I2 (0.83 g, 0.5 eq.) and 
CAN (1.78 g, 0.5 eq.) and the mixture was then stirred at 80°C for 1 hours. The solvent was 
removed under reduced pressure and the residue was purified by column chromatography to 
afford 1.21 g (53%) of the titled compound.
‘H-NMR (DMSO, 500 MHz): 6  9.51 (1H, bs, NH), 9.51 (1H, s, H-6 ), 4.96-4.87 (1H, m, H- 
1’), 4.71 (1H, bs, OH-3’), 4.60 (1H, bs, OH-5’), 4.1-3.95 (1H, m, H-3’), 3.43-3.29 (2H, m, H- 
5’), 2.11-2.00 (1H, m, H-2’), 1.87-1.68 (3H, m, H+4’+H-6’), 1.48-1.41 (1H, m, H-2’) 
13C-NMR (DMSO, 125 MHz) : 6  165.39 (C-2), 160.49 (C-4), 146.64 (C-6 ), 71.61 (C-3’), 68.32 
(C5), 63.25 (C-5’), 55.61 (C -l’), 48.85 (C-4’), 38.92 (C-2’), 32.32 (C-6 ’)
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3 -(3 -hydroxy-4 -(hydroxymethyl)cyclopentyI)-6 -(4 -pentylphenyl)furo[2 ,3 -<flpyrimidin-2 (3 //)-
one
[Cf2566]
HO
HO
Prepared according to Standard Procedure D (159 instead of IDU) using 4- 
ethynylpentylbenzene. The compund was purified by column chromatography (CHCl3 :MeOH 
95:5) to afford 0.38 g (32%) of the title compound as brown solid. A small portion (100 mg) 
was further purified by preparative HPLC (H2 O: ACN 0:100 in 20 minutes) to afford 40 mg 
of pure compound as white solid.
‘H-NMR (DMSO, 500 MHz): 6  8.65 (1H, s, H-4), 7.74 (2H, d, J 8.1 Hz, Phb), 7.32 (2H, d, J
8.1 Hz, Phc), 5.21 (1H, m, H -l’), 4.79 (1H, d, J 4.1 Hz, OH-3’), 4.64 (1H, t, J 4.8 Hz, OH-5’),
4.06 (1H, dq, J 7.4 Hz 4.1 Hz, H-3’), 3.57-3.51 (1H, m, H-5’), 3.47-3.41 (1H, m, H-5’), 2.62 
(2H, t, J 7.4 Hz, CH2a), 2.26 (1H, ddt, J 12.6 Hz 7.9 Hz 1.3 Hz, H-6 ’b), 2.06 (1H, ddd, J 12.9 
Hz 9.9 Hz 6.7 Hz, H-2’b), 2.01-1.92 (2H, m, H-2’a+H-4’), 1.59 (1H, qn, J 7.7 Hz, CH2P), 1.51 
(1H, ddd, J 12.6 Hz 9.9 Hz 9.1 Hz. H-6 ’,), 1.36-1.22 (4H, m, CH2y+CH2 6 ), 0.87 (3H, t, J 6 . 8  
Hz, CH3 O0 )
,3C-NMR (DMSO, 500 MHz): 6  170.46 (C7a), 154.62 (C6 ), 153.66 (C2), 144.00 (Ph-Cd),
140.00 (C4), 128.97 (Ph-Cc), 125.92 (Ph-Ca), 124.52 (Ph-Cb), 106.99 (C4a), 98.51 (C5),
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71.43 (C-3’), 62.64 (C5’), 56.94 (C -l’), 49.17 (C-4’), 39.71 (C2’), 34.88 (Ca), 33.32 (C-6 ’),
30.80 (Cy), 30.36 (CP), 21.89 (C5), 13.87 (Cco)
Anal. Calcd for C2 3 H28N2 O4 : C 69.67, H 7.12, N 7.07, O 16.14. Found C 69.70, H 7.15, N 
7.00,0  16.20 
MS: 419 (M+Na)
1 8 0  3-(2-deoxy-a-D-ribofuranosyl-5-[valynyl)-6-(4-pentylphenyl)furo[2,3-cf]pyrimidin-
2(3//)-one
[FV100]
n h 2 ho
33f (200 mg, 0.5 mmol) was dissolved in dry DMF (5ml), followed by the addition of 
polymer-bound triphenylphosphine [370 mg, 1.1 mmol, (3 mmol p/g resin)] and di-terf-butyl 
azodicarboxylate (DBAD) (231 mg , 1.0 mmol) to the mixture and stirred for 20 minutes. A 
solution of Fmoc-Val-OH (340 mg, 1.0 mmol) in DMF (5 ml) was added dropwise over a 
period of 30 minutes. The reaction mixture was stirred at room temperature under an argon 
atmosphere until complete disappearance of the starting material (overnight). The resin was 
filtered off and washed with ethyl acetate. Piperidine (1 ml, 10 mmol) was added to the 
solution and stirred for 10 minutes. The solvent was removed under reduced pressure without
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warming over 35 C and the residue was dissolved in ethyl acetate (20 mL), washed with 10% 
NaHC0 3  (3 x 20 mL) and brine (2 x 20 mL). The final residue was purified by column 
chromatography (gradient CH2 C12 : MeOH 100% 98% 95% 90%), to give 137 mg of 180 
(55% yield) as a yellow solid.
'H-NMR (CDCI3 , 500 MHz) 5: 8.3 (1H, s, H-4), 7.55 (2H, d, J 7.6 Hz, Ph), 7.15 (2H, d, J 7.6 
Hz, Ph), 6 . 6  (1H, s, H-5), 6.25 (1H, t, J 6.0 Hz, H -l’), 4.45-4.30 (4H, m, H-3’+H-4’+H-5’), 
3.23 (1H, d, J 5.0 Hz, Val-CH), 2.84-2.75 (1H, m, H-2’a), 2.53 (2H, t, J 7.6 Hz, CH2a), 2.17-
2.09 (1H, m, H-2’p), 2.00-1.90 (1H, m, Val-CH), 1.58-1.49 (2H, m, CH2 (3), 1.31-1.20 (4H, m, 
CH2Y+CH2S), 0.89 (3H, d, J 6 . 6  Hz, Val-CH3), 0.84 (3H, d, J 6 . 6  Hz, Val-CH3), 0.82 (3H, t,
7.0 Hz, CH3 w)
l3C-NMR (CDC13, 125 MHz) 6 : 175.16 (Val-CO), 171.62 (C7a), 156.26 (C6 ), 154.89 (C2),
145.19 (Ph), 135.29 (C4), 129.02 (Ph), 125.69 (Ph), 124.95 (Ph), 108.60 (C4a), 96.82 (C5), 
88.73 (C l’), 85.08 (C4’), 70.90 (C3’), 64.19 (C5’), 60.19 (Val-CH), 41.91 (C2’), 35.82 (Ca), 
32.32 (Val-CH), 31.44 (Cy), 30.89 (C|3), 22.50 (C6 ), 19.30 (Val-CH3), 17.24 (Val-CH3), 
13.99 (Co))
HPLC: H2 0 /CH3CN gradient 0-100 in 15 min: Rt 12.47 min (99.1%)
Anal. Calcd for CrTLs^CV. C 65.17%, H 7.09%, N 8.44%. Found C 64.87%, H 7.29%, N 
7.91%
MS: 520 (M+Na)
3-(2-deoxy-a-D-ribofuranosyl-5-[valynyl)-6-(4-pentylphenyl)furo[2,3-£/]pyrimidin-2(3//)-one
hydrochloric salt 
[FV100 HC1]
180 (0.3 g, 0.6 mmol) was dissolved in 3 ml of THF. Under vigorous stirring 1M HC1 (1 ml) 
was added dropwise at 0°C and the mixture were stirred for 10 minutes. The solvents were 
dried under reduce pressure to obtain 0.32 g (100%) of yellow oil that solidified with addition 
of Et2 0.
‘H-NMR (DMSO, 500 MHz) 6 : 8.60 (4H, bs, NH3+H-4), 7.76 (2H, d, J 6 . 8  Hz, Ph), 7.34 
(2H, d, J 6 . 8  Hz, Ph), 7.23 (1H, s, H-5), 6.24 (1H, t, J 6.2 Hz, H-l;), 4.53-4.45 (2H, m, H-5’), 
4.32-4.26 (1H, m, H-3’), 4.16-4.12 (1H, m, H-4’), 3.95 (1H, bs, Val-CH), 2.63 (2H, t, J 7.5
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Hz, CH2a), 2.47-2.40 (1H, m, H-2’„), 2.30-2.23 (1H, m, H-2’„), 2.21-2.14 (1H, m, Val-CH), 
1.64-1.55 (2H, m, CH2p), 1.36-1.23 (4H, m, CH2y+CH25), 0.99 (3H, d, J 6.3 Hz, Val-CH3), 
0.96 (3H, d, J 6.3 Hz, Val-CH3), 0.87 (3H, t, J 6.5 Hz, CH3oj)
i3C-NMR (DMSO, 125 MHz) 6: 175.16 (Val-CO), 171.13 (C7a), 168.88 (C6), 153.97 (C2),
153.70 (C6), 144.18 (Ph), 137.94 (C4), 129.04 (Ph), 125.77 (Ph), 124.58 (Ph), 107.22 (C4a),
98.75 (C5), 87.71 (C l’), 84.13 (C4’), 69.73 (C3’), 65.26 (C5’), 57.35 (Val-CH), 40.18 (C2’),
34.88 (Ca), 30.88 (Val-CH), 30.39 (Cy), 29.38 (Cp), 21.91 (C6), 18.26 (Val-CH3), 17.55 
(Val-CH3), 13.90 (Cw)
HPLC: H20/CH3CN gradient 0-100 in 15 min : Rt 12.47 mins (98%)
Anal. Calcd for C27H36C1N30 6: C 60.72%, H 6.79%, 7.87%. Found C 60.21%, H 6.67%, N 
7.34%
MS: 498 (M+H)
3-(2-deoxy-a-D-ribofuranosyl-5-[valynyl)-6-(4-pentylphenyl)furo[2,3-rf]pyrimidin-2(3/7)-one
succinate salt 
[FV100 Succinate]
180 (0.3 g, 0.6 mmol) was dissolved in 3 ml of THF. Under vigorous stirring succinic acid (1 
ml) was added dropwise at 0°C and the mixture were stirred for 10 minutes. The solvents 
were dried under reduce pressure to obtain 0.32 g (100%) of yellow oil that solidified with 
addition of EtiO.
'H-NMR (DMSO, 500 MHz) 6: 8.58 (1H, s, H-4), 7.73 (2H, d, J 7.5 Hz, Ph), 7.34 (2H, d, J
7.5 Hz, Ph), 7.50 (1H, s, H-5), 6.21 (1H, t, J 6.2 Hz, H-l;), 4.41-4.31 (2H, m, H-5’), 4.27-4.21 
(1H, m, H-3’), 4.15-4.10 (1H, m, H-4’), 3.32 (1H, d, J 5.0 Hz, Val-CH), 2.61 (2H, t, J 7.5 Hz, 
CH2a), 2.47-2.40 (1H, m, H-2’„), 2.38 (4H, s, Succ), 2.24-2.16 (1H, m, H-2’(1), 1.92-1.83 (1H, 
m, Val-CH), 1.63-1.53 (2H, m, CH2p), 1.35-1.18 (4H, m, CH2y+CH26), 0.91-0.82 (9H, m, 
2xVal-CH3+CH3co)
13C-NMR (DMSO, 125 MHz) 6: 174.03 (Val-CO), 173.91 (Succ-CO), 171.09 (C7a), 153.97 
(C2), 153.69 (C6), 144.15 (Ph), 137.68 (C4), 129.02 (Ph), 125.77 (Ph), 124.55 (Ph), 107.12 
(C4a), 98.60 (C5), 87.74 (C l’), 84.61 (C4’), 69.83 (C3’), 63.89 (C5’), 59.23 (Val-CH), 40.53 
(C2’), 34.89 (Ca), 31.42 (Val-CH), 30.80 (Cy), 30.38 (Cp), 29.46 (Succ-CH2), 21.91 (C5), 
18.84 (Val-CH3), 17.52 (Val-CH3), 13.88 (Cco)
MS: 498 (M+H)
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